[{"article": "Our result is statistically significant, but because the study wasn't specifically designed to test the effect of diet quality,\n\ninflammatory diets and BMI on drug response in general, it is necessary to see the work replicated in a larger study before any firm conclusions can be formed\".\nThe fact that there are two opposite sets of symptoms means that finding an effective treatment is difficult.\nBipolar Disorder (which used to be called 'manic depression') is characterised by episodes of mood swings, between being very up or very down with periods in between the two extremes.\nWhile current medications are useful, they are better at targeting mania symptoms (the 'up' phase), leaving a lack of effective treatment for people experiencing depressive episodes.\nResearchers also rated whether a participant was improving and, if so, how much, over the next 20 weeks.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The harms of NAC, according to Memorial Sloan Kettering Cancer Center, listed here,\u00a0are not mentioned.", "answer": 0}, {"article": "Bathing-suit season is here and with it, anxiety over cellulite. A new laser device that burrows under the skin is getting praise from some doctors who say it gives more dramatic and longer-lasting results than previous treatments, but others caution that more research is needed.\n\nCellulite is a dimpled, uneven appearance of skin caused by fat underneath. It affects some 85% of women and about 5% of men. Until recently, the main treatments to battle cellulite have been external treatments such as creams and radio-frequency and...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Potential harms were mentioned:\nCellulaze leaves tiny scars\u2014about two millimeters long\u2014which fade with time, surgeons say. Typically, compression garments are recommended for at least two or three weeks to prevent fluid buildup. And there will be bruises, so patients typically need to wait three to six weeks before venturing out in a bathing suit, surgeons say.\nThe procedure can cause a buildup of fluid in the area that has been treated, which can last for months and needs to be drained regularly by a doctor.\nIn a written statement, Cynosure says \u201ca few\u201d patients in early trials had the buildups, called seromas, adding that they need to be drained to prevent infections and other complications. The company says it has since lowered the recommended laser dosage and it isn\u2019t aware of any seromas since the device hit the U.S. market.\nBut none of these harms was quantified, so the scope of the potential harm wasn\u2019t clear.\u00a0 What does it actually mean when the story uses vague terms such as \u201ctypically\u201d\u2026\u201dcan cause\u201d\u2026\u201da few patients\u201d ?", "answer": 0}, {"article": "Switching to AstraZeneca PLC's breast-cancer drug Arimidex after treatment with older drug tamoxifen not only helps women live longer, but also increases their chances of staying cancer-free after initial therapy for breast cancer, according to a study in the online edition of the Lancet Oncology medical journal.\n\nThe data, which come from more than 4,000 patients in three clinical trials, have shown that switching treatment from tamoxifen to Arimidex reduces the risk of dying by 29%.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention the potential side effects of aromatase inhibitors. Both hormone therapies may increase menopausal symptoms such as hot flashes or vaginal discomfort, though\u00a0anstrozole slightly less so than tamoxifen.\u00a0 Anastrozole may increase the risk of bone or joint pain and\u00a0possibly may increase cholesterol. ", "answer": 0}, {"article": "For this case-control study, researchers recruited 5,307 colonoscopy patients, 60 percent of them men, at two Tennessee hospitals over a seven-year period ending in April 2010.\nAfter controlling for age, race, body mass index, smoking and other factors, the researchers found that women in the highest fifth for omega-3 consumption \u2014 those who consumed three or more servings of fish a week \u2014 were 33 percent less likely than women in the lowest fifth to have adenomatous polyps, a type likely to become cancerous.\nThe researchers found no effect in men, and no effect of omega-3 consumption on hyperplastic polyps, which are more likely to be benign.\n\u201cThis is more evidence to suggest that omega-3s are beneficial and may have anti-inflammatory action helpful in reducing cancer risk,\u201d said the lead author, Dr. Harvey J. Murff, an associate professor of medicine at Vanderbilt.\nA new study has found that consumption of omega-3 fatty acids from fish is associated with a reduced risk for one kind of colon polyp, but only in women.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not applicable.\u00a0 The harms of fish in the diet are not really in question, although some research has raised concerns about possible toxic effects of mercury found in some species.", "answer": 2}, {"article": "Scientists are also optimistic about using probiotics in developing countries where diarrhea is a big problem and can even be fatal.\nOn average, using probiotics reduced a bout of diarrhea by more than a day, and reduced the risk of a prolonged diarrhea episode -- four days or more -- by 59 percent.\nAnd, he says, researchers need to take a look at probiotic regimes that could best target different cases of acute diarrhea in both developed and developing countries.\nA Cochrane Library review of 63 studies found that probiotics can shorten the time a person has acute diarrhea -- with no negative side effects.\nProbiotics May Help Soothe The Stomach\n\nYogurts and supplements loaded with \"friendly\" bacteria may be able to fight the nefarious ones and soothe fickle bowels, according to a new study.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentioned that there were \u201cno negative side effects\u201d in the literature review. So, for that, we\u2019ll give it a satisfactory score.\u00a0 But a broader perspective on this issue could have addressed the potential for harm in hospitalization-associated diarrhea.", "answer": 1}, {"article": "Repatha, with a list price of more than $14,000 a year, was approved based on its ability to dramatically lower \u201cbad\u201d LDL cholesterol in patients who require more intensive therapy on top of widely-used statins, such as Lipitor, or who are unable to tolerate statins.\nThe data should pave the way for greater acceptance by health insurers and pharmacy benefit managers, who have been rejecting about 75 percent of prescriptions written for the expensive medicine despite multiple appeals by physicians.\n\u201cThese results show unequivocally the connection between lowering LDL cholesterol with Repatha and cardiovascular risk reduction, even in a population already treated with optimized statin therapy,\u201d Amgen research chief Sean Harper said in a statement.\n(Reuters) - Amgen Inc said its potent cholesterol fighter Repatha significantly reduced the risk of heart attacks, strokes and death in patients with heart disease, according to initial results of a large, eagerly-anticipated trial released on Thursday.\nAt the heart meeting in March, researchers will also provide details on risk reduction for each of the components, such as non-fatal heart attack, non-fatal stroke, and heart-related death.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story says that \u201cNo new safety problems cropped up in the 27,500 patient study.\u201d The\u00a0news release issued by the drug manufacturer Amgen about the same clinical trial revealed what was not known about potential harms for the use of the drug, as well as a number of contraindications, adverse events and harms that arose during the trial. The story would have done well to reference these.\u00a0", "answer": 0}, {"article": "In a separate analysis published in the same issue of JAMA Cardiology, researchers used data from the PARADIGM-HF trial to model the health consequences and cost-effectiveness of Entresto over a 30-year time period.3 They compared Entresto to the ACE-inhibitor enalapril and found Entresto was associated with more than a year longer average survival time, and that it was cost-effective compared to enalapril when these medications were used with other standard of care therapies.3 For every 1,000 patients treated with Entresto vs. enalapril, potentially 59.7 HF hospital admissions could be averted per each year alive in the model.3 In addition, Entresto increased life expectancy at an incremental cost-effectiveness ratio consistent with other high-value widely accepted cardiovascular interventions such as implantable cardioverter defibrillators (ICDs) and cholesterol-lowering statins before they became generic.3\n\nAbout Heart Failure\n\nHeart failure is a debilitating and life-threatening condition, which impacts nearly 6 million Americans and is the leading cause of hospitalization among Americans over the age of 65.4,8 About half of people with heart failure have heart failure with reduced ejection fraction (HFrEF).5 Reduced ejection fraction means the heart does not contract with enough force, so less blood is pumped out.9 Heart failure presents a major and growing health-economic burden that currently exceeds $30 billion in the United States, which accounts for both direct and indirect costs.10\n\nAbout Entresto\n\nEntresto is a twice-a-day medicine that reduces the strain on the failing heart.\nThe target treatment dose of Entresto is 97/103 mg twice daily.11\n\nNovartis is committed to providing patients with affordable access and resources through Entresto Central.\nThere can be no guarantee that Entresto will be submitted or approved for any additional indications or labeling in any market, or at any particular time.\nBefore they take Entresto, patients should tell their doctor about all of their medical conditions, including if they have kidney or liver problems; are pregnant or plan to become pregnant; are breastfeeding or plan to breastfeed.\nEntresto may cause serious side effects including serious allergic reactions causing swelling of the face, lips, tongue, and throat (angioedema) that may cause trouble breathing and death.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release includes extensive information on harms, including this summary of side effects: \u201cEntresto may cause serious side effects including serious allergic reactions causing swelling of the face, lips, tongue, and throat (angioedema) that may cause trouble breathing and death.\u201d", "answer": 1}, {"article": "A diet that includes tomatoes could lower the chance of having a stroke.\n\nA new study shows that men who had the highest levels of lycopene\u2014an antioxidant found in tomatoes\u2014had fewer strokes than men who had the lowest level of lycopene in their blood. Overall, the risk of strokes was reduced by 55%.\n\nThe study, based in Finland, will be published...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We\u2019ll rate this not applicable as we did for the competing stories, but with the caveat: Lycopene supplements haven\u2019t been well studied and might cause adverse effects.", "answer": 2}, {"article": "\"The issue is, can you detect these in patients that don't have advanced cancer?\" Venook said. \"The answer is, we don't know.\" The numbers tested by the MD Anderson researchers -- 251 patients with pancreatic cancer (five of whom had very early lesions), 32 with chronic pancreatitis and 120 healthy controls -- aren't nearly large enough to draw such conclusions. And getting a clear answer, Venook said, would probably require lengthy and expensive studies on very large populations.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This article, like others covering the study that we reviewed, ignored the potential harms from screening tests. In the real world, all screening tests carry the risk of false negatives, false positives and inconclusive results that could lead to more invasive tests and over-aggressive treatments.", "answer": 0}, {"article": "For more information, visit http://www.\nThe Journal of Medical Entomology is published by the Entomological Society of America, the largest organization in the world serving the professional and scientific needs of entomologists and people in related disciplines.\nIn order to test the effectiveness of the device, Christopher Bibbs and Rui-De Xue of the Anastasia Mosquito Control District in Florida studied how the device performed against hungry Aedes aegypti mosquitoes.\n\"Just look at all the bug zappers, repellent bracelets, sonic bug repellents, and other zany creations that wax and wane in popularity.\nA product called the OFF!\u00ae Clip-On\u2122 repellent device could be an effective tool for preventing bites from the Aedes aegypti mosquito -- the primary vector of Zika, chikungunya, dengue, and yellow fever -- according to an article in the Journal of Medical Entomology.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release doesn\u2019t give even a brief nod to harms. In addition to questions about the product\u2019s effectiveness, Consumer Reports pointed out that the active ingredient in the device is metofluthrin, a neurotoxin.\n\u201cThe label says, \u201cAvoid breathing vapor,\u201d but it\u2019s hard to imagine how, with the repellent swirling around you,\u201d according to Consumer Reports.\nThis seems to\u00a0be a critical oversight as the vapors will be inhaled by the people who are supposedly being protected as well as the mosquito.\nJohnson & Johnson\u2019s product website has a list of warnings buried under the topic, \u201cPrecautionary Statements.\u201d\n\u201cHAZARDS TO HUMANS AND DOMESTIC ANIMALS: CAUTION: Harmful if swallowed, inhaled, or absorbed through the skin. Avoid contacting skin, eyes, or clothing with treated refill cloth. Avoid breathing vapor. Wash thoroughly with soap and water after handling and before eating, drinking, chewing gum, or using tobacco. Remove and wash contaminated clothing before reuse. Store away from food, beverages and pet food. Do not use indoors or in enclosed spaces. Do not touch unit with metal instruments or wet hands. Do not allow materials of any kind to cover the unit while it is in use. Replace refill only when unit is off.\u201d ", "answer": 0}, {"article": "MONDAY, June 27, 2011 (HealthDay News) -- Brilinta, an experimental anti-clotting medication currently awaiting U.S. Food and Drug Administration approval, performed better than the industry standard, Plavix, when used in tandem with low-dose aspirin, a new study finds.\n\"The study highlights that if one chooses to use ticagrelor in subjects with acute coronary syndromes, it would be logical to use aspirin 81 milligrams per day (and not 325 mg daily),\" said Dr. Jeffrey S. Berger, assistant professor of medicine and director of cardiovascular thrombosis at NYU Langone Medical Center in New York City.\n\"Of note, there is little reason to ever use aspirin 325 mg except in the acute setting of a heart attack or stroke,\" he added.\nIn this latest analysis of PLATO findings, researchers found that patients who took Brilinta with low-dose aspirin were 16 percent less likely than those who took Plavix with low-dose aspirin to have a heart attack or stroke, or to die within a year.\nThe panel's recommendation was based in part on prior findings from this study, called the Platelet Inhibition and Patient Outcomes (PLATO) trial.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "In the setting of heart attacks, the major harms of the drugs are related to their benefits \u2014 how well they prevent future cardiovascular tragedies. However, all the drugs in this article, including aspirin, impart a risk of bleeding, which is part of the comparison in PLATO and this follow-up analysis. It was good that the article gives a mention, albeit a brief one in the quote from Dr. Berger, of the increased risk of bleeding with higher doses of aspirin.\u00a0", "answer": 1}, {"article": "CHICAGO (Reuters) - The hallucinogen psilocybin \u2014 known by the street name magic mushrooms \u2014 may help ease the anxiety that often accompanies late-stage cancer, U.S. researchers said on Monday.\nEverything had to be shut down,\u201d Grob said in a telephone interview.\n\u201cIt was something of a public health crisis.\n\u201cForty to 45 years ago, the culture was going through tremendous upheaval.\nThe treatments were given in random order and neither the doctors nor the patients were told which compound was administered.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "", "answer": 0}, {"article": "Such an analysis is months away.\n\u201cThe challenge now shifts from proving the efficacy of the method to developing the proper quality standards, infrastructure and guidelines to bring this needed benefit to those at high risk for the disease \u2014 now,\u201d Ms. Fenton said.\nPatients wishing to get a CT lung screen will most likely have to pay the roughly $300 charge themselves, since few insurers pay for such scans unless an illness is suspected.\nBut health officials involved in the study refused to endorse widespread screening of current or former smokers, saying more analysis of the study\u2019s results is needed to further identify who benefited most.\nAnd they pointed out that the study offers no reassurance about the safety of smoking or the advisability of CT scans for younger smokers or nonsmokers.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nThe final paragraph of the story points out that there is a risk of harms from the radiation used for the CT scans and that the scans cause false positives and may lead to tests and treatments done on people who actually don\u2019t have dangerous tumors. We wish some attempt had been made to quantify these harms \u2013 even if it meant drawing from past research \u2013 but we\u2019ll give the story the benefit of the doubt.\n", "answer": 1}, {"article": "Whether you've been relatively inactive or fairly athletic, age is the enemy of one of the most important sets of muscles in the body: the group of four known as the rotator cuff that surround the ball of the shoulder joint.\n\nAbout 54% of adults older than 60 have a completely or partially torn rotator cuff, compared with just 4% of those between 40 and 60. But tears are most frequently caused by degeneration of the tendon due to age, rather than injury from sports or trauma. Studies show that tears can be managed without...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does a credible job of explaining that there are complications with any surgery. They did not explore the potential of surgery \u2013 even without complications \u2013 to leave a patient with reduced range-of-motion or other results that are less than desired outcomes.", "answer": 1}, {"article": "Visit redrazz.org for more information, and follow us on our social media channels:\n\"We are excited about this new flurry of studies, which builds on previously published research aimed to better understand the potential health benefits of red raspberries,\" said Tom Krugman, Executive Director of the National Processed Raspberry Council (NPRC).\nIn an eight-week pilot study, researchers from the Institute for Food Safety and Health from the Illinois Institute of Technology examined the impact of consumption of red raspberry pur\u00e9e or fructo-oligosaccharide on the gut microbiota and the subsequent bioavailability of red raspberry polyphenols in healthy volunteers.\nIn a secondary objective of the blood sugar control study, researchers found that subjects in the PreDM group who reported the highest level of hunger at baseline experienced greater satiety after the control meal compared to raspberry containing meals (p<0.05).\nWhile additional research, particularly in humans, is warranted, preliminary evidence from these studies suggests that the actions of essential nutrients, fiber, and polyphenolic phytochemicals found in red raspberries may play a role in supporting key metabolic functions, including anti-inflammatory, anti-oxidative and metabolic stabilizing activity.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release didn\u2019t mention any harms from eating raspberries, but that may be because there are no documented harms. Unless you are allergic, it seems safe to eat raspberries in moderation like any other fruit or vegetable.\nStill, out of eight studies it\u2019s reasonable to think one of them examined potential harms or made a statement about the lack of harms. Even noting \u201cthere were no observed harms\u201d would be helpful.", "answer": 2}, {"article": "Half got the new gel and the other half received an inactive placebo.\n\u201cThe shorter application period is what makes ingenol mebutate a breakthrough in the treatment of actinic keratosis,\u201d researcher Mark Lebwohl, MD, says in a news release.\nThe new gel, Picato (ingenol mebutate), is applied once daily for two or three days, depending on the area being treated.\nThe new study included 547 people with actinic keratoses on their face or scalp and 458 people with these lesions on their mid-section or arms and legs.\nAt the end of the two-month study, 42% of people in the first group and 34% of those in the second group who got the new gel showed complete clearance of their lesions.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "In an odd line, the story states \u201cBecause the new gel is only used for a few days, any irritation is usually short-lived.\u201d\u00a0 But it doesn\u2019t describe the irritation in any detail \u2013 nor\u00a0 how often it occurs.\u00a0 This isn\u2019t telling readers much of anything useful.", "answer": 0}, {"article": "But there are some men who really have it bad.\"\nIt's also possible, he said, that the symptoms went away on their own, which commonly happens to men on hormone therapy.\nStill, \"our study shows that physicians and patients have an additional treatment for something that affects many men undergoing prostate cancer treatment and actually has long-term benefits, as opposed to more side effects,\" said lead author Dr. Hani Ashamalla, a radiation oncologist at New York Methodist Hospital, in a news release from the American Society for Radiation Oncology.\nThe question is whether the acupuncture reduced the hot flashes or a placebo effect played a role, said Freedland, who's familiar with the study findings.\nThe study, published in the April issue of the International Journal of Radiation Oncology, Biology, Physics, also found that acupuncture relieved the heart palpitations and anxiety often associated with hormone therapy for prostate cancer.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion of potential harms.\u00a0 Maybe none were found.\u00a0 Some past acupuncture studies report discomfort at the needling sites. One line could have easily addressed what was seen in this study or in related work.", "answer": 0}, {"article": "Rosser, however, chalked that up to the ethical issues it raises.\nHowever, the current non-invasive alternative \u2014 an ultrasound done at the end of the first trimester \u2014 isn\u2019t always good at spotting a baby\u2019s sex, Bianchi\u2019s team reported in the Journal of the American Medical Association.\n\u201cBut it should only be used by families that are at risk for sex-linked diseases.\u201d\n\nBianchi said she owns stock in Verinata Health, a company that is developing cell-free fetal DNA tests for Down syndrome, although that company had no role in the new study.\nThat leaves some room for error, which could be important if parents are making medical decisions based on the results \u2014 such as whether or not to get an invasive procedure to look for genetic disorders.\nThey found parents could trust the test 98.8 percent of the time when it said they\u2019d have a boy, and 94.8 percent of the time when it indicated a girl.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We give this a barely passing grade, because the story does quote one ethicist raising doubts about how parents may use the test.\u00a0She points out: \u201cRemember, gender is not a disease.\u201d Reuters does not use the word \u201cabortion.\u201d Seems to be a bit light on the harms side of the social equation.", "answer": 1}, {"article": "But these methods alone don't give reliable results.\n\"The thing we worry about quite often is ... if we have a test result that is negative we don't want to give false reassurance to the patient,\" he says.\nAnd for the test to be useful, \"you've got to find cancer that's going to otherwise be lethal, and not cancer that would otherwise be destined to do nothing,\" Prasad says.\nThe scientists at Hopkins have already launched their next study, which could involve tens of thousands of apparently healthy volunteers who are enrolled in the Geisinger Health Plan in Pennsylvania.\n\"We want this to be true, we hope that this is true, but we have learned through 30, 40, 50 years of cancer screening that we have to do the right studies at the outset to know that it's true,\" Prasad says.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does an excellent job of finding an independent source who explains that one of the potential risks of cancer screening tests is either identifying cancers that are not there, or are benign, and can lead to \u201cpointless and potentially dangerous treatments.\u201d\nThe opposite harm is also mentioned; that is, a screening test that erroneously gives a negative result, leading providers to falsely reassure a patient\u00a0that cancer is not there.", "answer": 1}, {"article": "Others have such high cholesterol that taking statins alone is not enough.\n\"It seems that the group that takes them, compared to the group that doesn't, has half the rate of cardiovascular events and mortality as those that don't,\" Dr. Seth S. Martin of the Johns Hopkins School of Medicine told CBS News.\nIn an editorial published along with the study, experts note that although the results are promising, more long-term research is needed to make definitive conclusions about the drug.\nThese new drugs \"could be for someone who needs an addition to statin, or it could be instead of statin,\" Martin said.\nBut some patients can't tolerate the side effects, which can include headache, difficulty sleeping, muscle aches, diarrhea, constipation and nausea or vomiting.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Every class of drugs has side effects, and there has been substantial concern about the possibility of neurocognitive side effects with this class of drugs. The fact that these drugs have to be injected under the skin could also potentially affect use and adherence to a medication regimen. We understand that this story is fewer than 300 words long, but there could have been a statement such as, \u201cMore study is needed to assess the potential side effects of this new class of drugs.\u201d", "answer": 0}, {"article": "\"If you have your choice, you want to get poked with a needle or you want to try this?\nAnd the same vaccine continues to be recommended and used in European Union markets, AstraZeneca says.\nThe vaccine's effectiveness was just 3 percent, so low that \"no protective benefit could be measured\" for children ages 2 to 17, the CDC said in a statement.\nThe company says its flu vaccine \"starter kit,\" which can vaccinate 500 people, costs $900.\n\"In vaccines, what's really hard is that there's a very, very high volume, and you're competing with a needle and syringe, which is tremendously low cost,\" Anquetil says.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The focus of the article headline is convenience and comfort. It follows through on that focus by doing a fairly good job of addressing side effects of the various delivery mechanisms, though again, the information is somewhat uneven. The most thorough description of harms is provided in the flu patch section of the story, where we learn that participants in the clinical trial had\u00a0some redness, itching and tenderness but no serious side effects. About the jet injection we learn it is much less painful than when it was used for smallpox vaccination back in the 1960s. The story also informs us that nozzles are changed between patients so the former problem with infection from using the same equipment has been resolved. No other harms (like the redness and itching associated with the patch, for example) are mentioned. The section of the story on nasal spray vaccines is short, and it doesn\u2019t include any information about side effects or harms.", "answer": 1}, {"article": "It takes an hour or less,\" he said.\nA total of 270,000 defibrillators have been recalled since January 2005, though it is unclear how many were inside patients and how many were on the shelf, according to the Food and Drug Administration.\nIt can correct a heart that beats too fast, as in ventricular tachycardia, or quivers chaotically, a condition known as ventricular fibrillation.\nSix percent of the 533 patients who decided to have their recalled defibrillators replaced over a 12-month period suffered major complications, including two deaths, according to a study published in Wednesday's Journal of the American Medical Association.\nCHICAGO -- When a manufacturer recalls an implanted heart defibrillator because of a potential flaw, patients and doctors must decide whether to leave the device in the body or replace it.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Article lists all harms noted in the study, both serious and less serious, and explains that the authors did not track what happened to patients who did not have devices replaced. The story did note that untreated abnormal rhythms can be \u2018potentially deadly\u2019. However, the article notes that manufacturers estimate the rate of failure for devices that are subject to safety advisories, and also lists both the minor and serious things that can go wrong with them. One big issue that is not dealt with well is that the initial decision threshold for putting these devices in place may change now, based on the higher failure rates and the higher rates of complications with replacement.", "answer": 1}, {"article": "So far, Freedman noted, the only hot-flash treatment that has consistently worked in studies is hormone replacement therapy (HRT).\nThose findings appear in a separate report in the journal Menopause.\nBut no one knows if altering serotonin levels actually does affect women\u2019s hot flashes.\nThey increase levels of the brain chemical serotonin, which may have a role in regulating body heat.\nBut there is little evidence that they work, according to the North American Menopause Society.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article did discuss some of the side effects of antidepressants.", "answer": 1}, {"article": "The device has gas sensors that detect various odorous molecules in sweat.\nStill, that means that 11% of cases would have been missed and 16% of people would have been told they had a life-threatening condition when they didn't.\nAug. 30, 2011 (Paris) -- German researchers say they\u2019re a step closer to developing an electronic nose that can distinguish between people who have heart failure and those who don't.\n5 Million Have Heart Failure in U.S.\n\nMore than 5 million Americans have heart failure, which occurs when the heart muscle loses its ability to pump enough blood throughout the body.\n\"Still, much more work is needed before we will know if the electronic nose will make it to the clinic,\" says Ruschitzka, who moderated a news briefing to discuss the findings.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes that, \u201c11% of cases would have been missed and 16% of people would have been told they had a life-threatening condition when they didn\u2019t.\u201d There could have been a little more discussion of the ramifications of a test with this kind of error rate.", "answer": 1}, {"article": "Beyond walking, weight lifting and other resistance training may improve bone mineral density in the lower back, and maintain bone density in the hips.\n\"Anything that makes bone bear weight is good for bone quality,\" said Dr. Kirkham Wood, head of orthopedic spine surgery at Massachusetts General Hospital.\n\"It's the cyclic loading and unloading of weight, not simple compression, that keeps bones strong,\" he added.\nWalking has not been shown to restore bone that is already lost to osteoporosis, but it can help preserve the bone density that a person has, said Dr. Carol Hartigan, a spine specialist at New England Baptist Hospital.\nIf a person simply stands, the muscles accommodate and do most of the work, he said - with no benefit to the bone.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does note that that fractures can occur as a result of weight lifting.\u00a0 But the focus of the column was on walking, and it didn\u2019t discuss the possibility of falling during walking and the importance of good footwear and a clear walking area.\u00a0 \nIt also concludes with the following statement: \u2018Not exercising also puts you at risk\u2019 \u00a0\u00a0This raises questions such as \u2013 at risk of what, and how great a chance is there of that happening, and to what extent it that chance diminished by exercising?\u00a0\n\u00a0", "answer": 0}, {"article": "All were enrolled in the CHARGE study (CHildhood Autism Risks from Genetics and Environment) from 2003 to 2009.\n\"It appears that women who reported taking prenatal vitamins starting three months prior to conception and through the first month after conception seem to have a reduced chance their child will develop autism ,\" says study researcher Irva Hertz-Picciotto, PhD, professor of epidemiology and environmental health at the MIND Institute and Department of Public Health, University of California, Davis.\nThe mothers with the high-risk form of MTHFR had a 4.5 times higher chance of a child developing autism, she says, than mothers without this high-risk form who did take the prenatal vitamins.\n\"Overall, it does look like there are at least a couple of genes here, either the mother's genotype or the child's genotype, that show this interaction ... magnifying the size of the effect from not taking the vitamins,\" Hertz-Picciotto says.\nOverall, Hertz-Picciotto says, \"For the women who didn't take prenatal vitamins, there was about a 60% higher risk of having a child with autism.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There\u00a0should have been some discussion of\u00a0the possible downsides of\u00a0getting too high a dose of certain vitamins, and that more is not necessarily better when it comes to supplements.\u00a0Especially now that many foods are fortified with folic acid, there is some concern about women receiving folic acid doses that could overwhelm the body\u2019s systems for metabolizing this vitamin, which\u00a0could lead to\u00a0unknown adverse effects on the fetus. Some women also report gastrointestinal problems, including nausea and constipation, when taking prenatal vitamins.", "answer": 0}, {"article": "MONDAY, Aug. 15, 2011 (HealthDay News) -- A traditional Chinese herbal treatment may reduce fever from H1N1 (\"swine flu\") influenza just as well as the prescription medication Tamiflu, a new study suggests.\nThe results: Both M-Y and Tamiflu were effective at eliminating fever, whether administered on their own or in combination.\nEven though the ephedra-containing herbal is not readily available in the United States, the M-Y herbal formula is available in many countries besides China, including Korea, Japan, India and Germany, the study authors noted.\nAll three approaches helped to resolve fever sooner than no intervention whatsoever, the authors said, noting it appeared that fever dissipated fastest when M-Y and Tamiflu were given together.\nOne group was given 75 milligrams of Tamiflu twice a day in capsule form; a second group received 200 milliliters of M-Y four times a day in liquid form; a third group took the same dosages of Tamiflu and M-Y together; and a fourth group received no treatment.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions adverse effects that have been associated with ephedra, one of the constituents of the herbal treatment being tested. It also says that minimal side effects were seen in all treatment groups of this\u00a0study. The story could have\u00a0commented on other possible side effects of herbals, such as potential\u00a0interactions with other medications.", "answer": 1}, {"article": "To contact Editor's Note author Mitchell H. Katz, M.D., email mediarelations@jamanetwork.org\nThe authors note a number of limitations in their study including that breast cancer was not the primary end point of the trial for which the women were recruited; the number of observed breast cancer cases was low; the authors do not have information on an individual basis on whether and when women in the trial underwent mammography; and the study cannot establish whether the observed beneficial effect was attributable mainly to the EVOO or to its consumption within the context of the Mediterranean diet.\n\"The results of the PREDIMED trial suggest a beneficial effect of a MeDiet [Mediterranean diet] supplemented with EVOO in the primary prevention of breast cancer.\nThe authors report that women eating a Mediterranean diet supplemented with EVOO showed a 68 percent (multivariable-adjusted hazard ratio of 0.32) relatively lower risk of malignant breast cancer than those allocated to the control diet.\nPlease see the article for additional information, including other authors, author contributions and affiliations, financial disclosures\n\nMedia Advisory: To contact study corresponding author Miguel A. Mart\u00ednez-Gonz\u00e1lez, M.D., email Jesus Diaz at jediaz@unav.es or call +34-636-355-333.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Consuming both nuts and olive oil have been shown in numerous studies to be a positive asset to the regular diet. \u00a0And yet these foods are very calorie-dense, and so one wonders if consuming so much of them could increase the risk for weight gain, which is in turn associated with breast cancer risk. But the release\u2019s lack of discussion on that point shouldn\u2019t be enough for a Not Satisfactory rating \u2014 we\u2019ll rule it Not Applicable.", "answer": 2}, {"article": "Infants who receive kangaroo care breast feed more easily, Lee says, and their mothers tend to breast feed for longer periods of time, which is \"all good.\"\nEven a little bit of kangaroo contact, he says, can be beneficial.\nBabies also seem to suffer less pain.\nAt Ronald Reagan UCLA Medical Center where Ali was born, the technique is routinely practiced for healthy mothers and newborns.\nIt is as it sounds: Like a kangaroo's pouch, mothers hold their naked newborns on their bare chest for the first few hours of life.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There aren\u2019t any obvious harms from this intervention.", "answer": 1}, {"article": "This increases the risk of diabetes.\n\"Our study showed that CPAP in patients with prediabetes can lower their risk of progressing to diabetes when CPAP is used for eight hours, a full night's sleep,\" said the study's lead author, Sushmita Pamidi, MD, a former fellow at the University of Chicago who is now on the faculty at McGill University in Montreal, Canada.\n\"Despite the demonstrated efficacy of lifestyle interventions and the availability of many drug treatments, the economic and public health burden of diabetes remains enormous,\" said Esra Tasali, MD, assistant professor of medicine at the University of Chicago and senior author of the study.\nUsing a simple device for eight hours a night to treat sleep apnea can help people with prediabetes improve their blood sugar levels and may reduce the risk of progressing to diabetes, according to a new study published online in the April 21, 2015, issue of the American Journal of Respiratory and Critical Care Medicine.\nThe most widely accepted treatment for sleep apnea is continuous positive airway pressure (CPAP), a device that blows a constant pressure of air into the lungs through a tube and face mask during the night.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "While the release does not mention any harms associated with CPAP, that is likely because there are no significant health risks associated with the use of CPAP devices. However, it would have been worth noting that CPAP devices can often cause significant discomfort for users (and their bedmates), particularly at first. Getting CPAP to work can also require a lot of tinkering with the device.", "answer": 1}, {"article": "Awair is the first smart air quality device that monitors, analyzes and provides feedback to improve the air you breathe.\nDry air can also exacerbate some illnesses and can be a problem as well.\u201d\n\nDifferent sources of air pollution in your home could include paints that release lead or volatile organic compounds (VOCs), carpets that harbor dirt, dust mites, and fungus and even nitrogen dioxide from gas stoves, but these aren\u2019t the worst culprits, Lahita said.\nIt analyzes the data in real-time and gives an Awair score on a 0 to 100 color-coded scale, 0 being the worst air quality.\nEvery room in your house could be susceptive to some form of an air pollutant, but now there is a new device and app that says it can help you breathe easier by tracking air quality.\nAs soon as you see other colored (amber and red) dots show up on top of the green dots, your environment is getting off the healthy ranges whether it being temperature, humidity, CO2, VOCs, and dust,\u201d Ronald Ro, the CEO and co-founder of Bitfinder Inc., the makers of Awair, told FoxNews.com.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The concern here is that the story discusses a series of potential circumstances, many of which are either unlikely to harm human health or would only be potentially harmful to some people. For example, dry air is not a health concern for many people. This creates a potential \u201coverdiagnosis\u201d problem. In other words, using a product like Awair could potentially lead people to be concerned about circumstances that don\u2019t actually threaten their health. This may result in unnecessary worry, stress or anxiety, or in causing people to spend money on treatments or technologies \u2014 such as humidifiers or air filtration system \u2014 that they don\u2019t need. To be clear, there is a very real market for technologies like humidifiers and air filtration systems, but not everyone needs them. The story doesn\u2019t address these issues at all. Also, potential harm could come from false positives in the tracking device, but that isn\u2019t addressed, either.", "answer": 0}, {"article": "For more information about our products and the organization, visit http://www.\nJanuary 30, 2018 - For older women undergoing mastectomy for breast cancer, direct-to-implant (DTI) breast reconstruction provides good outcomes in a single-step procedure, while avoiding some of the inconvenience and risks of staged approaches to breast reconstruction, reports a study in the February issue of Plastic and Reconstructive Surgery\u00ae, the official medical journal of the American Society of Plastic Surgeons (ASPS).\n\"The DTI approach is a powerful tool for breast reconstruction in elderly patients,\" comments ASPS Member Surgeon Andrea Moreira, MD, of the Cleveland Clinic.\nThe authors note some important limitations of their study--particularly the fact that it was a review study of one hospital's experience with a relatively new procedure.\nThe official journal of the American Society of Plastic Surgeons, Plastic and Reconstructive Surgery\u00ae brings subscribers up-to-the-minute reports on the latest techniques and follow-up for all areas of plastic and reconstructive surgery, including breast reconstruction, experimental studies, maxillofacial reconstruction, hand and microsurgery, burn repair and cosmetic surgery, as well as news on medico-legal issues.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "In framing this emerging technique as \u201csafe and effective,\u201d as well as highlighting complication rates that are no different from the standard approach, this news release may be minimizing the very real complication rates. The release states, \u201cComplication rates were similar between groups, including blood and fluid collections (hematoma and seroma), infection, unplanned surgery, and failed reconstruction.\u201d\nThe rates may not have been any different between the groups but that does not mean harms can be dismissed. It\u2019s not hard to find disquieting statistics on the rate of complications after mastectomy with reconstruction, for instance this study showing a 10.3% overall complication rate after mastectomy with implant \u2014 and 6% of implants being removed within 60 days.\nThe published study mentioned previous research had found greater complication rates with the direct-to-implant approach. These contradictory findings are not mentioned in the news release.", "answer": 0}, {"article": "\"\nIt can be hard to view those everyday decisions in light of more distant consequences, like having another heart attack or not living as long a life as desired.\nMuch of the buzz over mobile health interventions seems to be about how we can use an ever-growing variety of shiny new smartphone apps and sensors to better manage our health.\nFor example, vegetarian participants wouldn't receive the text message about how grilling steak is healthier than deep-frying it.\n\"I like to look for things that are able to be used in multiple corners of our world, from low-income settings to high-income settings,\" Chow says.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "As long as people aren\u2019t driving and checking their cell phones, there don\u2019t appear to be any harms associated with receiving well-meaning text messages four times a week, so we\u2019ll mark this one \u201cnot applicable.\u201d", "answer": 2}, {"article": "Zee and her fellow researchers had 13 adults ages 60 and older spend two nights in a sleep lab.\nA small new study published in suggests that one easy way for older adults to get deeper sleep and stronger memories is to listen to a certain soothing sound called \u201cpink noise\u201d\u2014a mix of high and low frequencies that sounds more balanced and natural than its better-known cousin, \u201cwhite noise.\u201d\n\nIt may sound strange, but previous studies have found that playing so-called pink noise during sleep improves the memory of younger adults.\n\u201cThat\u2019s very much tied to what part of the slow wave the stimulus is hitting on.\u201d\n\nThat doesn\u2019t mean there aren\u2019t benefits to other soothing background sounds.\n\u201cIt\u2019s just noticeable enough that the brain realizes it\u2019s there, but not enough to disturb sleep.\u201d The sounds were timed to match their slow-wave oscillations.\n\u201cWe wanted to see if it would work in older people, too,\u201d says senior author Dr. Phyllis Zee, professor of neurology at Northwestern University Feinberg School of Medicine.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article does not mention harms at all. There may be no real harm to hearing these sounds as one sleeps, but we\u2019d like to see that question addressed.", "answer": 0}, {"article": "Drs.\nThis is a very relevant finding, as over 200,000 patients still receive whole brain radiation in the United States each year, and the majority of patients with brain metastases have a limited number (typically three or less) of brain lesions.\nHowever, the data from our study shows that clinicians can no longer simply rely on the results of traditional lab tests or scans to assess the value of care; we have to understand the total impact of cancer therapies on our patients.\"\n\"We discovered that whole brain radiation added to focused radiation in the treatment of brain metastases \u2013 in other words, cancer that travels to the brain- reduces the number of new brain tumors over time; however, patients receiving the whole brain radiation had significantly more difficulties with memory and complex thinking than patients who only had the focused radiation,\" says Dr. Asher.\nThe study, released on July 26, 2016, shows that patients with the most common form of brain tumor can be treated in an effective and substantially less toxic way by omitting a widely used portion of radiation therapy.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The main point of the release, emphasized in several statements, is that whole brain radiation is more toxic to the brain than focused (or stereotactic radiation) without improving survival outcomes. So, while one might expect that the more targeted approach might cause harm by \u201cmissing\u201d some of the cancer, the story does a good job of pointing out the\u00a0LACK of additional harm by targeting the tumor rather than irradiating the entire brain.", "answer": 1}, {"article": "Blood tests determined blood selenium, good cholesterol and bad cholesterol levels at the start of the study.\n\"There are various reasons for that, including the fact that in the U.S. you have a wheat belt that means there is quite a high amount of selenium in the bread staple, which is not the case in the U.K.\"\n\n\"So, we can't extrapolate our findings to the U.S.,\" Rayman said.\n\"The issue is that there have been an awful lot of studies, about eight, that have looked at blood cholesterol, both good and bad, and have found an association with high blood selenium,\" said study author Margaret P. Rayman, a professor of nutritional medicine at the University of Surrey in Guildford, England.\n\"Overall, the evidence is inadequate to establish a protective role of selenium in cardiovascular disease or to recommend selenium supplementation to improve cardiovascular health,\" he said.\nNoting that blood selenium levels were relatively low across the board at the study's launch, the authors found that selenium levels did rise as a result of supplementation, while those taking selenium also experienced a slight drop in both bad cholesterol (LDL) and overall cholesterol levels.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The\u00a0story was a little confusing\u00a0on this point. It initially says that\u00a0selenium\u2019s\u00a0safety \u201chas not been studied,\u201d but later quotes a researcher who says there is an increased risk for type 2 diabetes with selenium supplements in individuals whose\u00a0blood levels are already high. The story does note that there were no serious side effects in the selenium supplement users participating in this study, but it\u00a0could have qualified this by mentioning the relatively short duration of the study (6 months) and the potential for problems with longer-term use.\u00a0Too much\u00a0selenium can also, in rare cases, result in condition called selenosis, which\u00a0includes symptoms such as\u00a0gastrointestinal upsets, hair loss, white blotchy nails, garlic breath odor, fatigue, irritability, and mild nerve damage.\nA toss-up here, but since the story indicated that this was not a risk-free intervention and reported on the study findings as appropriate, we\u2019ll rule it satisfactory.", "answer": 1}, {"article": "This year we are doing probably 30.\"\nIn addition, there's no nutrient malabsorption as there is with the bypass, because the small intestine is left intact; banding patients do not have to take nutrient supplements for the rest of their lives, the way bypass patients do.\nIn contrast to the bypass, the band does its work by separating the stomach into two parts: a tiny upper pouch and a larger pouch below the band.\nThus, when food empties from the stomach, it bypasses a few feet of upper intestine, which means that fewer nutrients (including fewer calories) are absorbed by the body.\nAnother difference between the band and the bypass that proves both a plus and a minus is that the band doesn't cause the dumping syndrome.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did mention the gastric banding following gastric bypass could be complicated by adhesion of organs to one another resulting from scarring from the first surgery. \u00a0And while mentioning that this might result in a longer time needed for the surgery, there was no discussion about what ramifications there might be for the patient or how often this scenario was encountered. \u00a0There was no discussion of other complication rates. ", "answer": 0}, {"article": "The Food and Drug Administration approved a device on Tuesday meant to treat cluster headaches \u2014 a rare form of headache that affects mostly men.\nThe company, which says gammaCore is already available in the European Union, expects to start selling it later this year in the U.S.\n\nVagus nerve stimulation is used to treat a range if disorders, including epilepsy, depression and overeating.\n\"The FDA release of gammaCore is an important advance in the treatment of the pain associated with cluster headache,\u201d Silberstein said in the statement provided by the company.\nThe device is a vagus nerve stimulator and it\u2019s not entirely clear how it works.\nFewer than 1 percent of people have cluster headaches and most have a form called episodic cluster headaches, which come and go, as the name suggests, in clusters.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The side effects were considered to be temporary and relatively minor, but should have been mentioned.\nDr. Silberstein noted, \u201cIt does not have the side effects or dose limitations of commonly prescribed treatments\u2026\u201d \u00a0This is perhaps true but a closer examination of the research results reveals that 11 percent of the participants treated with the gammaCore device saw lip or facial dropping/pulling or twitching during the sham controlled trial and 7 percent experienced these side effects during the open label part of the trial (when both the researchers and volunteers knew which treatment was being administered). ", "answer": 0}, {"article": "But this could take a few years to develop.\n\"This is the earliest phase, and you now have to show that it actually breaks down the gluten peptides that trigger a response in the stomach at a speed that will protect the human,\" said Dr. Joseph Murray, a professor of medicine in the division of gastroenterology and the department of immunology at the Mayo Clinic, in Rochester, Minn. \"Let's see how it goes with a whole slice of bread.\"\nFRIDAY, Feb. 8, 2013 (HealthDay News) -- For people with celiac disease, everyday foods such as bread, pizza crust and muffins are potential enemies.\n\"For those who are hypersensitive, this probably is not going to solve the problem, but it would allow them to go to dinner, and in case any gluten ended up in their meal, they wouldn't have to worry about it.\"\n\"It will probably be helpful to someone who gets a low-level exposure [to glutens] by accident,\" he said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story addresses harm, but in an unsatisfactory way, when it quotes a study author who says, \u201cIt shouldn\u2019t be toxic; it\u2019s just a protein you\u2019re eating.\u201d In fact, proteins can be plenty toxic, and until this new compound is tested in humans, we can\u2019t be certain of what its effects might be.\nAnd even if it\u2019s not directly toxic,\u00a0such a treatment might\u00a0give patients permission to indulge and overdo it with respect to gluten, a compensating behavior that might cancel out any benefit from neutralizing small amounts of dietary gluten.", "answer": 0}, {"article": "\"By wearing the brace, I could get back to sports and was able to call my physician and say 'why didn't we try this first?'\"\nAll study participants led active lifestyles before they got sidelined by knee OA, and said they hoped to return to their previous level of activities.\nThe brace used in the study was provided by Ossur, which also provided financial support to the study through a research grant and sponsored the media briefing.\nNew research presented at a media briefing Tuesday in New York City suggests that Peterson is not the only one to find relief from knee bracing.\n\"It absolutely gave me almost immediate relief,\" he says.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0There was no discussion of potential harms that might be associated with the use of the devices reported on. \u00a0Are there any short term or potentially longer term implications resulting from the use of a knee brace?", "answer": 0}, {"article": "\"To address inconsistencies in prior studies on vitamin D and to investigate associations in population subgroups, we analyzed participant-level data, collected before colorectal cancer diagnosis, from 17 prospective cohorts and used standardized criteria across the studies,\" said Stephanie Smith-Warner, PhD, an epidemiologist at the Harvard T.H.\nThe analysis included over 5,700 colorectal cancer cases and 7,100 controls from the United States, Europe, and Asia.\nColorectal cancer is the third most common cancer and third leading cause of cancer-related deaths in both men and women in the United States, with about 140,250 new cases and 50,630 deaths expected during 2018.\nThe few randomized clinical trials of vitamin D supplementation and colorectal cancer completed thus far have not shown an effect; but study size, supplementation duration, and compliance may have contributed to their null findings.\n\"This study adds new information that agencies can use when reviewing evidence for vitamin D guidance and suggests that the concentrations recommended for bone health may be lower than would be optimal for colorectal cancer prevention.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release indicates that vitamin D should ideally be obtained from the diet, and that there are no known harms to eating foods with vitamin D (an exception being when a mishap caused over-fortification of a local milk supply a few decades ago). Skin cancer risk associated with sun exposure was covered appropriately.", "answer": 1}, {"article": "\"There is a growing sense that VE [vasogenic edema] or ARIA [amyloid-related imaging abnormalities] is a manageable side effect and may actually be a sign that the drug is clearing amyloid from the brain and the blood vessels,\" said Salloway.\nThe other study, which involved looking at more than 2,000 MRI scans from 262 patients, found 36 cases of amyloid-related imaging abnormalities (ARIA) may have been linked to the bapineuzumab.\nBut only 8 of those 36 cases involved symptoms, and they were more likely to be found in patients with APOE-e4 who were taking higher doses of the drug.\nAlthough bapineuzumab has shown promise in certain Alzheimer's patients, other research found that patients taking a higher dose of the drug had an increased risk of brain inflammation from water retention.\n\"I think it is too early to tell from the data from this small Phase 2 safety trial,\" said Ian Murray, an assistant professor of neuroscience and experimental therapeutics at Texas A&M Health Science Center College of Medicine in College Station.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story indicated that some patients taking the higher does of the drug experienced\u00a0headache, memory loss, hallucinations, reduced coordination or other symptoms. \u00a0From the information in the story, it appeared that 8% (21/262) of patients participating in a second study using the lower dose of the medication had some anomalies on MRI scan but no reported symptoms.", "answer": 1}, {"article": "Our research shows for the first time that mefenamic acid, a simple [NSAID] can target an important inflammatory pathway called the NLRP3 inflammasome, which damages brain cells,\u201d David Brough, lead author of the study said, in a statement.\nBut, they also warned that these \u201cdrugs are not without side effects and should not be taken for Alzheimer\u2019s disease at this stage - studies in people are needed first.\u201d\n\nThe research was published in the journal Nature Communications on Thursday.\nBecause this drug is already available and the toxicity and pharmacokinetics of the drug is known, the time for it to reach patients should, in theory, be shorter than if we were developing completely new drugs,\u201d Brough said.\nFirst group was given mefenamic acid dose and the other group was given placebo for one month through a mini-pump implanted under the skin.\nResearchers observed that memory loss was fully reversed to the levels seen in mice without Alzheimer\u2019s.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "While the story does\u00a0allude to\u00a0harms, there are two problems. First, we are troubled that the explanation\u00a0was actually taken directly from the news release about the study. Second, we feel that it was too vague and not explored in any meaningful way. The story says only,\u00a0\u201cthey also warned that these \u2018drugs are not without side effects and should not be taken for Alzheimer\u2019s disease at this stage\u2013studies in people are needed first.'\u201d What are the side effects? We\u2019re not told.", "answer": 0}, {"article": "\u201cThis study also has an important message for schools and the need to provide students with the opportunity to consume more fruits and vegetables as part of the school meal program.\u201d\n\nFarvid wasn\u2019t able to document a strong relationship between vegetables and lower breast cancer risk, but says that may be because the study wasn\u2019t powered enough to detect an effect.\nThe added risk of cancer, however, was counterbalanced by a lower risk of heart disease.\nThe findings are among the first to look at how diet during adolescence can affect health later, and highlights the importance of establishing healthy habits from a young age, especially since many of the chronic diseases occur over many years and get rooted early in life.\nMORE: With Early Breast Cancer Treatment, Less May be More: Studies\n\nCertain fruits seemed to confer the biggest protection against breast cancer \u2014 apples, bananas and grapes were associated with the greatest reduction in risk while kale and oranges in adulthood also contributed to reduced breast cancer risk.\nIn the study, Farvid and her team could not find any significant relationship between fruit juice and breast cancer risk; that may be because fruit\u2019s anti-cancer effects may have to do with the fiber found in the whole fruit, which is stripped out of juice.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There are no significant risks with eating three servings of fruit per day during adolescence, so we\u2019ll rate this not applicable.", "answer": 2}, {"article": "Both drugs have been used for impulsive conditions, including ADHD.\nOffering the full portfolio of business education courses, from undergraduate through to MBAs, and with a strong Doctoral Programme, WBS is the complete business school.\n\"It has been shown to reduce impulsiveness in a variety of disorders such as alcohol dependence, schizophrenia and ADHD.\nThere are many factors that cause obesity but there is a growing weight of evidence that shows obesity is not just caused by a behavioural disorder, such as a lack of self-control, but that many overweight people are physically addicted to foods rich in fat and sugar.\nFood addicts suffer from the same neurobiological conditions so we believe it will help food addicts as well and our initial tests have backed up that theory.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Nowhere in the release is there any mention of possible harms from taking Modafinil, although a brief web search suggest there are numerous potential side effects associated with the drug including anxiety, backache, sleeping problems and potential heart complications.", "answer": 0}, {"article": "Where did this Ron DeSantis come from? Florida\u0092s governor surprises everyone but himself.\n\nA month into his term, Gov. Ron DeSantis has shattered assumptions that he would govern exclusively from the right. He has drawn unexpected praise from Republicans and Democrats.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "While mentioning that one child with cirrhosis was able to reduce the number of medications he needed from 11 to 4, the story did not provide any information about side-effects and potential harms associated with liver transplantation. \u00a0In addition, the story indicated that this child had failed to lose weight after the transplant, though it failed to discuss that the high dose of steroids after transplant needed to avoid organ rejection likely contributed to this situation. \u00a0Lastly, as liver transplant just replaces the diseased liver but doesn\u2019t change the underlying circumstance that lead to the condition \u2013 the story should have discussed the potential future need for organ replacement.", "answer": 0}, {"article": "Might insulin, a drug used for diabetes, help?\n3 (in press)\u201d and search for \u201cinsulin.\u201d\n\nLEARN MORE ABOUT dementia at ninds.nih.gov/disorders and www.familydoctor.org.\nAlso, among those in the 40-milligram group, people carrying what is sometimes called the Alzheimer\u2019s gene (APOE-e4) showed more improvement than non-carriers.\nMemory loss is often the first sign of dementia, which in later stages can interfere with such things as the ability to solve problems, control emotions or do such daily tasks as eating and dressing.\nStandardized tests given at the start and end of the study showed that working memory, sometimes thought of as short-term memory, improved for those given 40 milligrams of insulin but not for those given the smaller dose or the placebo.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story gets credit here for pointing out, as part of the explanation of the study\u2019s limitations, that a longer and larger study would be necessary to determine whether the drug is safe as a treatment for Alzheimer\u2019s. The competing Fox News story simply took the lead researcher\u2019s word for it that there were no harmful side effects.\nThat improvement aside, the story still had a responsibility to report on the harms that were documented in the study, which included dizziness and congestion. The story didn\u2019t do that, which is why we\u2019re rating it unsatisfactory here.", "answer": 0}, {"article": "March 7, 2011 -- Traditional Chinese acupuncture may be useful in reducing the severity of hot flashes and other symptoms of menopause, a new study suggests.\nHalf of them received traditional acupuncture treatment.\nLevels of estrogen and other hormones were measured before the study and after the first and last acupuncture sessions in both those receiving real and sham treatments.\nThose in the comparison group were treated with shams needles at the same acupuncture points.\nThe rest were treated with \u201csham\u201d acupuncture needles that were blunted and did not penetrate the skin.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No discussion of potential harms \u2013 only of benefits.", "answer": 0}, {"article": "In five weeks of trying the diet, Pelsser says, parents will know if their child is responding or not; if not, they can move on to other treatments.\nIn the study, published in The Lancet, 78% of children who stuck with the diet did respond by having fewer symptoms.\nThe diet studied, known as the restricted elimination diet (RED), can work, the researchers say, because they believe ADHD symptoms in some children might be affected by eating specific foods.\nU.S. experts had some caveats, saying that the results of the study, which included 100 children, should be repeated in other populations to see if the findings hold up.\n''I am of the opinion that every child deserves this diagnostic intervention,\" researcher Lidy Pelsser, PhD, of the ADHD Research Centre in Eindhoven, the Netherlands, tells WebMD.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story didn\u2019t mention that there were no adverse effects found from the study. We think that was worth mentioning given some of the understandable concerns raised by putting young children on any sort of restrictive diet. We do appreciate, too, that this story at least mentioned in passing concerns about malnutrition.", "answer": 0}, {"article": "All of these study participants \u2014 largely people in their 70s, all with a diagnosis of either \"mild cognitive impairment\" or atypical dementia \u2014 are living with the unconfirmed suspicion that they have Alzheimer's. The study is underwritten by the Centers for Medicare & Medicaid Services and the Alzheimer's Assn. It set out to find out whether knowing \u2014 getting the costly test that would offer either confirmation or reprieve \u2014 would change the way that patients with cognitive troubles are treated, or the way that they plan their lives.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story discusses the frustration of having a diagnosis with no known treatments. However, when it comes to the intervention specifically\u2013the PET scan\u2013there are the risks of false-positives and false-negatives. As in, what\u2019s the risk someone is diagnosed when they don\u2019t have the disease, or they\u2019re not diagnosed when they do indeed have the disease? Every screening test has these risks\u2013it\u2019s important to know how likely they are.\nAnd, PET scans themselves expose people to radiation and can cause allergic reactions to the tracer.", "answer": 0}, {"article": "\"It's kind of an extreme makeover of a cell,\" said Douglas A. Melton, co-director of the Harvard Stem Cell Institute, who led the research.\nThe work was hailed as a welcome development even by critics of research involving embryonic stem cells, which can be coaxed to become any tissue in the body but are highly controversial because they are obtained by destroying embryos.\nThe experiments, detailed online yesterday in the journal Nature, raise the prospect that patients suffering from not only diabetes but also heart disease, strokes and many other ailments could eventually have some of their cells reprogrammed to cure their afflictions without the need for drugs, transplants or other therapies.\n\"The goal is to create cells that are missing or defective in people.\n\"But these things always look easier on the blackboard than when you have to do them in actual patients.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion of possible harms that might be associated with gene therapy even though there have been human deaths resulting from the use of viral vectors to alter gene expression.", "answer": 0}, {"article": "\u201cWe have to be mindful of the placebo effect, and we have to take [the findings] with a grain of salt,\u201d Matthew Sullivan, an associate professor of microbiology at The Ohio State University, said in the release.\nThe study, which was published in the journal Microbiome, included 18 children with autism and moderate to severe gastrointestinal problems.\nThe Ohio State University, Northern Arizona University and Arizona State University researchers found a parallel between behavioral symptoms of autism and gastrointestinal distress, and improvements to both after fecal transplant.\n\u201cTransplants are working for people with other gastrointestinal problems,\u201d lead study author Ann Gregory, a microbiology graduate student at The Ohio state University, said in a news release.\nThe children ranged from 7 to 16 years old.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There are risks to introducing a donor\u2019s stool into a recipient. No mention of risk was included. A donor could have undetected disease or infection before donating.", "answer": 0}, {"article": "As author, Dr Antonello Bonci (Scientific Director, National Institute on Drug Abuse, and Adjunct Professor, John Hopkins University, Baltimore) said:\n\n\"Despite the fact that more than 20 million people worldwide suffer from cocaine use disorders2, there are no effective neurobiological treatments for patients with this devastating condition\".\nTargeted magnetic pulses to the brain were shown to reduce craving and substance use in cocaine-addicted patients.\nThe practical work was conducted by team of scientists led by Dr Luigi Gallimberti, from the University of Padova Medical School, Italy, who enrolled 32 patients who were seeking treatment for cocaine addiction at the hospital clinic.\nIt is also important to emphasize that, in this study patients were seeking treatment for their cocaine addiction in a hospital setting: the group studied, albeit small, was a \"real world\" sample.\nImportantly, we had found that increasing the activity in the prelimbic cortex could significantly reduce cocaine self-administration\".\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release states that the magnetic stimulation treatment is safe and non-invasive and is already in use to treat patients with depression and neuropathic pain.", "answer": 1}, {"article": "NEW YORK (Reuters Health) - A less common form of obesity surgery may spur more weight loss than its far more popular cousin, gastric bypass \u2014 but at the price of greater long-term risks, researchers reported Tuesday.\nThe technique is often reserved for \u201csuperobese\u201d patients with a body mass index (BMI) of 50 or higher \u2014 though some surgeons perform it with less severely obese patients too, explained Dr. Torgeir T. Sovik of Oslo University in Norway, the lead researcher on the new study.\nThe study involved 850 U.S. veterans who underwent some form of weight-loss surgery, at an average age of about 50, and more than 41,000 vets who had only non-surgical care.\nIn a 2008 study, it accounted for just 1 percent of weight-loss, or bariatric, surgeries done in the U.S., and 5 percent in Europe.\nHe pointed out, though, that larger, longer-term studies are still needed to show whether the extra weight loss with duodenal switch ultimately improves severely obese patients\u2019 health and extends their lives.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story shines in its details about the delicate weighing of risk vs. benefits for weight-loss surgery in general, and then for the duodenal vs. gastric bypass method in particular. Some readers might find it confusing that the story includes two separate publications about weight-loss surgery. The story leads with the small study comparing duodenal with gastric bypass, published in the Annals of Internal Medicine, but then delves into a larger Veterans Administration study from the Journal of the American Medical Association that looked at the longer-term results of all surgeries for obesity. We salute Reuters for providing the context and the controversy within medical practice, and quoting a principal investigator on the VA study, Edward Livingstone, who wrote an editorial that appeared in the Annals beside the duodenal paper.", "answer": 1}, {"article": "What if doctors had a pill that prevents breast cancer and nobody wanted to take it? That has pretty much been the situation with tamoxifen, an estrogen-like drug that was proved in 1998 to cut in half the chance of developing breast cancer if taken for five years by women with increased risk of the malignancy. The trouble is, tamoxifen also triggers menopausal symptoms like hot flashes and slightly increases the chances that a woman will develop blood clots and uterine cancer. As a result, women haven't been too eager to take the medication--nor have many doctors been all that enthusiastic...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Mentions harms of hormone therapy, such as an increased risk of blood clots and uterine cancers. Notes that there were \u201cfewer side effects\u201d (i.e. blood clots and uterine cancers) in the raloxifene group, but does not mention that the difference in side effects was not statistically significant for uterine cancer and blood clots. This information was not readily available on the National Cancer Institute (NCI) website or in reports of the study, but we give this a \u201csatisfactory\u201d score because the story presents caveats on the drugs. Mentions reduction in the risk of cataracts with raloxifene, which was statistically significant. Does mention that raloxifene, like tamoxifen, has bothersome side effects such as hot flashes and vaginal discharge, which are reported as comparable and mild to moderate in the NCI press release of the initial results of this trial. ", "answer": 1}, {"article": "U.S.News & World Report consistently names Cleveland Clinic as one of the nation's best hospitals in its annual \"America's Best Hospitals\" survey.\nThe findings, published in the Journal of Nutrition today, suggest that whole grains can be a key regulator of blood pressure, and could provide an effective nutritional strategy to reduce cardiovascular-related deaths and disorders.\nIn the study, a group of 33 overweight and obese adults followed a whole grain diet (intervention) or a refined grain diet (control) for two eight-week periods.\nOverall, there were substantial reductions in body weight, fat loss, systolic blood pressure, total cholesterol, and LDL cholesterol during both diet periods, but these differences were due to the people changing their normal dietary habits to carefully controlled diets.\nWednesday, Oct. 19, 2016, Cleveland: A team of Cleveland Clinic researchers, in collaboration with Nestl\u00e9 Research Center, conducted one of the largest controlled studies of its kind on whole grains and concluded that a diet rich in whole grains may significantly lower the risk of cardiovascular disease in overweight and obese adults under the age of 50.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention in the release of any harms arising from a diet rich in whole grains but we won\u2019t fault them from that. The benefits of whole grain foods have been well documented.\nProviding more detail on what the diets contained would have been helpful to readers.", "answer": 2}, {"article": "Drug list (formulary): To see a list of covered drugs for the plan you\u2019re considering, use the drop-down menus below.\n\nIf your employer is offering coverage, contact HR for the pharmacy plan name.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Does not mention the increase in \ncholesterol and cardiovascular disease among the women in the aromatase inhibitor group. Tamoxifen may have a positive, \ncholesterol-lowering effect, which is also not mentioned. ", "answer": 0}, {"article": "\"Although these initial findings are encouraging, we need to confirm the results in a larger trial,\" Houston said.\nThe study included the participants' history of falls and their fear of falling, blood tests at the beginning and at end of the trial to measure 25-hydroxyvitamin D (biomarker for vitamin D in blood), and a monthly diary recording falls during the trial period.\nAt the beginning of this pilot study, the research team found that more than half of the participants had insufficient concentrations of vitamin D in the blood (less than 20 ng/ml), while less than a quarter had concentrations in the optimal range (30 ng/ml or more).\n\"Falls in homebound older people often lead to disability and placement in a nursing home,\" said Denise Houston, Ph.D., R.D., associate professor of gerontology and geriatric medicine at Wake Forest Baptist and lead author of the study.\nWINSTON-SALEM, N.C. - Aug. 17, 2015 - Every year falls affect approximately one in three older adults living at home, with approximately one in 10 falls resulting in serious injury.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release makes no mention of possible harms caused by Vitamin D supplements, though the\u00a0FDA website cites a laundry list of concerns that it attributes to the American Association of Family Physicians: Nausea, vomiting, poor appetite, constipation, weakness, weight loss, confusion, heart rhythm problems, deposits of calcium and phosphate in soft tissues.", "answer": 0}, {"article": "Why are so few women being treated?\n\u201cThe management of menopause has been relatively similar in the UK, the USA and in Australia.\u201d\n\nUp to half of women in menopause experience so-called vasomotor symptoms, such as hot flashes and night sweats.\n\u201cWomen and doctors simply are not aware that symptoms can last this long.\u201d\n\nFinally, many women don\u2019t realize that non hormonal options can be safe and effective, she added.\nBut after the initial findings of the Women\u2019s Health Initiative study showed that HRT can increase the risk of breast cancer, stroke and other serious problems, many women stopped using it.\nThe women who did use hormones were mostly taking pills containing estrogen, rather than preparations that are absorbed into the skin and that are potentially safer, the researchers found.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story states several times that alternative therapies for menopausal symptoms, including vaginally applied estrogen, are safe. But elsewhere it acknowledges that pill-based treatment with hormones is associated with increased cancer risk. It would have been reassuring to provide some evidence backing up the claim that these alternative treatments are, in fact, safe \u2014 since that seems to be a key reason why women are reluctant to use these therapies. And certainly some of the nonhormonal options for hot flashes (e.g. antidepressant medication) carry a risk for side effects that could have been mentioned.", "answer": 0}, {"article": "NEW YORK (Reuters Health) - The inexpensive tests that look for hidden blood in a person\u2019s stool are effective for colon cancer screening, a study out Tuesday confirms.\nOf three study participants who were found to have cancers of the stomach or esophagus, for instance, none had a positive result on the iFOBT test.\nThe findings, reported in the Canadian Medical Association Journal, give some extra weight to fecal occult blood testing (FOBT) as a valid option for early detection of colon cancer.\nThe average American has a one in 200 chance of developing esophageal cancer, while the risk of stomach cancer is one in 114.\nThe downside of iFOBT being specific to colon tumors is that it is not useful for catching cancers of the stomach or throat.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Unlike many stories on screening tests, this one included information on false positive findings and the need for further testing. Story was careful to include the fact that in the study 10% of all participants had a false-positive finding on the stool test.", "answer": 1}, {"article": "The rats experienced overall improvement in contractile proteins and heart function too.\"\nIn the study entitled \"Long-term physiological T3 supplementation in hypertensive heart disease in rats,\" aging female rats with hypertension progressing to heart failure were treated for one year (half their lifetime) with a low oral dose of the active form of thyroid hormone, T3.\n\"What we have tried to do here is show the effect of safe doses of thyroid hormones and we're seeing amazing results in multiple studies, with dramatic improvements in heart function, gene expression, and collagen levels, just by restoring depressed thyroid levels in the heart,\" said Gerdes.\n\"This low dose of thyroid hormone safely restored depressed cardiac tissue T3 levels to normal while largely preventing the accumulation of collagen, or scar tissue, resulting from sustained high blood pressure,\" said Gerdes.\nThyroid hormones administered to female rats with high blood pressure led to encouraging cardiac improvements, according to a study in the American Journal of Physiology led by NYIT College of Osteopathic Medicine researcher Martin Gerdes.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not adequately discuss potential harms. Thyroid hormone treatment for other conditions, such as hypothyroidism, has been around for years. And, in those cases, it\u2019s known that such treatment can cause side effects such as heart palpitations and insomnia. But there are other risks as well, which the release itself points out in a very roundabout way. The release says that the study\u2019s lead author \u201chas long argued that medical opinion on thyroid treatment for patients with heart disease is largely shaped by outdated studies that used toxic doses of thyroid hormones.\u201d This sentence manages to highlight that there can be significant risks associated with the use of thyroid hormones (the \u201ctoxic doses\u201d reference), but it isn\u2019t clear what these risks are, and it\u2019s not made clear that there may be risks (even lesser risks) associated with the undefined \u201clow-dose\u201d applications of thyroid hormone used in this study.", "answer": 0}, {"article": "The study had several limitations.\n\u201cUnless low-dose aspirin is taken continuously, there is little protection against colorectal cancer,\u201d Dr. Soren Friis from the Danish Cancer Society Research Center in Copenhagen told Reuters Health.\nAn online risk calculator from the Centers for Disease Control and Prevention (available here: 1.usa.gov/1DlscTL) indicates that in the U.S., for an average white or black woman in her late fifties, the 10-year risk of developing colorectal cancer is between 1 and 1.4 percent, and her lifetime risk is between 5 and 5.4 percent.\nNonaspirin NSAIDs were also protective against colorectal cancer with consistent long-term use, \u201cand there was some indication that even non-continuous use of these agents may be (marginally) effective for the prevention of colorectal cancer,\u201d Dr. Friis said.\n\u201cThe public should not take any medication regularly without consulting with a physician.\u201d\n\nDr. Gurpreet Singh Ranger from Upper River Valley Hospital, Waterville, New Brunswick and Dalhousie Medical School, in Halifax, Nova Scotia, Canada, agreed with Dr. Friis.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story is straightforward in saying that all NSAIDs carry risks.\n\u201cLong-term use can cause gastrointestinal bleeding, for example, so the potential reduction in colon cancer risk needs to be balanced against potential side effects, the authors warn.\u201d\nIt would have been easy to also mention cerebral vascular bleeds, but that\u2019s a minor point.", "answer": 1}, {"article": "That study enrolled just 62 people, but the results were significant enough for NIH to fund new research _ at Pennsylvania, the University of Texas in Houston, Boston University and other sites _ enrolling about 650 cocaine users to see if modafinil really does work.\nThe main side effect so far: insomnia, not surprising as modafinil is sold today to help narcolepsy patients fend off that neurologic disease's sudden sleep attacks.\nIn addition to blunting cocaine's notorious cravings, modafinil might also counter the damage that cocaine wreaks on users' brain circuits _ damage that in turn fuels the cycle of addiction.\nThe prospect of that double-whammy has the National Institutes of Health spending $10.8 million researching modafinil as a potential cocaine treatment.\nBut for Dr. Nora Volkow, director of NIH's National Institute on Drug Abuse, the narcolepsy medicine tops the list of promising potential therapies.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story doesn\u2019t mention the incidence of side effects in the pilot study or from other trials. Insomnia is mentioned in the story, but we\u2019re not told how common this is in people who take the drug for withdrawal symptoms of cocaine dependence. Side effects were twice as common in the treatment group in the pilot study and included nausea, anxiety, tachycardia, loss of appetite and urinary tract infection. ", "answer": 0}, {"article": "Researchers say that rate of tumor control is more than double that found with conventional radiation treatment for inoperable lung cancer.\nThe next step is a clinical trial to evaluate the therapy in a larger number of patients and determine the proper dosage for maximum benefit and minimal risk.\nResearchers say surgical removal of tumors is the standard treatment for early-stage lung cancer, but some people are not candidates for surgery due to other coexisting illnesses such as emphysema and heart disease.\nSBRT is a noninvasive type of cancer treatment in which many small, highly focused radiation beams are used to deliver concentrated doses of radiation to tumor targets over a series of one to five treatments.\nMarch 16, 2010 -- An experimental type of highly focused radiation therapy may control inoperable lung cancer tumors and help people with the deadly disease live longer.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story indicates that 16% experienced significant but non-deadly side effects of treatment. But what were those side effects?\u00a0 How serious were they?\u00a0 Did they occur more or less often with SBRT than conventional radiation? ", "answer": 0}, {"article": "Nevertheless, for parents of children with autism, even a modest reduction would be worthwhile.\u201d\n\nDr Max Davie, of the Royal College of Paediatrics and Child Health, said it offered \u201ca hugely cheering message for families\u201d, while Uta Frith, emeritus professor of cognitive development at University College London, called it \u201ca remarkably positive story, because the intervention itself was neither intensive nor invasive\u201d.\nThe parents said there were also improvements in relations with other children, in social communication and in repetitive behaviours.\nAt the end of the first year, the researchers could see the children had improved, but the most dramatic development was seen at the follow-up six years later.\nThe families visited a clinic twice a week for six months, where parents were videoed with their children and a box of toys.\nIf the child said a word, the parent repeated it and added something.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article quotes\u00a0an outside expert\u00a0who notes that the training intervention was non-invasive and non-intensive.", "answer": 1}, {"article": "The researchers found that people without cancer had a longer history of taking NSAIDs than people who eventually developed melanoma.\n\u201cI think the jury is still out.\u201d\n\nThere\u2019s reason to hope NSAIDs might offer some protection against this type of cancer, however - earlier this year, a review found that people who use painkillers such as ibuprofen on a regular basis may be less likely to get bladder cancer.\nThe findings are interesting, but should not lead people to conclude that popping a few painkillers will reduce their risk of skin cancer, cautioned Dr. Maryam Asgari of Kaiser Permanente Northern California and the University of California San Francisco, who co-authored the 2008 study.\nFor one, you have to get the comparison right, she noted; there\u2019s always a concern that people without cancer who agree to participate in the study may be more health conscious to begin with, and it\u2019s this that protects them from cancer, not their use of NSAIDs.\nOverall, regular use of NSAIDs for more than 5 years appeared to reduce the risk of developing cancer by more than 40 percent, the authors report in the Journal of Investigative Dermatology.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story stated: \u201cNSAIDs \u2013 which include aspirin, naproxen (marketed as Aleve), and ibuprofen (Advil) \u2014 have side effects, she noted, such as stomach bleeding.\u201d\u00a0 It didn\u2019t note whether study looked at side effects in those taking them for five years. Still, we\u2019ll rule this satisfactory for remembering to include some mention of potential harms.", "answer": 1}, {"article": "Such screening is increasingly used in research.\nThe largest analysis to date of amyloid plaques in people\u2019s brains confirms that the presence of the substance can help predict who will develop Alzheimer\u2019s and determine who has the disease.\nData from nearly 9,500 people on five continents shows that amyloid can appear 20 to 30 years before symptoms of dementia, that the vast majority of Alzheimer\u2019s patients have amyloid and that the ApoE4 gene, known to increase Alzheimer\u2019s risk, greatly accelerates amyloid accumulation.\n\u201cThe papers indicate that amyloid imaging is important to be sure that the drugs are being tested on people who have amyloid,\u201d said Dr. Roger Rosenberg, the director of the Alzheimer\u2019s Disease Center at the University of Texas Southwestern Medical Center at Dallas, who wrote an editorial about the studies.\nThe findings also confirm that amyloid screening, by PET scan or cerebral spinal fluid test, can help identify people for clinical trials of drugs to prevent Alzheimer\u2019s.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Potential harms were expressed through the quote from Mount Sinai Hospital\u2019s Dr. Samuel Gandy, who said giving preventative medication to people at a young, healthy age \u2014 as early as age 30 \u2014 would be exposing them to possible drug side effects for decades.\nThe article also notes that some experts cautioned against early screening of pre-symptomatic people because no drug exists to prevent or treat Alzheimer\u2019s. This is important to point out, since it would be very distressing for most people to learn that they have incipient Alzheimer\u2019s and that they have no current way to treat it.", "answer": 1}, {"article": "To learn more about the Society and the field of endocrinology, visit our site at http://www.\n\"The study found it is possible to have a hormonal contraceptive for men that reduces the risk of unplanned pregnancies in the partners of men who use it,\" said one of the study's authors, Mario Philip Reyes Festin, MD, of the World Health Organization in Geneva, Switzerland.\n\"More research is needed to advance this concept to the point that it can be made widely available to men as a method of contraception,\" Festin said.\nThe hormones were effective in reducing the sperm count to 1 million/ml or less within 24 weeks in 274 of the participants.\nThe contraceptive method was effective in nearly 96 percent of continuing users.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release discusses adverse effects. It says researchers stopped enrolling new participants in 2011 due to the rate of reported side events, particularly depression and other mood disorders. It also mentions that men reported having injection site pain, muscle pain, increased libido and acne, and that 20 men dropped out due to adverse effects. It also says serious adverse events that were assessed as probably or possibly related to the study included one case of depression, one intentional overdose of acetaminophen, and a man who experienced an abnormally fast and irregular heartbeat after he stopped receiving the injections.\nFurther, it quotes a researcher saying that \u201cthe combination of hormones needs to be studied more to consider a good balance between efficacy and safety.\u201d\nDespite the attention to side effects there were a few gaps. The release didn\u2019t quantify the number of men who developed depression. It noted there was one suicide among the study group, but stated it was determined not related to the hormones. How was it determined that the injection did not contribute to the suicide when the hormone shots did contribute to mood disorders? The release doesn\u2019t say.\nThe news release also doesn\u2019t adequately explain the need to cancel the study due to harms. When compared to the side effects of other hormonal contraceptives used by women it appears to be safer.", "answer": 1}, {"article": "Weathers began her research on artemisinin and Artemesia annua (also known as sweet wormwood) more than 25 years ago.\nIn addition, while the combination therapy is designed to be less prone to the drug resistance that has rendered previous antimalarial agents ineffective, increasingly the malaria parasite is showing signs of resistance to ACT, particularly in Southeast Asia.\n\"To our knowledge, this is the first report of dried-leaf Artemisia annua controlling ACT-resistant malaria in humans,\" the authors of the Phytomedicine paper note, adding that more comprehensive clinical trials on patients with drug-resistant malaria are warranted.\nWeathers says the superior performance of DLA in comparison to ACT, as well as its ability to kill drug-resistant parasites and avoid the resistance trap, itself, is likely due to the synergistic effects of a complex array of phytochemicals contained in the plant's leaves, several of which are also known to have antimalarial properties and others of which may act both to enhance the absorption of artemisinin into the bloodstream and bolster its effectiveness against malaria.\nIn fact, she has already established a supply chain in Africa that includes growing and harvesting high-producing cultivars in East Africa, along with GMP (Good Manufacturing Practice) processing operations in Uganda where the leaves are dried, pulverized, and homogenized, where the powder is compacted into tablets, and where the tablets are tested to verify their dosage.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "We expect releases to state \u201cthere are no known harms\u201d if that is the case, but this story does not mention potential harms at all. The story speculates that the stronger value of the dried-leaf product may come from other phytochemicals (not named) that are in the leaves. What if one or more of those have other impacts on patients months from now? Just because a drug is \u201cnatural\u201d\u00a0doesn\u2019t mean it is free of side effects.\nMemorial Sloan Kettering has studied artemisia annua and states that people taking antiseizure medications should avoid artemisia since it can induce seizures and make these medications less effective.", "answer": 0}, {"article": "The new drug is no miracle cure and it is not approved for young children, who are one of the most vulnerable groups, so the C.D.C.\nFlu season has already begun, and last year\u2019s was one of the most lethal in decades; about 80,000 Americans died of flu or its consequences, the Centers for Disease Control and Prevention said earlier this month .\nThe new antiviral, generically known as baloxavir marboxil but sold under the brand name Xofluza, is a single dose treatment.\nThe pill will cost $150, according to a spokeswoman for Genentech, which will sell Xofluza in this country.\nGenentech will offer coupons that lower the price to $30 for patients with health insurance and to about $90 for the uninsured.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story addresses this issue head on, earning it a solid satisfactory rating from us. One point that would have made it even stronger would have been to note that the company selling Xofluza\u00a0warns that pregnant women and nursing mothers may want to avoid the drug, as it is not known whether the drug may harm the fetus or if it would pass into breastmilk for nursing mothers.", "answer": 1}, {"article": "WASHINGTON\u2014People with mild Alzheimer\u2019s disease who started taking an experimental Eli Lilly & Co. drug earlier in the course of their disease fared better than patients who started later in a clinical trial.\n\nThe outcome may bolster the company\u2019s case that the drug, solanezumab, can slow the decline of memory and function in mild Alzheimer\u2019s patients, despite prior studies with negative results. But the new data aren\u2019t final proof of the drug\u2019s benefit\u2014a separate, continuing study due to end in late 2016 is designed to...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story doesn\u2019t address harms at all. One of the most important aspects of clinical trials is determining whether an experimental drug causes significant side effects. And at least one of these drugs is associated with brain swelling associated with headache and confusion. To be clear, this is not about asking reporters to paint a grisly picture of potential harms. If a drug had no adverse side effects, that\u2019s great \u2014 but tell readers that. And if a drug does have adverse side effects, tell readers that too.\n[Editor\u2019s note: An updated version of the story now includes the following line:\u00a0\u201cSome patients receiving solanezumab experienced swelling in the brain and other adverse events, but researchers said the drug was generally well tolerated.\u201d This line was not in the version of the story that we originally reviewed. We applaud any effort to get better, more complete information to readers. But such updates do miss readers like us who only saw the original version of the story.]", "answer": 0}, {"article": "Contrary to earlier reports, giving acetaminophen (Tylenol, etc.)\n\"We found no matter how you slice it, there was absolutely no difference between Tylenol and Motrin,\" says senior investigator and corresponding author Wanda Phipatanakul, MD, MS, of Boston Children's Hospital's Division of Allergy and Immunology.\nWhile the study was modest in size, it was powered to detect any clinically significant differences, more so than past retrospective studies, Phipatanakul notes.\nThe 18-site study should settle a debate that originated when several retrospective studies seemed to indicate that children had exacerbations of their asthma when receiving Tylenol for pain and/or fever.\nSince the study was limited to young children with mild persistent asthma receiving asthma controller therapy, the authors also note that their findings may not apply to other age groups or children with more severe asthma.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Another major study question was whether frequent acetaminophen use in children with mild persistent asthma worsens symptoms. This was measured by the number of asthma exacerbations, percentage of days with full asthma control, use of \u201crescue\u201d medication and unscheduled healthcare visits for asthma. As mentioned in the \u201cQuantify Benefits\u201d section, this release\u00a0includes quantitative data from the original study in easy-to-read bullet form. Furthermore, the headline and quotations used in the news release reinforce the study\u2019s findings, making it clear that acetaminophen does not worsen asthma symptoms in children.\nFor these reasons, we give the news release a Satisfactory rating.", "answer": 1}, {"article": "In devising their models, the researchers updated assumptions that have cast doubt on the relevance of existing breast-cancer risk calculators, which relied on the experiences of women who got an earlier generation of screening mammograms and were more likely to die of breast cancer than is currently the case. Here, teams of modelers from Erasmus University in the Netherlands, Albert Einstein College of Medicine in New York and Harvard Pilgrim Healthcare assumed that women were getting digital mammograms, which offer improved cancer detection rates at lower radiation dosages than earlier mammographic methods. They took into account improved rates of breast cancer treatment effectiveness, and changing causes of mortality for women older than 50. They also took account of the fact that breast density decreases in older women.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article mentions overdiagnosis and a couple of its consequences.\nTo better communicate harms, it could have used some outside expert commentary about the numerous risk factors and comfort levels women and their physicians have when considering the frequency of mammography; and about the fact that there are no definitive answers about the ideal screening protocol for any individual woman.\nThe article also should have included specific information from the journal article about the economic costs of biopsies and other enhanced screening. While it\u2019s hard to quantify the emotional and psychological costs to women who undergo biopsies that are found to be negative, it is possible to quantify the economic costs to a person and to the larger healthcare system.", "answer": 1}, {"article": "However, the findings do not apply to every stroke victim.\n\u201cI really cannot overstate the size of this effect.\u201d\n\nThe key finding is that there is often more time than doctors realized in which brain cells can still be rescued by a procedure to remove the clot.\n\u201cThese striking results will have an immediate impact and save people from lifelong disability or death,\u201d Dr. Walter J. Koroshetz, director of the National Institute of Neurological Disorders and Stroke, said in a statement.\nThe researchers used a special type of brain imaging to identify the patients who still had live brain tissue that could be saved if the blood supply was restored.\nTraditional guidelines have set a limit of six hours after stroke symptoms begin, and said after that it would be too late to help.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Aside from acknowledging that not all stroke patients who fall in the extended time frame are eligible for this procedure, no harms were discussed. What are the harms of standard medical therapy for stroke, therapy plus thrombectomy surgery, and the special brain imaging?", "answer": 0}, {"article": "NEW YORK (Reuters Health) - In a new study of middle-aged New Jersey men, taking cholesterol-lowering drugs was linked to a lower chance of dying from prostate cancer.\nMarcella and his colleagues collected the medical records of 380 men who had died of prostate cancer and another 380 of the same age and race without prostate cancer or with non-lethal cancer.\nThe drugs run anywhere from $11 to more than $200 per month, and sometimes cause side effects including muscle pain, nausea and gas and liver dysfunction.\nClose to one in four of the men in both groups combined had ever taken a statin.\nMost of the men were white and in their mid- to late-60s, on average.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Good job briefly mentioning statin side effects of muscle pain, nausea, gas, and liver dysfunction.", "answer": 1}, {"article": "AMH controls the development of follicles in the ovaries from which eggs develop, and the scientists suspected it might be useful for judging ovarian function.\nThe test, which measures levels of a hormone produced by cells in the ovaries, was able to predict the age at which women reached menopause to within an average of 4 months, according to data to be presented at the conference of the European Society of Human Reproduction and Embryology in Rome on Monday.\nThe average difference between the predicted age and the women\u2019s actual age at menopause was a third of a year, and the maximum margin of error was three to four years.\nLONDON (Reuters) - Iranian scientists say they have developed a way of using a simple blood test to predict accurately when women will reach the menopause, offering the chance for women to plan for family and career far in advance.\n\u201cUsing this model, we estimated mean average ages at menopause for women at different time points in their reproductive life span.\u201d\n\nTehrani said the results showed \u201ca good level of agreement\u201d between predicted and actual age at menopause for the 63 women in the group who reached menopause during the study.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story provides no mention of any potential downsides of the testing. False positive results, for example, could cause unnecessary worry and anxiety and lead to needless fertility treatments.", "answer": 0}, {"article": "\"In these types of studies you think of things like this,\" Haber said, \"but how real it is, is something we're going to have to see.\n\"Critically, it was the stimulation at the gateway into the hippocampus, and not the hippocampus itself, that proved effective,\" senior study author Dr. Itzhak Fried, a professor of neurosurgery at the David Geffen School of Medicine at UCLA, said in a university news release.\nCurrently, deep brain stimulation is used to control the tremors associated with Parkinson's, symptoms of obsessive-compulsive disorder and some other psychiatric conditions, including depression.\nStimulation of the entorhinal cortex -- a region considered crucial to transforming daily experience into lasting memories -- produced the improvement, the researchers said.\nDuring the video game task, participants learned their way around a virtual town with and without five-second periods of deep brain stimulation, and were tested for their ability to reach predetermined landmarks.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Even though the researchers did not report any harms to participants in this study, the story should have mentioned that while similar treatments are considered safe enough in the right circumstances, implanting electrodes and electrical stimulation devices can cause bleeding, strokes, infections, mood changes, movement disorders, sleep problems and other harms.\nA recent study of deep brain stimulation (DBS) involving 99 Parkinson\u2019s patients concluded that DBS\u00a0 \u201chas an adverse effect on executive functions with implications for daily life of the patients and their relatives.\u201d Almost 10% of those DBS patients had psychiatric events including a suicide attempt.\n\u00a0", "answer": 0}, {"article": "Castle said there could be a few reasons that doctors opt to screen women more often than is recommended.\nBut, he added, \u201ca single negative HPV test is very good at ruling out disease.\u201d\n\nEven when doctors use just a Pap test, Roland said, a woman who has had a few normal tests in a row can go two or three years before her next screening.\nResearchers based at the Centers for Disease Control and Prevention (CDC) found that many primary care doctors would bring women back for cancer screening annually \u2014 while recommendations generally call for a three-year wait after normal tests.\nResults from a survey of the same doctors have shown that many also give the HPV test alongside Pap smears to women under 30 \u2014 which is not recommended, because HPV is common in young women and often goes away on its own (see Reuters Health story of July 4, 2011.)\nNEW YORK (Reuters Health) - Most doctors opt for screening women for cervical cancer more often than guidelines suggest, according to a new study.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did a good job explaining that there can be harm from screening too often \u2013 something that often isn\u2019t explained in screening stories:\n\u201c\u2026any extra screening increases the chance of getting a \u201cfalse positive\u201d result on a test \u2014 meaning the test finds something that doesn\u2019t turn out to be cancer. In that case, women would need more invasive tests to rule out disease, Roland said, and risk \u201cundue harm\u201d from those procedures.\n\u201cSome of it is, don\u2019t go looking before you need to go looking because you\u2019ll find stuff that you\u2019d rather not find,\u201d said (one observer), who was not involved in the new study.", "answer": 1}, {"article": "Dr. Shari Lusskin, director of reproductive psychiatry at the New York University Langone Medical Center, echoed that sentiment.\nThe researchers found a 63 percent response rate in women who received the depression-specific acupuncture, while the response rate was 44.3 percent in the control acupuncture and massage groups.\nThe depression-specific protocol was designed just for this study, and the control acupuncture was specifically designed to avoid using acupuncture needles in any areas known to affect depression.\nBut, she added, because this is the first study of its kind, and the acupuncture protocol used was specifically designed for this study, \"you always need replication of the findings.\"\n\"Many women think it's safer for the baby to go off antidepressants, but there's a real risk to the baby for untreated depression in pregnancy.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The study reported some cases of pain at needle insertion sites and bleeding, but the story didn\u2019t mention this.\u00a0 Even with a treatment that is generally very safe, women should be aware of any risks.", "answer": 0}, {"article": "Reduction in high blood pressure has added health benefits because it can potentially reduce the likelihood of heart attacks, strokes, chronic heart failure and kidney disease.\nThe randomized, double-blind study included 264 participants with an average age of 58, of whom 58 percent were women.\nThe study is very useful in telling and confirming that we should talk to the patients, no matter how we do it,\u201d said Bernard Wong, a cardiologist based in Hong Kong.\nParticipants were also largely white and well-educated, with most having a postsecondary education, so the results of the study might not be generalize well to other groups.\nOne of the caveats of the study was that participants were highly motivated people looking for ways to cope with and decrease their blood pressure.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story makes no mention of harms that might arise from the use of web-based tools and videos, but it\u2019s hard to envision how they could harm study participants.", "answer": 2}, {"article": "We need to wait for these results, expected later this year, to see how effective this approach is compared to chemotherapy alone.\u201d\n\nProfessor Udai Banerji\u200b, author of the study and deputy director of the Drug Development Unit at The ICR and Royal Marsden, acknowledged in an interview with Newsweek the cohort of patients was small, \"however anything more than 20 patients usually gives one a rough idea [of the effectiveness of a treatment].\"\n\u201cIn other words, there was no sign of who might benefit the most with treatment,\" he explained.\nOver half of patients with ovarian cancer and over a third with lung cancer saw their tumors shrink, according to the study, which was published in the Annals of Oncology.\nCombined with paclitaxel chemotherapy, the scientists were able to block cancer cells from harnessing p-S6K.\nThe cancers had spread across the bodies of each participant, who did not respond to standard treatment.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Potential harms were not mentioned. According to the study, the most common side effects were fatigue, nausea, anemia, and diarrhea.", "answer": 0}, {"article": "What if you could lose weight and reduce your risk of life-threatening disease without any changes in what you eat -- other than a five-day special diet once every few months?\nThe diet, which was designed to mimic the results of a water-only fast, allowed for participants to consume between 750 and 1,100 calories per day.\nIn effect, the diet reduced the study participants' risks for cancer, diabetes, heart disease and other age-related diseases, according to the findings published Feb. 15 in Science Translational Medicine.\nThe next step for researchers is a large, FDA phase III clinical trial to test the FMD on patients diagnosed with age-related diseases or at high risk for them.\nThe researchers also noted that participants considered \"at risk\" because they had risk factors such as high IGF-1, cholesterol, blood pressure or blood sugar levels, made significant progress toward better health.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention of any potential side effects. Certain people may not be ideal candidates for an extreme low-calorie diet, even intermittently. The release does not comment on this.", "answer": 0}, {"article": "As expected, this process is often inaccurate.\nThe researchers tested the device, which is about the size of a hand, with 771 patient samples at Hospital of University of Pennsylvania and found that it provided false positives only about one percent of the time (was 97. to 99.9 percent accurate).\nThe work could lead to faster and lower-cost lab results for fast-moving viral and bacterial epidemics, especially in rural or lower-resource regions where laboratory equipment and medical personnel are sometimes not readily available.\nThe WSU researchers found that their portable smartphone reader worked nearly as well as standard lab testing in detecting 12 common viral and bacterial infectious diseases, such as mumps, measles, herpes, and Lyme Disease.\nIn rural or underserved areas, doctors sometimes must rely on a patient's symptoms or use their own judgement in looking at test sample color results to determine whether a patient has an infection.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Tests, even accurate ones, have downsides which were not mentioned in this release. The release stated that the device \u201cprovided false positives only about one percent of the time.\u201d If field workers fanned out across a city and tested 100,000 people, that 1% false positive rate would mean that about a thousand people would be told they were infected when they actually were not. The release did not mention false negatives (telling an infected person that he or she is not infected).", "answer": 0}, {"article": "Why so few?\n\"You have a lot of gun-shy patients because of a lot of bad experiences,\" says Michael John Coleman, founder of the patient group MAGNUM, also known as the National Migraine Association.\nOne reason is that it's hard to persuade people to take medicines on days when they feel fine, says Elizabeth Loder, a neurologist at Brigham and Women's Hospital in Boston.\nMedicines backed by the strongest evidence include anti-seizure drugs (divalproex sodium, sodium valproate and topiramate), blood pressure drugs (metoprolol, propranolol and timolol) and, for menstrual-related migraines, a medicine called frovatriptan, the guidelines say.\n\"The life toll that poorly controlled headaches take is really underappreciated,\" she says.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This story doesn\u2019t sugar coat the side effects of these drugs. A spokesman for a patient group notes that many patients \u201cspend months or years taking medicines that don\u2019t work and make them miserable.\u201d", "answer": 1}, {"article": "Until more research is in, what should a woman with a personal history of breast cancer do?\nWith the MRI screen, \"we found cancer in just over 3 percent of women [with a personal history], which was double [that found in those with a genetic or family history],\" she said.\nMONDAY, Nov. 29, 2010 (HealthDay News) -- Women who have had breast cancer should consider annual screening with breast MRI in addition to an annual mammogram, new research indicates.\nCurrently, the American Cancer Society recommends annual breast MRI plus mammography for women at very high risk for breast cancer, such as those with a known genetic mutation known as BRCA or those with a very strong family history.\nStudying the effectiveness of MRI screening on all three groups of women, Dr. Wendy DeMartini, an assistant professor of radiology at the University of Washington Medical School, said MRI imaging found proportionally more cancers in women who had been treated for breast cancer than in the women considered at very high risk.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nThe story dismisses the potential harms of adding MRI scans. It paraphrases an expert as saying there is no downside to getting an MRI, \u201cexcept perhaps an increased risk of false positives and perhaps a need to pay out of pocket.\u201d As noted above, the out of pocket costs of ongoing scanning could cost a woman thousands of dollars. The researchers reported that 9 percent of the women with a history of breast cancer underwent biopsies following their MRI scans. Two out of three of those women were found to not have cancer. The story should have been more clear about this false positive rate.", "answer": 0}, {"article": "Abbott Diagnostics developed both the new and the conventional troponin tests used in the study.\nThe issue with available troponin testing has been that they must be repeated two more times over the next 12 to 16 hours for accurate readings.\nTUESDAY, Dec. 27, 2011 (HealthDay News) -- A new test measuring levels of troponin I in the blood may help determine whether someone is really having a heart attack earlier than is currently possible.\nResearchers led by Dr. Till Keller at the University Heart Center in Hamburg, Germany, compared the new highly sensitive troponin I test with the current test and other blood markers for heart attack among 1,818 people who showed symptoms of a possible heart attack.\n\"We need a blood test that can tell people when they walk in or soon thereafter that they are having a heart attack because the sooner you make the diagnosis, the sooner you can start the right therapy.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Since the sensitivity and specificity of the new test was not quantified, the story provided only a glowing report of progress \u2013 of benefit.\u00a0 There was no discussion of potential harms.\nMost physicians and most organizations would frown on making a diagnosis of a heart attack based simply on a blood test.\u00a0 Up To Date, an authoritative resource suggests that patients with a suspicion of having a heart attack have an electrocardiogram, undergo a brief medical history, have a physical examination and have blood drawn for biologic markers.\u00a0 The story suggests that this new blood test can be used alone to make the diagnosis or rule it out.\u00a0 Exaggerating the benefits of a test without placing it into the context provides the readers with a false impression of the test and its utility.\u00a0 Making decisions on the basis of a single blood test could lead to patient harm.", "answer": 0}, {"article": "But in Vertex\u2019s trial, about 70 percent of those who achieved an effective cure were able to do so in 24 weeks, or about six months.\n\u201cIf you can promise them six months with a reasonable chance of a cure, that\u2019s a meaningful advance,\u201d said Dr. Scott L. Friedman, chief of the division of liver diseases at the Mount Sinai School of Medicine in New York.\nThe standard therapy of interferon and ribavirin was given for either 24 weeks or 48 weeks, depending on how the patients were faring after four weeks and 12 weeks.\nSome 2.7 million to 3.9 million Americans are estimated to have hepatitis C, and 12,000 die from it each year, according to a recent report by the Institute of Medicine.\nThe existing treatment is a combination of alpha interferon, which is injected, and ribavirin, an oral drug.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story makes the standard treatment sound terrible. But it glosses over the side effects of the new treatment, saying only that it causes a \"nasty rash.\" Where is the rash?\u00a0That can make a world of difference. Does it cause the skin to break and bleed? Does it interfere with basic functions like sight, breathing, eating? It says that 7% of the people in the drug group dropped out, while about half that percentage dropped out of the placebo group.\u00a0Again, some absolute numbers would be good here, as would some context about what percentage of patients experience side effects with the standard treatment or with the competing drug in the same family\u00a0of drugs\u00a0mentioned earlier in the story. And the story could have been more clear that all patients get the standard therapy, IFN and ribavirin. So they will face the side effects of the current regimen, PLUS the side effects of this new agent.", "answer": 0}, {"article": "The best moment in Rene\u00e9 Ford's life came the day her son Chase, then 2, tried to kick his doctor. It was July 2005, and that angry gesture marked the first time the boy had moved below the neck in more than a month.\n\nThese days when you look at Chase, you don't at first notice any sign of what happened to him that year--not the fall he took while jumping on the couch nor the paralyzing blow to the neck as he hit the wooden armrest. More and more, Chase can do the kinds of things any other 4-year-old can...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention any possible harms of treatment. Specifically, it would be important to mention that in new spine injuries with fractures, there can be instability that needs to be treated first. Mobilization activities such as these could be harmful in that situation.", "answer": 0}, {"article": "Feb. 1, 2010 -- Twelve weeks of fish oil pills made teens at high risk of psychosis much less likely to become psychotic for at least one year.\nIt may be that fish oil works better in young people with pre-psychotic conditions than in older people with more established psychiatric disorders.\nThis happened to only two of 41 teens who began the year with 12 weeks of fish oil capsules rich in omega-3 fatty acids.\nThe finding comes from a placebo-controlled clinical trial that enrolled 81 young people -- average age 16 -- teetering on the brink of psychosis.\nThere's also evidence that fatty acids interact with chemical signaling in the brain.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "As the story indicates, fish oil supplements are not associated with serious side effects, unlike antipsychotic drugs that can lead to weight gain and sexual dysfunction.\u00a0 The story might have noted that some people taking fish oil supplements have reported mild gastrointestinal side effects (e.g. diarrhea). ", "answer": 1}, {"article": "Want to embed a link to this study in your story?\nThe following related elements also are available on the For The Media website:\n\nThe editorial, \"Opioid vs Nonopioid Acute Pain Management in the Emergency Department,\" by Demetrios N. Kyriacou, M.D., Ph.D., Senior Editor, JAMA, Chicago; Northwestern University Feinberg School of Medicine, Chicago.\nThe findings suggest that ibuprofen-acetaminophen is a reasonable alternative to opioid management of acute extremity pain due to sprain, strain, or fracture, but further research to assess longer-term effect, adverse events and dosing is warranted.\nBottom Line: For adults coming to the emergency department for arm or leg pain due to sprain, strain, or fracture, there was no difference in pain reduction after 2 hours with ibuprofen-acetaminophen vs three comparison opioid-acetaminophen (paracetamol) combinations.\nWhy The Research Is Interesting: The United States is facing an opioid epidemic with almost 500,000 individuals dying from opioid overdoses since 2000.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does address the harms associated with the use (or misuse) of opioid analgesics. However, the release doesn\u2019t address the potential harms from ibuprofen or acetaminophen in a meaningful way. The closest it comes is a sentence noting that \u201cfurther research to assess longer-term effect, adverse events and dosing is warranted.\u201d But there are some things we already know. As the Mayo Clinic notes, ibuprofen use may increase risk of heart attack or stroke, and may also cause stomach or intestinal bleeding. And acetaminophen can harm the liver if taken in too large a quantity. Granted, the risk of these things is low \u2014 particularly if it is used only in the short term to address acute pain \u2014 but it would have been relatively easy to address.\nThe JAMA study didn\u2019t assess harms either; still a statement to this effect could have been made.", "answer": 0}, {"article": "May 12, 2010 (Baltimore) -- The powerful sleeping medication Xyrem can help relieve the hallmark symptom of pain in people with fibromyalgia, suggests a study that pitted the drug against a placebo.\nXyrem, which is approved by the FDA for the treatment of narcolepsy, corrects the same disturbed sleep patterns that studies have shown are common in fibromyalgia patients, Jones says.\nMore than half of people who took Xyrem reported at least a 30% improvement in pain, says Kim Dupree Jones, PhD, of Oregon Health & Science University in Portland.\nThe National Fibromyalgia Association estimates that about 10 million Americans, mostly women, have fibromyalgia, an unexplained condition characterized by chronic pain and fatigue.\nXyrem also helped reduce fatigue, stiffness, and other symptoms, she tells WebMD.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The most common side effects in the study were quantified for each Xyrem group. It also mentions the high potential for abuse and \"date rape drug\" association. While the story quotes a consultant to the drug manufacturer without support regarding the lesser abuse risks in narcolepsy, there\u2019s evidence in the literature, such as in this article, to support the anecdote.\u00a0\nIt would have been nice to read some of the important drug interactions that are possible with Xyrem. It has a boxed warning in its\u00a0prescribing information.", "answer": 1}, {"article": "The potential use of psilocybin in patients diagnosed with life-threatening diseases comes at a moment when medical care at the end of life is a subject of growing concern among patients and physicians. Research finds it's still common for dying patients to get painful and futile procedures. Palliative and hospice care, both aimed at easing the discomfort of the seriously ill, are growing specialties in American hospitals. An increasing number of patients, meanwhile, are demanding the right to die with a physician's help.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story addresses this issue thoroughly. Well done.", "answer": 1}, {"article": "Participants who had been assigned to the aspirin arms of the studies were 20 percent less likely after 20 years to have died of solid tumor cancers than those who had been in the comparison group taking dummy pills during the clinical trials, and their risk of gastrointestinal cancer death was 35 percent lower.\nMany Americans take aspirin to lower their risk of heart disease, but a new study suggests a remarkable added benefit, reporting that patients who took aspirin regularly for a period of several years were 21 percent less likely decades later to die of solid tumor cancers, including cancers of the stomach, esophagus and lung.\n\u201cThis is important as a proof of principle that a single simple compound like aspirin can reduce the risk of cancer substantially,\u201d said the study\u2019s lead author, Dr. Peter M. Rothwell, professor of neurology at the University of Oxford.\nThe risk of lung cancer death was 30 percent lower, the risk of colorectal cancer death was 40 percent lower and the risk of esophageal cancer death was 60 percent lower, the study reported.\nThe specific dose of aspirin taken did not seem to matter \u2014 most trials gave out low doses of 75 to 100 milligrams \u2014 but the participants in the longest lasting trials had the most drastic reductions in cancer death years later.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did say, \u201cBut even as some experts hailed the new study as a breakthrough, others urged caution, warning people not to start a regimen of aspirin without first consulting a doctor about the potential risks, including gastrointestinal bleeding and bleeding in the brain (hemorrhagic strokes).\u201d It could have put a number to these harms, as the NPR Shots story did. ", "answer": 0}, {"article": "JACKSONVILLE, Fla. \u2014 Researchers at Mayo Clinic\u2019s campus in Florida have conducted the world\u2019s first prospective, blinded and placebo-controlled clinical study to test the benefit of using bone marrow stem cells, a regenerative medicine therapy, to reduce arthritic pain and disability in knees.\nThe researchers say such testing is needed because there are at least 600 stem cell clinics in the U.S. offering one form of stem cell therapy or another to an estimated 100,000-plus patients, who pay thousands of dollars, out of pocket, for the treatment, which has not undergone demanding clinical study.\n\u201cThis is just a theory that can explain our results, so it needs further testing.\u201d\n\nAnother explanation is that merely injecting any substance into a knee offered relief from pain.\nBut, depending on how they are processed and used, stem cells can, in fact, be regulated by the U.S. Food and Drug Administration as biological products or drugs requiring rigorous safety and efficacy approval processes.\nThe findings in The American Journal of Sports Medicine include an anomalous finding \u2014 patients not only had a dramatic improvement in the knee that received stem cells, but also in their other knee, which also had painful arthritis but received only a saline control injection.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Descriptions of BMAC treatments note that there are minimal side effects, mostly pain at the injection site that lasts a few days and can be treated with painkillers. But there are potential short- and long-term complications (including infection) of bone marrow aspiration and injections into a joint which were not addressed.", "answer": 0}, {"article": "At Cooper, cardiologist Phillip Koren said he and colleagues have used the Lariat on the left atrial appendage of about 10 patients in the last six months. The closure was unsuccessful in a few of those cases, but in those, there have been no strokes, said Koren, deputy director of the Cooper Heart Institute. None of the 10 patients suffered adverse events from the device.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story has many levels of harm to cover, and it does so in Satisfactory fashion. First, it identifies that a recent study published in JAMA of 309 cases of the use of the Lariat device showed urgent follow-up required in seven patients \u2013 2.3 percent of the cases, and one death. Second, the story explains how and why some physicians choose to use a device off-label, not for a purpose identified at the time of its limited approval by the FDA. One of the physicians calls this a \u201cregulatory loophole\u201d and the JAMA study recommends further research before other doctors use the Lariat device for this purpose.\nOur wish list for this story would have included some yardstick or context to help us understand these harms. How often would patients getting some alternative to the Lariat be expected to have a bad outcome? And in any group of\u00a0309 sick old people with failing hearts, how many bad outcomes should you expect, no matter what device is used? Another missing piece is one of the timing of the harms. Presumably these reports refer to short-term complications, most commonly within 30 days of the procedure, that can most directly be attributable to the device and/or its placement. What isn\u2019t mentioned and warrants comment is that these devices are meant to make permanent changes. And we really don\u2019t know what the long-term issues are with such devices.", "answer": 1}, {"article": "Incidence of hypercalcemia (the presence of abnormally high levels of calcium in the blood) was lower with abaloparatide (3.4 percent) vs teriparatide (6.4 percent).\nAs a result of its mechanism of action, it has been hypothesized that the drug abaloparatide, a synthetic peptide, would have a more pronounced anabolic (i.e., bone growing) action on bone compared with the osteoporosis drug teriparatide.\nThe way forward for fracture prevention involves not only the development of better therapies to prevent fracture and easier delivery systems but also improved adoption of existing osteoporosis therapies for patients with prior fractures and minimization of adverse effects, particularly those associated with long-term use.\u201d\n\n: Both authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported.\nIt has been estimated that the lifetime risk of osteoporotic fracture for a 60-year-old woman is 44 percent.\n\u201cFurther research is needed to understand the clinical importance of risk difference, the risks and benefits of abaloparatide treatment, and the efficacy of abaloparatide vs other osteoporosis treatments,\u201d the authors write.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release says that there were no significant differences in harms seen between the drugs and the placebo without describing all the side effects. But it also mentions that hypercalcemia (elevated calcium level) was lower with the new agent compared to the existing comparator drug. While this was not explained in depth, we\u2019ll give the release the benefit of the doubt for this brief mention of harms.", "answer": 1}, {"article": "Cancer is the No.\n\"You don\u2019t want to go screening people for hallmark (cancer) mutations unless you absolutely know that when you find it, that there is a tumor there and that it is a tumor that needs to be treated,\" said Wyndham, who was not involved in the study.\nThe first goal would be to try it in people at high risk of cancer but no symptoms yet \u2013 such as smokers, or people with cancer-causing gene mutations like BRCA mutations, Velculescu said.\nThe agency has chastised a company called Pathway Genomics over its \"liquid biopsy\" test , saying the company had not shown the $699 test worked as advertised.\n\u201cThe surprising result is that we can find a high fraction of early-stage patients having alterations in their blood,\u201d said Velculescu, who led the study team.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story is dealing with a proposed new blood test for early-stage cancer, so it would require a blood draw.\u00a0 While the risks of problems with that is small, the larger risk is from false positives or false negatives from the test.\u00a0 The story says, \u201cThere were no false positives in 44 people who did not have cancer, they said.\u201d\u00a0 It also points our that the test didn\u2019t detect the cancer in all cases, giving readers a reasonable expectation of risk of harms from wrong results.\nIdeally the story would have included comments from a researcher not involved with the study about the sensitivity and specificity of such tests (factors that determine false-positive and false-negative rates), and how they would perform in a larger population. \u00a0The other risk here is overdiagnosis\u2013finding cancers that don\u2019t need to be treated.", "answer": 1}, {"article": "The research team was led by Hoon-Ki Sung of The Hospital for Sick Children in Ontario, Canada.\nSuch fasting already shows benefits after only six weeks.\nThey exposed groups of mice to sixteen weeks of intermittent fasting.\nThere are changes in certain gene pathways involved in the immune system and the body's reaction to inflammation.\nThe research team in this study wanted to better understand the reactions that interventions such as fasting trigger on a molecular level in the body.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not mention any potential harms that could exist for intermittent fasting.", "answer": 0}, {"article": "Boutot and Bertone-Johnson suggest that more prospective studies of their findings are warranted, including studies that compare soy-based and non-soy vegetable proteins.\nBoutot and Bertone-Johnson add, \"Though relatively few women in our study consumed very high levels of vegetable protein and our power for analyses of more extreme intake levels was limited, women consuming 9 or more percent of their calories from vegetable protein had a hazard ratio of 0.41 (95 percent confidence interval = 0.19-0.88)\" compared to those eating less than 4 percent.\n\"A better understanding of how dietary vegetable protein intake is associated with ovarian aging may identify ways for women to modify their risk of early onset menopause and associated health conditions,\" write first author and then-graduate student Maegan Boutot, with her advisor, professor Elizabeth Bertone-Johnson.\nBoutot, Bertone-Johnson and colleagues in the School of Public Health and Health Sciences at UMass Amherst, with others, evaluated the relationship between diet and risk of early menopause among members of the Nurses' Health Study II (NHS2), an ongoing prospective study of 116,000 women aged 25-42 when they entered it in 1989.\nFor a woman with a 2,000 calorie per day diet, the authors explain, this is equal to three to four servings of such foods as enriched pasta, breakfast cereal, tofu and nuts, or about 32.5 grams a day.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release doesn\u2019t discuss harms such as allergic reactions or other adverse effects from eating certain plant foods such as soy, wheat, and nuts. However, a discussion of harms doesn\u2019t seem to be warranted since the news release does not advocate consumption of a specific foods, but rather suggests that a moderate increase in a range of plant foods might offer a benefit.", "answer": 1}, {"article": "The U.S. National Institute of Neurological Disorders and Stroke has more about autism.\n\"Although it would be wonderful if a relatively simple, video-based intervention could reduce the recurrence risk of autism spectrum disorder in later offspring, further studies are needed to examine this very issue,\" he said.\n\"Research has shown that subtle markers of autism are identifiable in the first year of life,\" explained Dr. Ron Marino, associate chair of pediatrics at Winthrop-University Hospital in Mineola, N.Y. \"Video feedback seems like a natural and potentially very potent extension of intervention when it can be most effective,\" he added.\nTHURSDAY, Jan. 22, 2015 (HealthDay News) -- A therapy involving \"video feedback\" -- where parents watch videos of their interactions with their baby -- might help prevent infants at risk for autism from developing the disorder, a new study suggests.\n\"But our findings suggest that targeting the earliest risk markers of autism -- such as lack of attention or reduced social interest or engagement -- during the first year of life may lessen the development of these symptoms later on.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The harms of this intervention could include the time and expense of an experimental approach whose benefits were not shown to be statistically significant in the one study reported on herein. The study abstract notes the possibility of negative effects\u00a0in language and responsivity to vowel change. The story didn\u2019t touch on any of this.\u00a0 It emphasized potential benefits and ignored potential harms.\u00a0 In our view, there is a harm in this kind of reporting.", "answer": 0}, {"article": "\"For high-risk people, those with heart disease or [who] have had a stroke who are taking a standard dose of a statin, further reduction in LDL cholesterol will give them extra benefit,\" said Dr. Colin Baigent of the Clinical Trial Service Unit and Epidemiological Studies Unit at University of Oxford in the United Kingdom, who was involved in both studies.\nThe researchers found that in trials comparing statin doses, taking high-dose statins reduced the odds of having a stroke by an additional 15 percent, compared to the usual doses of statins.\nIn addition, there were no significant effects of statins on deaths due to cancer or other non-vascular causes, and no excess risk of cancer, even at low LDL cholesterol concentrations.\nThe reduction in LDL cholesterol from the higher dose ended up decreasing the risk of a major cardiac event by 6 percent, the researchers found, although the statistic in itself was not clinically significant.\nThe researchers noted that the higher dose of Zocor (simvastatin) did result in a risk of a muscle disease 10 times higher than that associated with the lower dose.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story presented information about the increased incidence of myopathy and the more severe rhabdomyolysis observed with higher dosage statin use.\u00a0The story did, however, contain an error in referring to creatine kinase as an indicator of kidney damage. \u00a0It is an indicator of muscle damage.", "answer": 1}, {"article": "Your body also makes vitamin D after the skin absorbs some of the sun\u2019s rays.\nSunlight is one of the most important sources of vitamin D.\n\nResearchers will present their findings in April at the American Academy of Neurology's 62nd Annual Meeting in Toronto.\nGrowing evidence has suggested that vitamin D, found in fortified milk, may lower one\u2019s risk of MS. Now, researchers with the Harvard School of Public Health in Boston have shown that it\u2019s possible this protective benefit could begin while a baby is developing in the womb.\n\"We also found the risk of MS among daughters whose mothers were in the top 20% of vitamin D intake during pregnancy was 45% lower than daughters whose mothers were in the bottom 20% for vitamin D intake during pregnancy.\"\nFeb. 9, 2010 -- Pregnant women who drink plenty of milk may be protecting their child from developing multiple sclerosis (MS) in the future.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We don\u2019t know if any of the mothers who reported a high intake of vitamin D experienced adverse effects; however, it\u2019s worthwhile to mention that excessive intake of vitamin D supplements is associated with harms, including nausea, vomiting, constipation, and weakness. Additionally, information about how to safely get enough sun exposure to convert vitamin D to its active form would have been helpful.", "answer": 0}, {"article": "There are still many questions regarding the pacemaker, produced by Nanostim Inc.\nStill, a new company-funded study shows that \"this is now a possibility\" that could reduce infections and the severity of pacemaker surgery, said study author Dr. Vivek Reddy, director of the Cardiac Arrhythmia Service at Mount Sinai Hospital in New York City.\nStill, he said, the new device will probably be more expensive than other pacemakers, and may pose special risks of its own.\n\"When the battery of the implanted leadless pacemaker is exhausted, a new implant is necessary, with all the potential risks associated with this,\" Doppalapudi said.\nCurrently, pacemakers include two components: a battery-powered generator that produces the electrical \"prompts\" that the wires deliver to the heart when needed, Reddy said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story explained that:\n\u201cresearchers implanted the pacemaker in 32 people for the first time through a puncture in the skin; in 10 patients, they had to reposition it. \u2026one patient died of a stroke while convalescing after suffering a heart injury during implantation and another had the pacemaker replaced with a defibrillator.\u201d\nOne independent expert in the story said the new device \u201cmay pose special risks of its own.\u201d\nAnother said, \u201cWhen the battery of the implanted leadless pacemaker is exhausted, a new implant is necessary, with all the potential risks associated with this. It is not known if it will be feasible to safely retrieve the old device. If the old device is left in place, it is not known what the long-term effects of this will be.\u201d", "answer": 1}, {"article": "Philadelphia, PA, August 14, 2017 - Stanford University scientists have described a new type of test that can detect genetic mutations in minute amounts of DNA released from cancer cells into the blood.\nThe test, which is called single color digital PCR, requires only a fraction of a tube of blood and can detect as few as three mutation-bearing molecules in a single reaction.\nThe main advantage is that the new technique does not rely on pre-amplification, which can introduce errors and biases.\n\"This test is simple enough to set up and analyze without extensive training, and therefore, it can be implemented by anyone, making it highly accessible to any laboratory.\n\"For monitoring patient tumors, only a handful of blood tests are available which are limited to only several types of cancers.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention of harms. The assumption here is that more regular monitoring of patients via blood samples will lead to better outcomes, when we actually know from repeated studies that more monitoring for disorders leads to more unnecessary treatments and surgeries.\nWhat is the false positive rate? The false negative rate? What are the possible clinical harms that can result from either of these scenarios?", "answer": 0}, {"article": "\"The protection started at more than 45 grams [about 1.5 ounces] a week,\" says researcher Susanna C. Larsson, PhD, of the Karolinska Institutet in Stockholm, Sweden.\nOct. 10, 2011 -- A healthy chocolate habit -- about two chocolate bars a week -- appears to help women reduce their risk of stroke, according to new research.\nWhile other studies have found a link between eating chocolate and reduced stroke risk, this research found a slight difference in protection, depending on type of stroke.\nThose who ate the most chocolate were protected a bit more from strokes caused by hemorrhage than strokes caused by obstruction such as blood clots.\nIn this group, the median intake (half ate more, half less) was about 2.3 ounces a week.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although the story warns that milk chocolate may be \u201chigh in sugar, fat, and calories,\u201d it doesn\u2019t spell out the implications of eating too much milk chocolate in an attempt to reap health benefits. (To the contrary, the story suggests that eating larger amounts of U.S. milk chocolate with low cocoa content might yield the same result\u00a0as eating less of the higher-cocoa Swedish chocolate.)\u00a0Eating\u00a0more than a modest amount of chocolate is likely to cause weight gain,\u00a0which would probably negate any beneficial effects on stroke and increase the risk for other health problems.", "answer": 0}, {"article": "That's the tantalizing premise behind Deplin, a prescription form of the B-vitamin folate. Although it has been on the market since 2006, Deplin is generating growing buzz at psychiatric conferences and among clinicians and patients, particularly those who haven't responded to antidepressants or did for a while only to have their depression return.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes that patients receiving Deplin during a short-term study reported no increase in side effects compared with those receiving a placebo. However, the story did not mention that there are potential harms associated with the administration of synthetic folate that would not show up in a small, short-term study such as this one.\u00a0There are concerns, for example, that too much folate might increase the risk for colorectal cancer or hasten cognitive decline in individuals with poor vitamin B-12 status. At the very least, the story should have noted that current studies are not capable of identifying potential adverse effects of long-term Deplin therapy.", "answer": 0}, {"article": "\u201cDoes everybody need to practice at least 20 minutes a day three times a week?\nThis is a much larger study, and the findings are robust.\u201d\n\nAbout four out of five people experience low back pain at some point in their lives, prompting Americans to spend $50 billion a year on medications, physical therapy and related costs.\n\u201cAt a certain point in time you learn what your back needs.\u201d\n\nAs an alternative to yoga, stretching may be a viable option.\n\u201cMore participants in the yoga and stretching groups were very satisfied with their overall care for back pain.\u201d\n\nDr. Sherman said that like many other therapies for low back pain, yoga probably would not work for everyone.\nThe study is the largest and most thorough to date to look at whether yoga has an effect on chronic low back pain, a problem that affects millions and has no surefire long-term remedy.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article did not discuss adverse events in any of the groups, though the study reported on them. This is an important point, as the New York Times article observed that many people with back pain shy away from exercise programs for fear of exacerbating their symptoms.\n\n\n\n ", "answer": 0}, {"article": "COPENHAGEN (Reuters) - Merck & Co scored a double hit on Sunday with new clinical data showing its Keytruda immunotherapy offered big benefits in previously untreated lung cancer patients, either when given on its own or with chemotherapy.\nThe various findings suggest that treating lung cancer - the biggest cancer killer globally - with powerful new immune system-boosting medicines is going to involve more permutations than some experts originally expected.\nIn the event, researchers reported that Merck\u2019s combination cut the risk of disease progression or death by 47 percent compared to chemotherapy alone after 10.6 months, while 55 percent of patients saw their tumors shrink versus 29 percent.\nMany now believe that combination therapy is the way ahead, with Bristol and AstraZeneca working primarily on using two immunotherapies together, while Roche and Merck look at adding chemotherapy.\nAn editorial in the New England Journal of Medicine, where the Merck monotherapy results were published, said Keytruda could become \u201ca new standard of care\u201d.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Both chemotherapy and immunotherapy carry risks. But the story doesn\u2019t discuss the general potential harms of either, nor what was reported\u00a0in the study.\nAs the NEJM study offered up, \u201cserious treatment-related adverse events occurred in a similar percentage of patients in the pembrolizumab (Keytruda) group and the chemotherapy group (21.4% and 20.7%, respectively).\u201d And, \u201cdiscontinuation of treatment because of treatment-related adverse events occurred in 7.1% of patients in the pembrolizumab group and in 10.7% of patients in the chemotherapy group.\u201d\nThese serious adverse events included diarrhea and pneumonitis in the Keytruda group, and anemia, fatigue, and decreased appetite in the chemo group (among other events).\nSome independent\u00a0commentary on how these drugs impact quality of life\u2013especially for very sick patients with advanced cancer\u2013would have been very useful.", "answer": 0}, {"article": "But Cao doesn't think people should start taking aspirin to prevent cancer until more research is done.\n\"People who are uncertain about whether they should be using aspirin should talk to their health care provider, who knows their personal medical history and can help weigh their individual risks and benefits,\" Jacobs said.\nSome, though not all, previous studies have indicated that aspirin might slightly lower risk of certain other cancers, including breast cancer, prostate cancer and lung cancer, he added.\nWhile not common, aspirin can cause serious, even occasionally fatal, stomach bleeding, even at low doses, he said.\n\"The results of ongoing research to develop more tailored treatment based upon a personalized assessment of risks and benefits is critical before recommending aspirin for preventing cancer,\" she said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes prominently the possible harms: \u201cWhile not common, aspirin can cause serious, even occasionally fatal, stomach bleeding, even at low doses, he said.\u201d", "answer": 1}, {"article": "Buck scientists strive to discover new ways of detecting, preventing and treating age-related diseases such as Alzheimer's and Parkinson's, cancer, cardiovascular disease, macular degeneration, osteoporosis, diabetes and stroke.\nWhile the medication remains the single most effective agent in the management of PD symptoms, long-term use causes its own side effects, among them abnormal involuntary movements or AIMS.\nHowever, this study provides additional evidence on top of prior work from Dr. Andersen's lab and others that lithium may have therapeutic potential in PD, which is a hypothesis that should be tested in clinical trials,\" he said.\nThis study, published online in Brain Research, involved Parkinsonian mice that were given Carbidopa/Levodopa (sold as Sinemet\u00ae), a drug used to boost levels of the neurotransmitter dopamine, which is lost in PD.\n\"This study suggests potential therapeutic benefit in PD,\" said David K. Simon, MD, PhD, Associate Professor of Neurology at Harvard Medical School in Boston.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release is silent on the issue of the potential for toxicity with lithium augmentation. \u00a0Although the research was conducted in mice, the researchers did note the potential for toxicity in their publication, \u201c\u2026in a few reported cases lithium treat- ment was suggested to be detrimental to PD patients and to cause side effects\u2026\u201d Since lithium is also used in the treatment of psychiatric disorders, it\u2019s possible the release could have pulled from the literature on this use to discuss potential side effects.", "answer": 0}, {"article": "The findings appeared online Feb. 5 in the BMJ.\nDespite the fact the American Heart Association (AHA) currently recommends that 5 percent to 10 percent of all calories come from polyunsaturated fat (principally from omega-6), the NIH team found no evidence to support the notion that linoleic acid confers health benefits.\nThe original \"Sydney Diet Heart Study,\" was initially conducted between 1966 and 1973, at a time when the cholesterol-lowering benefits of all polyunsaturated vegetable acids (PUFAs) were touted with a broad brush.\nWEDNESDAY, Feb. 6, 2013 (HealthDay News) -- Enduring dietary wisdom -- that polyunsaturated vegetable fats are better for your heart than saturated animal fats -- may be turned on its head by a fresh analysis of a nearly 50-year-old study.\n\"And so, we were interested in trying to evaluate just one of these compounds, linoleic acid, by looking at this old trial using modern statistical methods, and also by re-including some original data that had gone missing from the first analysis,\" Ramsden explained.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not Applicable. The primary focus of the story was addressing the potential harm of consuming too much linoleic acid. The story should have quantified these harms better, but since we\u2019ve already docked points above under Benefits, we\u2019ll grade this N/A here to avoid dinging it twice for the same flaw.\u00a0 We can\u2019t give it credit for a satisfactory score, though, for the same reason.", "answer": 2}, {"article": "The researchers from Harvard's T.H.\nThe findings showed that breast cancer risk was 12 to 19 percent lower among women who ate more dietary fiber in their youth, depending on how much more they ate.\nThis is just one mechanism by which we can reduce risk and it does warrant further study.\"\nEating a high-fiber diet as a teenager, including lots of fruits and vegetables, may be another tool to help women lower their risk for later breast cancer.\nHigh consumption of foods rich in fiber such as fruits, vegetables and whole grains in early life may help to reduce breast cancer incidence,\" lead author Maryam Farvid, a visiting scientist at Harvard, told CBS News.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We\u2019re not aware of any harms from incorporating additional fiber into one\u2019s diet by eating more fruits and vegetables. We\u2019ll rate this Not Applicable.", "answer": 2}, {"article": "The World Journal of Surgery article, by lead author breast surgeon Michael J.\nCross, concluded that the 3-D marker is an \"effective method for delineating the tumor bed with a significant utility for RT (radiation therapy) planning.\"\nThe study also noted that the device provides a helpful guide for post-treatment mammograms and other long-term follow-up to check for any cancer recurrence in these patients.\nA second study, presented at the American Society for Radiation Oncology (ASTRO) 2016 annual conference, describes the extra utility that BioZorb can provide, by significantly reducing the amount of normal breast and surrounding tissues that are exposed to radiation treatment.\n\"Through our experience with this marker, we've observed that its use results in less radiation dose to the patient compared to whole breast radiation, plus a better overall cosmetic outcome,\" said Dr. Cross, a nationally known breast surgeon at Breast Treatment Associates, in Fayetteville Ark.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There was no indication of harms in the news release. However, the original article did note side effects that arose in two patients. It would have been good to note them in the release. The published study also acknowledged that skin changes and dermal lymphedema (swelling) were a concern among patients but were not specifically tracked. Again, a mention of that in the release would have been helpful to patients.", "answer": 0}, {"article": "When left untreated, however, B.P.H.\nSurprisingly, his case is not unique.\u201d\n\nMany doctors are now urging men to become proactive earlier to prevent chronic problems in the future.\nBut for patients who have trouble getting back to sleep, \u201cthere are many effective options, and patients almost always end up with less bothersome symptoms once they choose to do something,\u201d he said.\n\u201cThere is a big difference between having the symptoms and being bothered by the symptoms,\u201d said Dr. Kevin T. McVary, professor of urology at the Feinberg School of Medicine at Northwestern University.\n\u201cMy father used to be up 10 times a night and said it wasn\u2019t a problem for him,\u201d said Dr. Franklin C. Lowe, professor of urology at Columbia University College of Physicians and Surgeons.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The only harm associated with any of the treatments was the possible need for additional treatment some time in the future for the minimally invasive and surgical options mentioned. \u00a0However \u2013 there was no mention of the sexual function and incontinence issues that may accompany these invasive treatments; nor was there discussion of the side effects associated with medication use.", "answer": 0}, {"article": "Kite Pharma is racing to get the first FDA approval of an experimental gene therapy to fight cancer.\n\nAn experimental gene therapy that turns a patient\u2019s own blood cells into cancer killers worked in a major study, with more than one-third of very sick lymphoma patients showing no sign of disease six months after a single treatment, its maker said Tuesday.\n\nIn all, 82 percent of patients had their cancer shrink at least by half at some point in the study.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This is a major\u00a0strength of this article. It makes it clear CAR-T treatment is not without major risks which include: treatable anemia, brain toxicity, and a \u201cdangerous condition where the immune system overreacts in fighting the cancer\u201d (likely, \u201ccytokine release syndrome\u201d). Deaths directly caused by CAR-T therapy in this and other trials are\u00a0mentioned.", "answer": 1}, {"article": "When it's functioning properly, BRCA actually helps repair damaged DNA and prevents tumors, but when BRCA1 and BRCA2 go awry, they encourage breast cancers.\nThis targeted form of treatment takes advantage of a weakness in the BRCA gene to further cripple the cancer cell's ability to repair itself, grow and spread, said Weiss, who was not involved with the study.\nIn addition, several ongoing studies are looking at combinations with PARP inhibitors \"to try to expand who may benefit or lengthen how long they may work,\" Litton said.\nThe trial was funded by drug maker Pfizer, and the results were published Aug. 15 in the New England Journal of Medicine.\nIn January, the FDA approved the first PARP inhibitor, Lynparza, to treat BRCA-mutated breast cancer.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story explained some of the harms, notably blood disorders, and included the rate of harms in both the treatment group and the control group, which is a useful comparison to include.\nOne detail that also would have been useful to include: The rate of severe adverse events was similar in both the treatment and control groups. The drop-out rate (how many women dropped out of the study due to side effects) was slightly higher in the talazoparib group.", "answer": 1}, {"article": "There are some caveats.\nThe workings of deep brain stimulation as a whole are a mystery, although Mayberg said it may work by changing the brain's rhythms.\nThe St. Jude Medical Neuromodulation company, which has provided consulting fees to Mayberg and some of the other study authors, is currently recruiting patients for a study that could pave the way for its approval as a treatment for depression, Mayberg said.\nAfter two years, of the 12 patients still in the study, seven patients (58 percent) were in remission.\nStill, the study suggests that brain stimulation \"not only just helps patients who haven't been able to recover from depression, but it seems to be associated with the absence of relapses.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There\u2019s just one line in the story about harms: \u201cPatients didn\u2019t suffer from side effects, she noted.\u201d The story also says, \u201cThe workings of deep brain stimulation as a whole are a mystery, although Mayberg said it may work by changing the brain\u2019s rhythms.\u201d If how it works is a mystery, we think a little more space should have been devoted to potential harms. There were a total of 8 adverse events related to either the surgery or the device, two of which were deemed serious (infection). The story misses these events entirely.", "answer": 0}, {"article": "\u201cThe key to maximizing protection against colorectal cancer after colonoscopy is performance by an operator with excellent examination\u201d and growth-removal technique, \u201cin a well-prepped colon,\u201d Kahi told Reuters Health by e-mail.\nTumors may simply have gone unidentified on the exam, or were seen but not completely removed.\nBoth groups could do things to improve the detection rate, they said.\nAnother less expensive test is fecal occult blood testing, which involves taking stool specimens at home and mailing them to the doctor\u2019s office or medical lab.\nDr. Charles Kahi of the Indiana University School of Medicine, in Indianapolis, noted that the rate found in the new study was a bit higher than previously reported.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not quantify potential harms from colonscopies, such as colon perforation.", "answer": 0}, {"article": "\u201cWe believe the benefits increase with age.\nBut there are harms, and particularly in their 40s, women have to make a decision for themselves.\u201d\n\nOne potential harm is false positives, in which a suspicious mammogram finding leads to more tests, sometimes even biopsies, but turns out to be harmless.\nThe guidelines state that from ages 40 to 74, screening will reduce the odds of dying from breast cancer, with women 40 to 49 benefiting the least and those 60 to 69 benefiting the most.\nThe guidelines relied in part on a study of records from 405,191 women who had digital mammograms from 2003 to 2011, which found that false positives were common, especially in younger women.\nDr. Constance Lehman, a professor of radiology at Harvard Medical School and director of breast imaging at Massachusetts General Hospital, who is not on the task force, said she was pleased to see that although its advice had not changed, the group had placed more of an emphasis than before on the importance of women\u2019s having the freedom to decide how often to be screened and when to start.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This is really a strong point for the story. The story devotes several paragraphs to explaining \u2014 and quantifying \u2014 the potential harms of false positives and overdiagnosis. It then spends an additional two paragraphs trying to place these harms in context. For example, citing a cancer expert\u2019s position that the potential harms are significantly outweighed by the potential benefits. The story also made clear that there was an emphasis in the recommendations that women be able to decide for themselves on when to begin screening, and how often to be screened. That\u2019s an important point \u2014 women should know that they have a role to play in weighing risks against potential benefits and \u2014 ultimately \u2014 making decisions about their health.", "answer": 1}, {"article": "The drug\u2019s manufacturer hopes prisons will be the gateway to a larger market.\nIn the biggest study, sponsored by the National Institute on Drug Abuse, about 300 offenders \u2014 most of them heroin users on probation or parole \u2014 were randomly assigned to receive either Vivitrol or brief counseling and referral to a treatment program.\nBut most jails and prisons reject methadone and buprenorphine, the other government-approved medications for opioid addiction, because they are habit-forming and can be abused.\nAlso known as extended-release naltrexone, the medication won Food and Drug Administration approval for alcohol dependence in 2006 and in 2010 to prevent relapse in post-detox opioid users.\n\u201cThere\u2019s been pushback with other medications, people saying, \u2018We\u2019re just changing one drug for another.\u2019 That argument goes out the window when you\u2019re talking about a blocker\u201d like Vivitrol.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although the story does make clear that evidence so far suggests that short-term use of Vivitrol does not eliminate overdoses in the longer term, it does not reflect on adverse events reported in the NEJM article as a result of the trial, which included such issues as reactions at the injection site, headaches and nausea.", "answer": 0}, {"article": "Reductions in pancreas, stomach and brain cancers were difficult to quantify because of smaller numbers of deaths.\n\u201cYes, okay, it\u2019s a tragedy if a person is rushed into hospital and given a transfusion (because of a stomach bleed) but in relation to the things we are preventing, that is trivial.\u201d\nIn Rothwell\u2019s study, published in The Lancet, researchers found the 20-year risk of death was reduced by about 10 percent for prostate cancer, 30 percent for lung cancer, 40 percent for colorectal or bowel cancer and 60 percent for oesophageal cancer in those taking aspirin.\nHis suggestion was that healthy people could start taking a small 75 mg dose of aspirin every day from the age of about 40 or 45 and continue doing so until they reached around 70 to 75, when the risk of the aspirin causing stomach bleeding rises.\nThe researchers added, however, that treatment with aspirin during the trials lasted for only for between four and eight years on average, so the effects on risk of deaths due to cancer may underestimate possible results of longer-term treatment.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nThe story dismisses concerns about ulcers and other bleeding caused by aspirin. Indeed, the last sentence of the story in fact says the risk is trivial. ", "answer": 0}, {"article": "It has been 51 years since the first birth-control pill became available in the U.S., bringing dozens of contraceptive options for women in its wake. There are currently two options on the market for men\u2014vasectomy or a condom.\n\nThe research pipeline is full of possibilities, though. Scientists at Columbia University Medical Center have halted sperm production and started it again in mice with no apparent side effects, using a drug that blocks receptors for vitamin A. An injectable synthetic substance, in Phase 3 clinical trials...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "While harms weren\u2019t quantified, we can accept that given the clear and concise summary of what\u2019s been shown in studies so far.", "answer": 1}, {"article": "Surgery for a painful, common back condition known as spinal stenosis resulted in significantly reduced back pain and better physical function than treatment with drugs and physical therapy, according to the latest findings from a large federally funded research effort.\n\nThe results from the Spine Patient Outcomes Research Trial, or Sport, echo findings it reported last April involving degenerative spondylolisthesis, another common spinal problem. A separate, earlier report from the same study found nonsurgical treatment for...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did not mention harms of either type of treatment. The researchers reported that about 1 in 10 people who received surgery had an intraoperative or postoperative complication, although few of these were serious. ", "answer": 0}, {"article": "However, the treatment failed to improve secondary goals of the trial, such as heart-pumping efficiency and six-minute walking distance, and Vericel shares fell more than 31 percent by afternoon trading on Monday.\nVericel last month reported that the study succeeded.\n\u201cThe idea is to find a treatment for this group of people before they get to that stage,\u201d Henry said.\nThey are then injected directly into the patient\u2019s heart.\nIn addition, 38 percent of stem cell patients required hospitalization, versus 47 percent for placebo.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Harms were not discussed, although they are important, especially considering the failure of the therapy to improve secondary outcomes.", "answer": 0}, {"article": "Like allergy shots, the oral immunotherapy takes time.\nThe researchers, led by Dr. Gabriele Di Lorenzo of the University of Palermo, describe the benefits as \u201cmodest.\u201d\n\nIn an email, Di Lorenzo told Reuters Health that the findings suggest that sublingual immunotherapy is \u201chighly effective in many, but not in all patients.\u201d He said that more work is needed to identify which patients might be most likely to benefit.\nThe most common side effects include itchiness and irritation in the mouth, ears and eyes, swelling of the mouth or tongue, headache and gastrointestinal problems like stomach pain and heartburn.\nThe ultimate cost-effectiveness of sublingual immunotherapy has also yet to be determined; in the UK, for example, Grazax treatment costs about 2.25 pounds ($3.50) per day.\nEven though the effectiveness is less than that of allergy shots, the convenience of an at-home version of immunotherapy is a plus, and the sublingual therapy tends to have fewer side effects than shots, according to Nelson.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "1clip_filelist.xml\"/>1clip_themedata.thmx\"/>1clip_colorschememapping.xml\"/>\n\n\n\n \nThe story provides a list of the most common side effects associated with sublingual immunotherapy; however, a more complete report would have also mentioned more serious, albeit rare, reactions. It would also be useful for readers to know that in the 1518 patients who received sublingual immunotherapy, there were 3286 reported adverse events (2.6 per person), compared to 1570 reported adverse events in the placebo group (1.34 per person). Furthermore, 54 (3%) patients in the sublingual immunotherapy group dropped out of the studies due to adverse events, compared to 12 (1%) in the placebo group.\n", "answer": 0}, {"article": "CHICAGO -- The diabetes drug Actos was able to slow the progression of plaque buildup in artery walls, while an older diabetes drug failed to stop the progression in patients with diabetes and coronary-artery disease, according to a study released Monday.\n\nUntil now, no diabetes-therapy regimen has been shown to reduce the progression of coronary atherosclerosis within the arterial walls among patients with Type 2 diabetes, a disease characterized by high blood-glucose levels that result from the body's inability to use insulin.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention any harms of the drug.", "answer": 0}, {"article": "Lee believes ibuprofen strips could be useful for sports participants, helping alleviate conditions such as tendonitis, and repetitive strain injuries.\nWe\u2019re controlling the dosage and we\u2019re keeping it there for a prolonged period of time.\u201d\n\nThe patches could help treat conditions like chronic back pain, neuralgia and arthritis without the need to take potentially damaging doses of the drug orally.\nWe\u2019ve tested them in our polymers with very good results, we\u2019ve been able to get increased loadings of drugs in the polymer and we\u2019ve shown almost across the board that we can get a steady release rate of that drug from the polymer as well.\u201d\n\nThe team says TEPI patches could go on sale within three years, and Medherant is working with some large, unnamed, pharmaceutical companies to get them ready for market.\nAccording to Andrew Lee, co-founder of Medherant, \u201cwe\u2019ve only been in the lab about 12 months, but in the 12 months we\u2019ve essentially assessed about 90 percent of the drugs that are currently available as either creams or patches.\nAn ibuprofen patch that delivers the painkiller directly through the skin to the site of pain, at a consistent dose for up to 24 hours, has been developed by UK researchers.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story provides no information on the potential side effects of this method of drug delivery. Ibuprofen is a drug and all drugs have side effects. It sounds like the TEPI patches will have the same possible side effects as topical gels or other patches, which are mostly limited to irritation on the skin and other minor issues. It is claimed that the TEPI patches cause little discomfort, but how was this assessed?", "answer": 0}, {"article": "Learning how to improve cell growth may therefore improve the therapy,\" says Noonan.\nResults of the trial involving a particular type of tumor-targeting T cell, known as marrow-infiltrating lymphocytes (MILs), are described in the May 20 issue of Science Translational Medicine.\nFor the clinical trial, the Johns Hopkins team enrolled 25 patients with newly diagnosed or relapsed multiple myeloma, although three of the patients relapsed before they could receive the MILs therapy.\nOther Johns Hopkins scientists who contributed to the research include Carol Ann Huff, Janice Davis, M. Victor Lemas, Susan Fiorino, Jeffrey Bitzan, Anna Ferguson, Amy Emerling, Leo Luznik, William Matsui, Jonathan Powell, Ephraim Fuchs, Gary L. Rosner, C. Epstein, Lakshmi Rudraraju, Richard F. Ambinder, Richard J. Jones and Drew Pardoll.\nThose studies, she says, are trying to extend anti-tumor response and tumor specificity by combining the MILs transplant with a Johns Hopkins-developed cancer vaccine called GVAX and the myeloma drug lenalidomide, which stimulates T cell responses.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "We\u2019ll give this criterion a satisfactory rating since the release specifically spells out, \u201cNone of the participants had serious side effects from the MILs therapy.\u201d However, the study is really too small, and the time\u00a0span too short, to comment substantively on the possible harms that might be seen if and when the treatment is more widely used. The research paper actually makes the point that the new procedure doesn\u2019t require the \u201csurgical removal of tissue,\u201d and the procedure can be done at bedside rather than an operating suite. But\u00a0the removal of cells from the bone marrow is still an invasive procedure that carries its own risk of infection or other problems. The release would have benefited from at least mentioning this aspect.", "answer": 1}, {"article": "Israel is director of the respiratory therapy department at Brigham and Women's Hospital in Boston.\n\"There was a small but significant improvement in the airway narrowing in these patients, which we didn't expect because we didn't think the mast cells were necessarily promoting that airway narrowing all the time,\" Israel said.\n\"All in all, we were expecting a significantly greater pattern of side-effects, and we didn't see it,\" Israel explained.\nGleevec (imatinib) reduced the \"twitchiness\" of airways, making them less likely to reflexively constrict when exposed to an allergen or asthma trigger, said senior researcher Dr. Elliot Israel.\n\"By blocking the signal that helps keep mast cells alive, we were hoping to reduce the number of these cells,\" Israel said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story just barely passes the bar on this one, reporting that side-effects \u201cwere not as severe as expected.\u201d It adds: \u201cOne person dropped out because of a sharp decline in white blood cells, which bounced back after the drug was discontinued. Another person dropped out because of leg cramps associated with the drug.\u201d\nIt also quotes an independent expert saying the drug is \u201ctoxic.\u201d For lay readers, that might be a confusing term.\nAlso, there\u2019s no mention of the general risks of imatinib, which include infections, bleeding, liver problems, and heart problems. The fact that this is a type of chemotherapy could have been mentioned, too.", "answer": 1}, {"article": "This translates into a 36 percent lower risk of dying among the screened population.\nThe results are in keeping with those of a much larger study published last month, which showed that these 3-D X-rays, or CT scans, reduced the death rate among 53,000 current and former heavy smokers by 20 percent compared with screening using regular chest X-rays.\nNEW YORK (Reuters Health) - More research is suggesting that heavy smokers may benefit from screening for lung cancer, to detect tumors in their earliest stages.\nThis latest study, published in the journal Lung Cancer, looked at death rates in a different, smaller population of heavy smokers, and estimated that those who received up to two CT scans would have between a 36 and 64 percent lower risk of dying, compared to those who went unscreened.\nThe three groups of people had some important differences, such as in average age and how long and heavily they had smoked, so the researchers had to use mathematical tools to try to eliminate the influence of those differences, said Hanley.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nWhile too many news reports take a \u201cwhy not?\u201d attitude toward medical screening tests, this story confronts some of the potential harms. It refers to a recent report that more than one in five \u201cinitial lung CT scans show suspicious lesions that turn out not to be cancer, but lead to needless invasive follow-up procedures and radiation exposure, as well as stress and anxiety for patients and their families.\u201d", "answer": 1}, {"article": "We could not find the requested page.\n\nPlease visit our home page to explore our services.", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release says the test\u2019s ability to diagnose normal moles was 36 percent, \u201capproaching the levels achieved by expert dermatologists performing visual examinations of suspect moles under the microscope.\u201d\nBut as noted above, that statement downplays the fact that the test will result in a very high number of false-positives. A 36% specificity means that nearly two thirds of non-malignant moles will test positive and require additional follow-up. A test that correctly identifies nearly all melanomas, but also flags more than half of normal growths as melanomas, isn\u2019t all that useful.", "answer": 0}, {"article": "When it comes to health, I\u2019m skeptical of willpower. Sure, I talk to my students about personal responsibility, but when it comes to the health of populations, I look for big fixes more than for small acts of will.\n\nThat\u2019s why my ears perked up when I heard that two old physician friends had decided to start taking, as a preventive measure, some of the medications often included in what the field has dubbed the \u201cpolypill.\u201d My friends are both top doctors in their 60s, with good diet and lifestyle, and this is now part of their...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story doesn\u2019t mention important harms of the various medications that might go into the pill. We\u2019re told only that \u201cthe doses are low, so it\u2019s relatively safe.\u201d We wanted to see a nod to side effects, risks and trade-offs of using these drugs\u00a0in a broad preventive manner.\u00a0Taking a baby aspirin every day, for example, can increase the risk of serious gastrointestinal bleeding, which is why guidelines don\u2019t recommend that everyone over 50 take them.\nThe story does state that a polypill might actually backfire by causing people to think it will protect them, and therefore they exercise less and eat worse.", "answer": 0}, {"article": "So she started her own company.\nThe Fertilome test can help you decide if it is right for you.\u201d\n\nThe company\u2019s website also features testimonials from women who say they have used Fertilome to help guide their decisions.\nPetrozza said he worries that women might wrongly interpret a long litany of genetic risks to mean that their hopes to start a family are \u201cdoomed.\u201d He also said he sees the test as \u201cvery costly for what it\u2019s trying to do \u2014 and not really giving, at least at this point, what I would consider meaningful information.\u201d\n\nThe Fertilome test was eight years in the making.\nBut the report does not explain that the condition is fairly rare \u2014 affecting just 1 in 1,000 women by age 30 and 1 in 250 women by age 35 \u2014 so the absolute risk is still very small.\nCelmatix held webinars earlier this summer for OB-GYNs, telling them that the test could help \u201coptimize management plans from the very start.\u201d\n\nDr. Aimee Eyvazzadeh, a reproductive endocrinologist in private practice in the Bay Area, is among a few doctors who\u2019ve been given vouchers by the company to offer the test for $500.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "One of the strengths of this story is its explanation of the actual risk to a woman with a particular genetic variant identified by the test.\u00a0 The test results cast risk in terms of relative likelihood (i.e., they determine if a woman is more likely, as a result of a genetic variant, to develop a specific condition that could affect her ability to get pregnant) while the story supplements that with numbers characterizing the \u201cabsolute\u201d risk (that condition is rare in the first place, so even an increased risk is small in absolute terms). \u00a0Sources in the story also identify another harm: misinterpretation of results can heighten anxiety. The story could have gone further, to contemplate the possibility that women may make wrong decisions based on the incomplete information provided by the test.", "answer": 1}, {"article": "Obesity puts children at greater risk of developing preventable conditions like heart disease and diabetes at a younger age, and suffering poor health later in life.\nDr. Evangelia Charmandari, associate professor pediatric and adolescent endocrinology at at the Medical School of the National and Kapodistrian University of Athens and lead author of the study, said: \"These findings suggest that simple vitamin D supplementation may reduce the risk of overweight and obese children developing serious heart and metabolic complications in later life.\u201d\n\nThe findings are set to be presented at the 57th Annual European Society for Pediatric Endocrinology Meeting, and have therefore not yet been reviewed.\nAccording to findings presented at the European Society of Endocrinology annual meeting in Barcelona, individuals with higher levels of total body and abdominal fat appeared to have lower levels of vitamin D.\n\nRachida Rafiq, the lead author of the study told Newsweek at the time: \"Our results are significant as vitamin D deficiency and obesity are very common problems in our society nowadays,\" she told Newsweek, and argued that it is an important potential relationship to explore.\n\"Although these initial findings indicate that vitamin D could be used in the treatment of obesity, there remains a lack of evidence on the safety and long-term effects of supplementation, particularly if there is no vitamin D deficiency,\u201d said Charmandari.\nRelated: Household cleaning products might be making your children fat\n\nIn what is believed to be the first study to investigate the links between vitamin D supplementation and the weight and health of obese children and adolescents, researchers from University of Athens Medical School and Aghia Sophia Children's Hospital, Athens, recruited 232 particpants.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The possible harms of taking too much vitamin D are fairly well-known for adults, less is known about how it affects kids. Nevertheless the harms are\u00a0numerous and significant. At least a small sample of those risks should have been included in the story, e.g. putting too much calcium in the blood, a greater risk of forming kidney stones, and a greater risk of developing kidney diseases.\nThe story did at least point out \u201cthere remains a lack of evidence on the safety and long-term effects of supplementation, particularly if there is no vitamin D deficiency.\u201d", "answer": 0}, {"article": "I know it's a cure.\n\"Those stem cells are given back to the patient where they can go back to the bone marrow and make the blood cells for the rest of the patient's life,\" Kohn said.\nThat means an actual cure for the disease, said Kohn, who is also director of the Human Gene Medicine Program at UCLA.\nThe Vaccaros turned to Dr. Donald Kohn at the Broad Stem Cell Research Center at UCLA, where Kohn focuses on the development of new methods to treat genetic diseases of blood cells.\n\"I had a baby to compare her to and I just knew, something was wrong with her,\" Vaccaro told CBS News.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Harms were not discussed in any way. With such a serious disease, harms would have to be significant to outweigh the potential benefits, but they should still be mentioned.\nThe story\u2019s depiction of the procedure doesn\u2019t convey the full scope of what\u2019s involved. It states, \u201c\u2026.the\u00a0treatment involves taking bone marrow from the patient to gather stem cells. A cloned gene is then added to correct what was missing at birth\u2026\u201dThose stem cells are given back to the patient where they can go back to the bone marrow and make the blood cells for the rest of the patient\u2019s life.\u201d Although it sounds pretty straightforward, a look at the actual procedure as listed at ClinicalTrials.Gov\u00a0provides a more complete picture. The stem cells are collected under general anesthesia and treatment with busulfan (which can cause significant side effects) to reduce bone marrow cell production in preparation for the stem cell infusion.", "answer": 0}, {"article": "Eliquis is scheduled to be submitted for F.D.A.\nevent of the year.\u201d\n\n\u201cIf everything checks out,\u201d Jami Rubin of Goldman Sachs said in an interview, \u201cthat will confirm in our minds that Eliquis has potential to take a majority share of the $10 billion anticoagulation market.\u201d\n\nMore than 2.6 million people have atrial fibrillation in the United States, according to the Centers for Disease Control and Prevention.\nIn the first seven months on market, about four in five cardiologists and two in five primary care doctors had prescribed it to more than 250,000 people, Wa\u2019el Hashad, Boehringer\u2019s vice president for cardiovascular marketing, said in an interview last week.\nAlthough the study was financed by the drug makers, which raises the issue of bias, it met the gold standard for medical research as a randomized, double-blinded trial in which doctors and patients did not know who took which pill until the end.\nThe study included 18,201 people in 1,034 clinical sites in 39 countries and was consistent worldwide, the sponsors said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentioned some of the disadvantages associated with this use of the medication reported on. \u00a0It did not specifically detail whether there were any harms associated with this medication or how well people in the study were able to stick with the dosing schedule.\nOn this issue, this story was not as complete as its HealthDay competition, which reported:\n\u201cThe new trial comes on the heels of another study on apixaban that was stopped early due to safety concerns. In that trial, published in July in the New England Journal of Medicine, apixaban\u2019s use was associated with raised odds for bleeding \u2014 without providing patients with any reduction in heart attack risk.However, \u201cin that case, apixaban was given to patients with coronary artery disease who were also taking two other blood thinners,\u201d Ansell noted. \u201cThe three of them together showed that the risk of bleeding was just too high and there was no real benefit in that population. But, that\u2019s an entirely different problem, compared with atrial fibrillation,\u201d he said.\u201d ", "answer": 0}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2009/11/02/financial/f035110S68.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The study points out the potential adverse effects associated with this drug.\u00a0 ", "answer": 1}, {"article": "MUSC operates a 750-bed medical center, which includes a nationally recognized Children's Hospital, the Ashley River Tower (cardiovascular, digestive disease, and surgical oncology), Hollings Cancer Center (a National Cancer Institute designated center) Level I Trauma Center, and Institute of Psychiatry.\nEndovascular therapy within 24 hours is the standard of care for emergent large-vessel occlusion, but the chance of achieving a good outcome decreases by approximately 20 percent for each hour that passes before treatment.\nIt is also not clear how the device would work for patients with cranial implants, as metal interferes with the device's operating radio frequencies.\nCompared to the neurologists' diagnoses, the device displayed 92 percent specificity -- the ability to detect the difference between patients with severe stroke and those with other conditions such as mild stroke or healthy participants with no brain pathology.\nThis is because the accuracy of the device simplifies the decision made by emergency personnel about where to take patients first, according to Raymond D. Turner, M.D., professor of neurosurgery and chief of the Neuroscience Integrated Center of Clinical Excellence at MUSC.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There are no harms mentioned in this news release. One big concern with both diagnostic and screening tests is the consequence of a false negative test result which could lead to a patient receiving the wrong, unnecessary or no treatment.", "answer": 0}, {"article": "\"This is [similar] to the effect that we and others have shown for [cholesterol-lowering] statins,\" he said, noting that \"bisphosphonates and statins share the same metabolic pathway.\"\nThe findings in this study show that bisphosphonates are associated with a reduced risk of developing colorectal cancer, but they cannot confirm a causal effect -- that is, the study doesn't prove that the use of bisphosphonates is responsible for the lower risk of colorectal cancer.\nTUESDAY, Feb. 15, 2011 (HealthDay News) -- People who take drugs called bisphosphonates to prevent bone loss may also reduce their risk of developing colorectal cancer by almost 60 percent compared to those not on the drugs, a new study suggests.\n\"The magnitude of the reduced risk is less important because this is an association study; however, it is very significant after controlling for a dozen other known risk factors,\" Rennert said.\n\"The adverse effects profile is of major importance if bisphosphonates are going to be recommended for cancer prevention in healthy people,\" the study authors cautioned.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We give this story and the Reuters Health story credit for at least mentioning some of the risks of taking bisphosphonates. \u201cThe researchers noted, however, that the risks of using bisphosphonates include the possibility, in rare cases, of osteonecrosis of the jaw (destruction of the jawbone or jaw tissue). Bisphosphonates used for osteoporosis have also been linked to a rare fracture of the thigh, according to the U.S. Food and Drug Administration.\u201d But neither story quantified the harms in any way. This story also failed to point out, as the Reuters Health story did, that \u201cearlier study from the UK had found no link between bisphosphonate and colon cancer. Indeed, it found a higher risk of throat cancer in patients on the medication.\u201d\n", "answer": 0}, {"article": "American veterans coping with PTSD are traveling to lodges in the Amazon that offer ayahuasca, a hallucinogenic brew. Some say it has helped them manage emotional trauma from war, but others say it\u2019s not worth the journey. Photo: Ryan Dube/WSJ\n\nAfter surviving firefights and a roadside bomb in Afghanistan, U.S. Army veteran Asa Barrett tried antidepressant drugs and therapy to overcome depression and bouts of anger. Nothing worked.\n\nBut then, like many other foreigners, he journeyed to Peru\u2019s remote Amazonian jungle to drink ayahuasca, a centuries-old, sacred indigenous brew that some Western scientists think can help to heal psychological traumas.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Potential harms are called out clearly starting with the headline, which reads: \u201cIs Peru\u2019s Psychedelic Potion a Cure or a Curse? Foreigners are flocking to try a traditional brew called ayahuasca that some say eases psychological distress \u2014 but it has dangers, too.\u201d\nThe story mentions vomiting as a common reaction in the third paragraph. More serious risks are addressed in paragraph nine, which says \u201csome scientists \u2014 and users \u2014 warn that ayahuasca can be dangerous. It can be fatal when mixed with other drugs, such as antidepressants, and should be avoided by those who are bipolar or schizophrenic, since it has been known to trigger psychotic episodes.\u201d\nThe story also tells of purported deaths related to ayahuasca use, but these incidents are not flushed out in detail, leaving the reader to wonder about their significance. It paraphrases comments from a U.S. Navy official who says DMT can cause seizures, comas and respiratory arrests and lead to hallucinations that \u201ccan be so traumatic that they can worsen medical conditions such as PTSD.\u201d Another user mentions \u201cnightmarish hallucinations.\u201d\nHowever, there are no firsthand accounts of these known harms,\u00a0unlike the many accounts of positive experiences.", "answer": 1}, {"article": "As the study's authors point out, \"The mechanism(s) by which circumcision reduced acquisition of an STI [sexually transmitted infection] is thought to be related to the microenvironment of the thin, lightly keratinized mucosal lining of the inner foreskin.\"\nCircumcision, of course, removes this protective environment.\nStay out of the sun, or utilize a proper sunscreen.\nFor 91% who reported circumcision, the procedure was performed shortly after birth.\nFirst, a bit of background.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Possible harms of circumcision, such as pain, are not discussed.", "answer": 0}, {"article": "Hawk reviewed the study for the American Association for Cancer Research, which is meeting in Anaheim, Calif., where the study was to be presented on Wednesday.\nThere also was a trend toward fewer cancer deaths among multivitamin users, but the difference was so small it could have occurred by chance alone.\nYet no government agency recommends their routine use \"regardless of the quality of a person's diet,\" says a fact sheet from the federal Office of Dietary Supplements.\nThe result is a surprise because many studies of individual vitamins have found they don't help prevent chronic diseases and some have even caused problems.\n\"It's a very mild effect and personally I'm not sure it's significant enough to recommend to anyone\" although it is promising, said Dr. Ernest Hawk, vice president of cancer prevention at the University of Texas MD Anderson Cancer Center and formerly of the National Cancer Institute.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story states that side effects were\u00a0similar between vitamin and placebo group participants, with the exception of their being\u00a0more rashes among vitamin users. The story also touches on potential harms from dietary supplements in general (e.g. they are minimally regulated\u00a0and not subject to\u00a0strict testing for purity) and for specific groups (e.g. people on blood thinners or with cancer, whose\u00a0vitamin use might interfere with their treatment).", "answer": 1}, {"article": "Liao feared that cutting open Holmes\u2019 chest and sternum for an open bypass surgery would disrupt his rehabilitation from the cardiac arrest and delay his plans to return to athletics.\nThe learning curve for cardiac surgeons was too steep, though, and the system\u2019s tools weren\u2019t as useful for heart surgeries as they were for other procedures, said Dr. Goya Raikar, a cardiothoracic surgeon at Regions Hospital in St. Paul.\nThe number of da Vinci robots has doubled in Minnesota in less than two years, with two at the university and four at the Mayo Clinic in Rochester.\nThe robotic systems come with million-dollar price tags and are used for a limited number of surgeries \u2014 mostly the removal of cancerous prostates in men or uteruses in women.\n\u201cThe system and instruments have kind of caught up to the point where heart surgeons are taking a close look at this now,\u201d he said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention negative outcomes that may be associated with the daVinci machines. It does not indicate whether complication rates are higher, lower or equal.\u00a0 \nThe story also fails to mention the potential harm if the machine is used to justify a hospital\u2019s investment or support surgical revenues regardless of whether it\u2019s the best use for a particular patient. ", "answer": 0}, {"article": "\"It was a very aggressive cancer and we needed to start treatment right away,\" said Chris Mullin, Brian's father.\nOne tagged with antibody, the cancer can be more easily recognized and attacked by the body's own white blood cells.\nThis new treatment is still experimental, but it's a step forward in the strategy of manipulating a person's own immune system to fight cancer.\nAfter two years, 46 percent receiving standard treatment alone were free of tumor recurrence versus 66 percent of those like Brian who also received the antibody.\n\"Cancer did not cross my mind at all,\" said Eileen Mullin, his mother.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story failed to mention the side effects associated with the treatment. \u00a0This was a glaring omission. \u00a0The side effects of treatment includes pain, vascular leak syndrome, and allergic reaction. \u00a0", "answer": 0}, {"article": "A large, new study may be reassuring to women considering mastectomies because of a history of breast cancer in their families.\n\nStanford University researchers affirmed that women with mothers and sisters who carry one of the BRCA gene mutations but who aren't carriers themselves don't have an especially heightened risk of breast cancer.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story was concerned primarily with the implications of a negative BRCA test result, so we won\u2019t fault it for not going into detail on the many potential harms of a positive or ambiguous test result. The story did stipulate that BRCA-negative women may still have an elevated risk of cancer if they have a family history of the condition, which is an important caveat.", "answer": 1}, {"article": "What causes the disc to herniate in the first place?\nIn an effort to determine which approach is best, Dr. Weinstein's launched a major study of over 1,200 patients with back pain.\n\"I think that it be important for people to have good information,\" he adds.\nIf you get a tear in your tire, or your car, you would get a bulge,\" Dr. Weinstein explains.\n\"However what was really interesting is that patients who decided not to have surgery who could wait also did very well.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although harms of surgery are rare, the story should have mentioned\u00a0the possible complications such as wound infection or need for reoperation. The story also does not address potential harms of non-operative treatment, such as permanent nerve damage from cauda equina syndrome.", "answer": 0}, {"article": "But a P.P.I.\nBut while certain common foods \u2014 like raw onions, garlic, citrus juices, coffee and chocolate \u2014 are likely to cause reflux in most people with the condition, Dr. Aviv and other experts emphasize that everyone is different, and trial and error is the most effective way to determine an individual\u2019s trigger foods and drinks.\nSmoking and alcohol can loosen tension of the upper esophageal sphincter and cause symptoms of reflux like hoarseness, postnasal drip and shortness of breath by irritating the mouth, larynx and trachea, Dr. Aviv reports.\nOne characteristic often associated with acid reflux \u2014 being overweight, especially with abdominal obesity \u2014 largely explains why the condition has become so common in Western countries.\nAccordingly, the 28-day \u201chealing\u201d diet he suggests consists almost entirely of natural, unprocessed foods, especially lean protein foods like light-meat poultry, fish, egg whites and low-fat dairy, beans (combined with whole grains), and nonacidic vegetables and fruits.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not address potential harms. However, it\u2019s difficult to think of harms associated with quitting smoking, reducing alcohol intake or eating a healthier diet. There may be harms associated with not addressing GERD if lifestyle changes are not adequate, but the story does note that patients may need to take PPIs if lifestyle changes are insufficient. Ergo, the story earns a satisfactory rating here.", "answer": 1}, {"article": "But there are dangers to this approach.\n\u201cThe challenge for the next few years is to find out the limitations, the boundaries, the real mechanisms.\u201d\n\nStill, whatever the role of inflammation in epilepsy, Elisa Moller says that anti-inflammatories were a miracle intervention for her son.\n\u201cIt was not known that inflammation was a common feature of different types of epilepsy.\u201d\n\nNormal brain function is regulated by the glial cells, which protect neurons and induce an inflammatory response if the brain is injured.\nAnd it remains unclear whether inflammation might be implicated in all forms of epilepsy or which patients might benefit from anti-inflammatory treatment.\nBut this response also can contribute to seizures, some experts believe, either because components of the immune system stimulate neurons or because the glial cells\u2019 capacity to regulate the brain is diminished when they become \u201cdistracted\u201d by an injury.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Very low in the story, it mentions harms, saying, \u201cBut there are dangers to this approach. Steroids \u2014 potent anti-inflammatories that some doctors are using for experimental treatments \u2014 can have harmful long-term side effects. And it remains unclear whether inflammation might be implicated in all forms of epilepsy or which patients might benefit from anti-inflammatory treatment.\u201d", "answer": 1}, {"article": "So the animals learn to binge.\nAs reported in the PNAS paper, the characteristic anticipatory signal appeared when he expected to make $5 but not for smaller sums, suggesting some level of specificity.\nThe results point to a real-time biomarker for impulsive behavior, says Dennis Turner, a Duke University neurosurgeon who was not involved in the study but wrote an October review about ongoing research on a range of potential brain stimulation biomarkers.\nSo it seems like a nice opportunity,\" says Halpern, noting that addictive disorders haven't had new therapies for decades.\nYet if offered fattier, tastier chow each day for just an hour, within 10 days the mice realize if they \"don't eat this now, that guy's coming back to take it away,\" Halpern says.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article didn\u2019t discuss harms. Bleeding in the brain, infection, and device failure are all known risks. This would have helped balance out the researcher\u2019s unchallenged assertion that this procedure is \u201csafe.\u201d This is especially important to balance when talking about medical devices, which are not as regulated as drugs.", "answer": 0}, {"article": "Genetic factors that increase prostate cancer risk include inheritable variations in genes known as BRCA1 and BRCA2.\nThe findings suggest that by narrowing the focus of prostate cancer screening to those whose genes put them at most risk, doctors would catch more cancers early as well as reducing the potential for costly and damaging overdiagnosis.\nThe study found that the predictive value of screening these men \u2014 expressed as the number of cancers detected relative to the number of tissue samples taken \u2014 was 48 percent, far higher than the 24 percent achieved in population-wide screening.\nBut fears about overdiagnosis, which can lead to treatments such as surgery, radiation or hormone therapy that can cause serious side-effects such as impotence and incontinence, have so far dissuaded many European countries from nationwide screening.\nLONDON (Reuters) - Men who have a certain genetic variations that put them at higher risk of prostate cancer may benefit from regular screening for the disease, a study by British scientists found Friday.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions several important potential drawbacks of PSA screening and correctly points out that many European countries do not routinely screen for prostate cancer. It also includes some important context, noting\u00a0\"a study in the United States last year found that routine prostate cancer screening had resulted in more than a million being diagnosed with tumors who might otherwise have suffered no ill effects from them.\"", "answer": 1}, {"article": "If it does, Orlistat (xenical) -- currently sold only by prescription -- could be available over-the-counter (OTC) later this year.\nNor is Orlistat a quick fix for unwanted pounds.\nThey range from flatulence and increased bowel movements to diarrhea and anal leakage.\nWhen fat that's eaten isn't absorbed, it must be eliminated.\nThus, the gastrointestinal problems.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story explains that about 70% of users experience gastrointestinal \ncomplications and lists some. ", "answer": 1}, {"article": "\"All clinical trials to date have failed due to side effects ranging from stroke, skin fibrosis and cardiovascular issues.\n\"The development of osteoporosis drugs by pharmaceutical companies has focused heavily on blocking CatK in recent years,\" said Dieter Br\u00f6mme, a professor in the faculty of dentistry and a Canada Research Chair in Proteases and Disease.\n\"CatK is a multifunctional enzyme with important roles in other parts of the body and we think completely blocking it is what causes unexpected side effects in other drugs,\" said Preety Panwar, a research associate in the Br\u00f6mme lab.\nMost drugs in development have been so called active site-directed inhibitors, which act like master keys and lock the entire enzyme, blocking both its disease-relevant functions such as collagen degradation and its other normal functions.\n\"Our compound only locks the collagen -degrading CatK activity, preventing the unregulated breakdown of collagen in bones without any other negative impacts.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No potential harms are mentioned. According to WebMD, red sage: \u201ccan cause some side effects, including itching, upset stomach, and reduced appetite. There is some concern that it might also cause drowsiness, dizziness, and a blood condition called thrombocytopenia.\u201d The safety of long-term use hasn\u2019t been rigorously studied.", "answer": 0}, {"article": "Current evidence definitely supports screening, he said.\nLike the previous experiences, the Augusta area screening that started in 2014, also reiterated the ability of LDCT to find lung cancer early, said Schroeder, corresponding author of the study in Southern Medical Journal.\nThe pioneering National Lung Screening Trial, which began in 2002 and included 33 largely urban centers, found 292 cases of lung cancer among the 26,722 high-risk individuals screened in the first year, for a rate of 1.1 percent.\nAUGUSTA, Ga. (March 9, 2017) - The first year of free lung cancer screening in the Augusta, Georgia area found more than double the rate seen in a previous large, national study as well as a Massachusetts-based screening for this number one cancer killer.\nThe higher rates, coupled with the majority of cases being found in early, treatable stages, point toward the need for ongoing, accessible free screening in high-risk populations and underserved regions, say researchers at the Georgia Cancer Center at Augusta University.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "CT scans expose a patient to a significant amount of radiation, which this release doesn\u2019t address at all. Do the benefits of a potential early diagnosis outweigh the risks associated with radiation exposure? That\u2019s for each patient (and his or her physician) to decide. But a patient needs to be aware of those risks in order to make an informed decision.\nIn addition, an important limitation was not addressed in the release (nor was it spelled out in the study abstract). According to a 2017 article in the journal Chest, \u201cA significant limitation of lung cancer screening is the false-positive rate. One of the major concerns with the NLST [National Lung Screening Trial] has been the high false-positive rate of screening with LDCT (27.3%).\u201d", "answer": 0}, {"article": "Dec. 14, 2009 -- A less invasive needle biopsy may be nearly as effective as surgical biopsy at diagnosing breast cancer, and with far fewer side effects.\n\"Based on currently available evidence, it appears reasonable to substitute core needle biopsy procedures for open surgical biopsy given the comparable sensitivity and lower complication rates,\" write researcher Wendy Bruening, PhD, of the ECRI Institute Evidence-Based Practices Center in Plymouth Meeting, Pa., and colleagues.\nIn addition, the study showed women initially diagnosed with breast cancer with needle biopsy were more likely to be treated with a single breast cancer surgery than those initially diagnosed by open surgical biopsy.\nIn most cases, the lump or lesion is benign or noncancerous and does not require further treatment.\nNeedle biopsies also had a much lower rate of complications (less than 1% compared with 2%-10% with open surgery).\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions \"complications\" and \"side effects\" but does not discuss exactly what these include with either procedure.\u00a0 Surgical biospy is more invasive and risks include infection, scars and slower\u00a0 wound healing compared with CNB.\u00a0 Women who have CNB and are diagnosed with breast cancer have fewer surgeries than women diagnosed via surgical biopsy.\u00a0 Women at higher risk of developing breast cancer (genetic factors, prior pre-cancerous lesions or biopsies, older age)\u00a0may feel more confident of their results via surgical biopsy v. CNB.\u00a0\u00a0", "answer": 0}, {"article": "http://www.\n\"Future studies are needed to address potential differences in outcomes between TF- and TA-TAVR groups,\" said Dr. Thourani, \"but I'm thrilled that we're able to give elderly people the chance to continue enjoying life in their golden years.\nThe ability to safely treat AS patients has become increasingly important; the US government predicts that the number of Americans over the age of 85 will exceed 11 million in the next 20 years.\nFor the study, the researchers used two different approaches: transfemoral TAVR (TF-TAVR), which is the traditional approach performed via the groin, and transapical TAVR (TA-TAVR), which is performed via the heart muscle.\nFounded in 1964, The Society of Thoracic Surgeons is a not-for-profit organization representing more than 6,800 cardiothoracic surgeons, researchers, and allied health care professionals worldwide who are dedicated to ensuring the best possible outcomes for surgeries of the heart, lung, and esophagus, as well as other surgical procedures within the chest.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "This is a close one. The release (and related study) looks at both TF-TAVR and TA-TAVR patients. It\u00a0notes the frequency of adverse health outcomes associated with the two procedures. For example 30-day stroke risk for TF-TAVR was 3.6 percent, and 35 percent of TF-TAVR patients had \u201cmajor complications, such as bleeding or vascular issues.\u201d Stroke risk for TA-TAVR was 2.0 percent and 32 percent of TA-TAVR patients had major complications.\nThat\u2019s useful information, but the release neglects to mention the higher mortality rate observed in the TA-TAVR group compared with TF-TAVR \u2014 a difference that was not trivial. Overall, 4.6% of patients in the TF-TAVR died within 30 days or as a complication of the procedure. Among the TA-TAVR, the rate was 13%.\nOverall, we think the lack of any mention of death rates related to the procedure unbalances the discussion of harms. We also think it\u2019s problematic that the headline of the release describes TAVR as \u201csafe,\u201d when the second half of the release makes clear that there are substantial health risks associated with the procedures. Since the patients in this study were not randomly assigned to the valve treatment or conservative care, it is difficult to know for sure how the risks compare. The release could have done more to highlight that these patients are at high risk based upon age and their valve disease, and that it isn\u2019t clear whether the complications and deaths associated with these procedures are greater than what would be expected with conservative care.", "answer": 0}, {"article": "Article reference: R.M.\n\"The results are compelling and strongly argue for a change in practice,\" says Vincenzo Berghella, M.D., the Director of Maternal Fetal Medicine and Professor in the Department of Obstetrics and Gynecology at the Sidney Kimmel Medical College at Thomas Jefferson University.\nOf those, about half (or 593 women) received IV fluids at a rate of 250 milliliters per hour, and the other half (622 women) received fluids at the lower rate of 125 milliliters per hour.\nBy pooling the data of several studies, Thomas Jefferson University researchers showed that a higher rate of IV fluids not only decreased c-section rates, but also shortened the overall length of labor by one hour, as well as shortened the pushing phase.\nWith a university and hospital that date back to 1824, today Jefferson is comprised of six colleges, nine hospitals, 34 outpatient and urgent care locations, and a multitude of physician practices throughout the region, serving more than 100,000 inpatients, 373,000 emergency patients and 2.2 million outpatients annually.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "An important potential risk of pulmonary edema (fluid build-up in the lungs) due to higher levels of intravenous hydration is not mentioned in the release, although it was reported in the article.\nAdditionally, the release neglects to explain that the only studies pooled for this analysis were those performed on low-risk, first-time mothers whose labor was not induced. The original research report notes that the effectiveness and safety of giving increased fluids to women who had given birth previously, whose labor was induced or who have other medical issues, is unclear. This is an important caveat that belongs in the news release.", "answer": 0}, {"article": "June 22, 2010 -- Drinking lots of coffee probably isn't entirely good for you, but it does lower your risk of mouth and throat cancer.\nThe protection was seen for oral and pharyngeal cancer, but not for cancer of the larynx.\nBut the numbers came out this way: People who drink more than four cups of coffee each day have 39% lower odds of getting mouth or throat cancer, compared to people who don't drink coffee.\nNor was the effect boosted by consumption of fruits and vegetables, also shown to protect against head and neck cancers.\nThough there weren't enough data on decaf drinkers to draw conclusions, drinking tea -- even massive quantities -- was not protective.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "If a story like this is going to promote the benefits of coffee, it should at least wink in the direction of possible harms of drinking 5 or more cups of coffee per day. This story didn\u2019t wink. ", "answer": 0}, {"article": "So, how does naltrexone work?\nThe analysis also found that another drug, acamprosate, is effective at helping people who have already stopped drinking to maintain abstinence, perhaps partly by easing the physical and emotional cravings experienced by heavy drinkers who quit.\nBut there's good evidence that the combination of counseling and drugs such as naltrexone can help people cut back on drinking, or move toward abstinence.\nPart of the challenge, researchers say, is that many drinkers don't realize that a medicine long used to help people addicted to opioids quit their drug habit can help alcoholics and other heavy drinkers cut back, too.\n\"The biggest problem we have in the field is that less than 10 percent of individuals with an alcohol use disorder get any treatment whatsoever,\" says George Koob, director of the National Institute on Alcohol Abuse and Alcoholism.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story briefly mentions the drug is \u201csafe,\u201d but does not discuss any side effects of the drug, nor notable interactions or contraindications. For example, this drug can\u2019t be used if the person is prescribed or otherwise taking opioids, too, or has certain types of liver damage.", "answer": 0}, {"article": "FDA advisers urge approval for first gene therapy for inherited disease\nThe one-time infusion, known as CAR T-cell therapy, is made by Kite Pharma, which is based in Santa Monica, Calif., and recently was bought by Gilead Sciences for $11.9 billion.\nEven so, Yescarta's cost is likely to stoke the ongoing debate about high drug prices.\n\u201cThere's nothing worse than telling patients, 'I'm sorry, we are done here, we don't have anything else to offer,' \" he said.\nIn addition, the agency is requiring hospitals and clinics that dispense Yescarta to be certified after undergoing special training.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story wisely documents the harms found in the trials for the drug, including patient deaths. This is important, and helps balance the glowing patient anecdote from a woman whose cancer went into remission.", "answer": 1}, {"article": "These findings suggest the pills may help protect against death in patients with pneumonia.\n\u201cGiven the potential low number needed to treat to prevent a death suggested by this study, we believe that a strong case exists for randomized trials of statins in people with serious infection to determine if a simple and practical intervention at the point of diagnosis of pneumonia has a beneficial effect.\u201d\n\nDouglas\u2019s team, whose research was published in the British Medical Journal, used data from computerized medical records of doctors\u2019 practices in Britain to identify statin users.\nPatients with a record of pneumonia were followed for six months to see if they died, and the researchers found that 13 percent (109 out of 847) of statin users died compared with 20 percent (578 out of 2,927) of non-statin users.\n\u201cStatins are safe, cheap, and an easy intervention in terms of delivery,\u201d said Ian Douglas, a lecturer in epidemiology at the LSHTM who led the research.\nDouglas noted that since this study looked at patients who were already taking statins when they developed pneumonia, a full randomized clinical trial was needed to find out whether starting a statin at the time of diagnosis has a similar effect.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story glosses over potential harms when it unquestioningly accepts one of the researcher\u2019s claims that statins are \u201csafe, cheap, and an easy intervention in terms of delivery.\u201d Even if we accept that this is true for patients who take statins to prevent heart disease, it might not be true for patients who start taking the drug once they contract pneumonia. The story should have mentioned this, as well as the other common adverse effects of statin medication, which include muscle pain and gastrointestinal upset.", "answer": 0}, {"article": "Among randomized controlled trials (RCTs), there was a statistically significant reduction in CHD risk in higher risk populations, including:\n\u2022 16 percent in those with high triglycerides and 14 percent in those with high LDL cholesterol.\n\"The meta-analyses of Alexander and colleagues suggests that omega-3 fatty acid intake may reduce risk of adverse CHD events, especially among people with elevated levels of TGs or LDL-C....omega-3 fatty acid intake of at least 1 gram of EPA+DHA per day, either from seafood or supplementation (as recommended by the American Heart Association), continues to be a reasonable strategy,\" said the authors.\n\"The 6 percent reduced risk among RCTs, coupled with an 18 percent risk reduction in prospective cohort studies -- which tend to include more real-life dietary scenarios over longer periods -- tell a compelling story about the importance of EPA and DHA omega-3s for cardiovascular health.\"\n\"There are important public health implications related to reducing the risk of coronary heart disease, and therefore we are encouraged by the results of this comprehensive analysis,\" said Dr. Harry Rice, Vice President of Regulatory and Scientific Affairs for the Global Organization for EPA and DHA Omega-3s (GOED), which funded the study.\n\"It's also important that the observed risk reductions were even stronger in patient populations with elevated triglycerides and LDL cholesterol levels, two risk factors that affect more than one quarter of the American population.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not mention any potential problems associated with omega-3s. And there are potential harms. For example, the University of Maryland Medical Center notes that patients should consult with their doctors about potential interactions with prescription drugs before taking omega-3 supplements, and adds that \u201cHigh doses of omega-3 fatty acids may increase the risk of bleeding, even in people without a history of bleeding disorders, and even in those who are not taking other medications.\u201d There are concerns about other potential harms as well, such as whether fish oil supplements may increase risk for prostate cancer. We don\u2019t expect a news release to include an exhaustive summary of all the possible harms associated with a particular intervention. But we do expect a news release to at least acknowledge that the potential for harms exists, when appropriate.", "answer": 0}, {"article": "Australian drug maker CSL Ltd. published results of a study that found 75 percent to 96 percent of vaccinated people should be protected with a single dose \u2013 the same degree of effectiveness as the regular winter flu shot.\nThe winter flu vaccine is widely available now, and U.S. health authorities urged people to get it out of the way now before swine flu shots start arriving in mid-October.\nThe dose question has an important ramification: It means people will have to line up for influenza vaccinations twice this year instead of three times \u2013 once for the regular winter flu shot and a second time to be inoculated against swine flu, what doctors call the 2009 H1N1 strain.\nBut scientists had feared that people of all ages would need two shots about a month apart because the new H1N1 strain is so genetically different from normally circulating flu strains that most of the population has little if any immunity.\nWaiting to get the first inoculation out of the way \"is not in anybody's best interest,\" added Dr. Nancy Nielsen, past president of the American Medical Association.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\n \nThe story says that the participants in the H1N1 flu vaccine trials reported side effects similar to those seen with seasonal flu vaccination; that is, almost half had some soreness or rash at the injection site or a headache.\n However, the story should have pointed out that these small and very brief trials don\u2019t reveal whether the new H1N1 flu shots may be linked to the sort of rare cases of Guillain-Barre diseases that were seen during the rushed attempt to vaccinate people against a variety of swine flu in 1976.", "answer": 1}, {"article": "TUESDAY, Aug. 2, 2011 (HealthDay News) -- There's still no cure for the common cold, but there may be a way to shorten its misery: A new study suggests that higher doses of zinc lozenges in certain formulations may cut the length of colds by more than 40 percent.\nWhile surprised to note how strong the correlation was between daily doses of zinc and its effect on colds' duration, he said he and his colleagues still don't know why it seems to work.\n\"When focusing on those studies which have used large daily doses of zinc, there is strong evidence that zinc lozenges shorten the duration of colds.\"\n\"I would tell my patients we still don't have a cure [for the common cold], and we don't know if zinc works.\"\nDespite the popularity of zinc supplements, controversy over their effectiveness has continued since a much-publicized 1984 study first suggested a cold-limiting effect.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story suggests that, \u201cNo prior studies showed zinc lozenge use \u2014 even up to 150 mg per day \u2014 might cause harm aside from bad taste or constipation\u201d We give it a pass since it does note the major side effects seen.", "answer": 1}, {"article": "The boxes are a new idea for many Americans.\n\u2018\u2018They do it because they want to be nurturing and they are, but it\u2019s not safe.\u2019\u2019\n\nTo get the boxes, prospective moms can register through babyboxuniversity.com, watch a handful of videos on sleep safety and pass a quiz.\nThe idea for baby boxes started in Finland in the 1930s, and is tied to a sharp drop in sudden infant deaths, according to Dr. Kathryn McCans, a pediatrician who chairs New Jersey\u2019s Child Fatality and Near Fatality Review Board.\nBut when they\u2019re linked to a practice that started in Finland decades ago to help babies sleep safely, they\u2019re taking on a new purpose as so-called baby boxes make their way to the U.S.\n\nParents are beginning to take baby boxes home from hospitals along with their newborns.\nThe boxes aren\u2019t the only option for safe sleeping, of course, but health officials say they\u2019re a useful part of a broader safe-sleep education program.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not include any mention of harms. Just because something doesn\u2019t seem harmful, we would still like a story to note \u201cThere are no known harms\u201d because that means they\u2019ve given it some thought.", "answer": 2}, {"article": "Based on the overall results, Devinsky believes CBD should be evaluated for epilepsy types beyond Dravet syndrome, which is caused by a genetic mutation and affects about one in 20,000 to 40,000 children in the United States.\nShe added that the new study is \"critically important\" for the epilepsy community, which believes a CBD-based medical product would be a first-in-class therapeutic option.\n\"No one study decides an issue; the sample size is still relatively small (because this is a rare syndrome and so hard to study large numbers of cases) and the duration of treatment so far has been relatively short,\" Hall, who was not involved in the research, wrote in an email.\nDespite the generally positive results, most study participants reported side effects that included vomiting, fatigue, diarrhea and some liver issues.\n\"Tiredness (somnolence or fatigue) was most common; others were decreased appetite, diarrhea and vomiting,\" Devinsky explained.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story nicely refers to the harms up high and then returns to them in greater detail later in the piece. It also does something we see too rarely, which is mention how many patients dropped out of the study.", "answer": 1}, {"article": "\u201cWhat does it mean, to improve metabolic health?\nA leading biologist at the Massachusetts Institute of Technology, with backing from five scientists who are Nobel prize recipients, is wading into the murky world of dietary supplements with a new antiaging pill that is said to restore muscle tissue, improve brain function, and increase energy levels by improving \u201cmetabolic health.\u201d\n\nLeonard Guarente, one of the best-known antiaging researchers in the region, and the roster of eminent scientists have formed Elysium Health, which on Tuesday will debut its first product, a pill called Basis.\nMost of them have no scientific basis, and you don\u2019t know what you are getting.\u201d\n\nGuarente was involved in several other efforts to develop antiaging medicines that did not pan out.\n\u201cWe are filling a space by combining natural compounds with scientific validation.\u201d\n\nThe active ingredients in Basis are nicotinamide riboside, a substance that makes NAD and is found in traces in many foods such as milk, and pterostilbene, an antioxidant found in blueberries.\nBut as a supplement, Basis and similar products only have to be shown to be safe for humans to take, with labels that are not misleading.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story suggests that supplements such as\u00a0Basis \u201chave to be shown to be safe for humans to take\u201d prior to being sold, and the story does not mention any potential harms. This language will likely give readers a false sense of security. How can we be sure that a product is \u201csafe for humans to take\u201d if it\u2019s never been tested in humans? Even if we don\u2019t know what specific harms might occur with this supplement, the story could have referenced examples of previous supplements that passed regulatory muster but were subsequently shown to cause serious harm (e.g. ephedra). It could also have mentioned the harm to your wallet of spending $700 a year on an untested product.", "answer": 0}, {"article": "If you need a reason to become a dog lover, how about their ability to help protect kids from allergies and obesity?\nThe theory is that exposure to dirt and bacteria early in life--for example, in a dog's fur and on its paws--can create early immunity, though researchers aren't sure whether the effect occurs from bacteria on the furry friends or from human transfer by touching the pets, said Kozyrskyj.\nThe study also showed that the immunity-boosting exchange occurred even in three birth scenarios known for reducing immunity, as shown in Kozyrskyj's previous work: C-section versus vaginal delivery, antibiotics during birth and lack of breastfeeding.\n\"The abundance of these two bacteria were increased twofold when there was a pet in the house,\" said Kozyrskyj, adding that the pet exposure was shown to affect the gut microbiome indirectly--from dog to mother to unborn baby--during pregnancy as well as during the first three months of the baby's life.\nThe study, funded by the Canadian Institutes of Health Research and the Allergy, Genes and Environment Network (AllerGen NCE), was published in the journal Microbiome, along with an editorial in Nature.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There are no harms mentioned in the release release. Presumably there are some dangers of exposing babies in the womb and newborns to pet dogs and cats but we aren\u2019t given any hint that they exist or what they are. One of the most common \u201charms\u201d associated with furry pets is allergies, the very condition this study purports to lessen or prevent.", "answer": 0}, {"article": "PITTSBURGH, June 2, 2016 - Surgery to remove the primary tumor in women diagnosed with stage IV breast cancer, followed by the standard combination of therapies, adds months to the patients' lives, compared with standard therapy alone, an international clinical trial led by a University of Pittsburgh Cancer Institute (UPCI) professor revealed.\nAt about 40 months after diagnosis, the women who received the surgery plus standard therapy lived an average of nine months longer than their counterparts who received standard therapy alone.\nNearly 42 percent of the women who received surgery lived to five years after diagnosis, compared with less than 25 percent of the women who did not receive surgery.\n\"Our thinking is similar to how you might approach a battle against two enemies,\" said Dr. Soran.\nHalf the women received standard therapy, which avoids surgery and consists of a combination of chemotherapy, hormonal therapy and targeted therapy, while the other half first had surgery to remove their primary breast tumor, followed by the standard therapy.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention in the release of the risks associated with surgery. It\u2019s unclear from the abstract whether the study captured the risks involved in the surgeries.", "answer": 0}, {"article": "(Reuters Health) - Getting too little sleep during the week can increase some risk factors for diabetes, but sleeping late on weekends might help improve the picture, a small U.S. study suggests.\n\u201cBy catching up on sleep on the weekends, people are reducing average extent and severity of the effects of sleep deprivation,\u201d Gangwisch added by email.\n\u201cIdeally, we would all get sufficient sleep on a nightly basis.\u201d\nAfter the four nights of sleep deprivation, the volunteers\u2019 insulin sensitivity had fallen by 23 percent and their bodies had started to produce extra insulin.\nAnd it doesn\u2019t prove that catching up on sleep will prevent diabetes.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Hard to imagine the \u201charms\u201d of getting more sleep, so we\u2019ll rate this Not Applicable.", "answer": 2}, {"article": "NEW ORLEANS (Reuters) - Abbott Laboratories Inc\u2019s experimental Absorb heart stent, designed to dissolve and thereby restore the blood vessel\u2019s natural flexibility, has proven safe and effective a year after being implanted in patients, researchers said.\nThe findings, which follow similarly promising 6-month and 9-month data on the plastic device, were described at the annual scientific sessions of the American College of Cardiology in New Orleans.\n\u201cThe baby will grow and the biodegradable material will disappear,\u201d he said.\nDuring the same period, no blood clots were reported among patients who were far enough along in testing to be evaluated in the 101-patient study.\nHe said Absorb and stents like it will likely be the next generation of stents and ultimately improve outcomes for patients.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story simply stated:\u00a0\u201cAbbott said 6.9 percent of patients suffered major cardiac events \u2014 including heart attacks \u2014 over a 12-month period, which the device maker described as a low rate.\u201d\u00a0 Do independent experts consider that a low rate?\u00a0 We wouldn\u2019t know from the story.\u00a0 And is a 12-month period sufficient to call the device \u201cproven safe and effective\u201d as the opening sentence does?", "answer": 0}, {"article": "For more information about NIH and its programs, visit www.nih.gov.\n\u201cThis important study would not have happened without funding from the National Institutes of Health and the cooperation of two competing companies,\u201d said Adam R. Glassman, M.S., principal investigator of the DRCR.Net Coordinating Center at the Jaeb Center for Health Research.\nThe risk of heart attack, stroke, or death from a cardiovascular condition or an unknown cause by end of the trial was higher among participants in the Lucentis group.\n\u201cThis rigorous trial confirms that Eylea, Avastin, and Lucentis are all effective treatments for diabetic macular edema,\u201d said NEI Director Paul A. Sieving, M.D., Ph.D. \u201cEye care providers and patients can have confidence in all three drugs.\u201d\n\nEylea, Avastin, and Lucentis are all widely used to treat DME, a consequence of diabetes that can cause blurring of central vision due to the leakage of fluid from abnormal blood vessels in the retina.\nAt two years, Eylea participants were able to read about 3.5 additional lines on an eye chart; Lucentis participants were able to read about three additional lines, and Avastin participants improved about 2.5 lines, compared with visual acuity before treatment.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release notes that \u201cThe risk of heart attack, stroke, or death from a cardiovascular condition or an unknown cause by the end of the trial was higher among patients in the Lucentis group. Twelve percent of Lucentis participants had at least one event, compared with five percent of the participants in the Eylea group and eight percent of the participants in the Avantis group.\u201d \u00a0This is useful information. The release also points out that more study is needed to determine if these treatments affect the rate of heart problems or if this observation was due to chance.", "answer": 1}, {"article": "\"More than 30 years since the discovery of the antidepressant effects of sleep deprivation, we still do not have an effective grasp on precisely how effective the treatment is and how to achieve the best clinical results,\" said study senior author Philip Gehrman, PhD, an associate professor of Psychiatry and member of the Penn Sleep Center, who also treats patients at the Cpl.\nThe findings of this meta-analysis hope to provide relief for the estimated 16.1 million adults who experienced a major depressive episode in 2014.\nSuch drugs typically take weeks or longer to experience results, yet 16.7 percent of 242 million U.S. adults filled one or more prescriptions for psychiatric drugs in 2013.\nPrevious studies have shown rapid antidepressant effects from sleep deprivation for roughly 40-60 percent of individuals, yet this response rate has not been analyzed to obtain a more precise percentage since 1990 despite more than 75 studies since then on the subject.\n\"Regardless of how the response was quantified, how the sleep deprivation was delivered, or the type of depression the subject was experiencing, we found a nearly equivalent response rate.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There are many harms associated with sleep deprivation and these are not mentioned. Johns Hopkins has an info-graphic identifying some of them which include adverse effects on mood, memory and health.", "answer": 0}, {"article": "LONDON (Reuters) - In an analysis that set off a fierce debate over the health effects of salt, researchers said on Wednesday they had found no evidence that small cuts to salt intake reduce the risk of developing heart disease or dying prematurely.\nThis gave the researchers enough data to be able to start drawing conclusions, they said.\nThe Cochrane review attracted sharp criticism from nutrition experts.\n\u201cThe people in the trials we analyzed only reduced their salt intake by a moderate amount, so the effect on blood pressure and heart disease was not large,\u201d he said.\nHigh blood pressure, or hypertension, is a major risk factor for cardiovascular diseases \u2014 the leading causes of death worldwide.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not applicable in this story about reducing salt consumption.", "answer": 2}, {"article": "Jan. 6, 2010 -- A new imaging technique that measures the random motion of water within the brain may prove useful for detecting early signs of Alzheimer's disease.\nIn a study published in the Jan. 19 issue of Neurology, Carlesimo and colleagues found that DTI scanning predicted declines in memory performance with more accuracy than traditional MRI.\n\"This type of brain scan appears to be a better way to measure how healthy the brain is in people who are experiencing memory loss,\" Carlesimo says in a news release.\n\"This might help doctors when trying to differentiate between normal aging and diseases like Alzheimer's.\"\nThe technique, known as diffusion tensor imaging (DTI) or diffusion MRI, is used to assess changes in the white matter regions of the brain.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0The story did not mention that 13% of the individuals in the study were unable to complete the test due to claustrophobia and that for 17% of the individuals tested, there were technical difficulties which made their test results unusable.\u00a0 \u00a0\n", "answer": 0}, {"article": "Asked if he's suggesting that it's some kind of a rejuvenation drug that would turn a 70-year-old into a 35-year-old, Westphal tells Safer, \"That might be pretty hard to do.\nYeasts are one thing, human beings are more complicated.\nIn one experiment, a group of rhesus monkeys is on a major diet.\nThe control animals are nearing the end of a typical monkey lifespan, about 27 years, and major differences in their overall health are becoming clear.\nIt is found in high concentrations in the skin of the grape, and seems to play a role in protecting it from invading bacteria and fungi.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention any harms, potential or known.", "answer": 0}, {"article": "With the FDA's announcement, drugs like pembrolizumab have also begun to change the way that physicians, patients and government regulators think of cancer. No longer will they see all cancers of the lung, breast, colon, brain, liver, pancreas and prostate as distinct from one another. Instead, they will look for the common genetic mutations that give rise to cancers no matter where they're found. And they'll treat those cancers with a drug that uses that common signature as a homing beacon, either for the immune system or for targeted cancer drugs to attack.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not alert readers to the serious risks of immunotherapy for cancer. The drug label begins with this alert: \u201cKEYTRUDA can cause your immune system to attack normal organs and tissues in many areas of your body and can affect the way they work. These problems can sometimes become serious or life-threatening and can lead to death.\u201d\nThe story also quotes a researcher gushing about the potential benefits of pembrolizumab, but does not report that this same researcher recently reported the case of a patient who suffered a severe case of scleroderma while taking the drug.\nNot covering the downsides of immunotherapy is something we see a lot\u2013for tips on how to write more accurately about this, see:\u00a0Too many stories ignore or under-report the harms of cancer immunotherapies. Here\u2019s what the public needs to know.", "answer": 0}, {"article": "Visit http://www.\n\"By using this technology in the angiosuite, hospitals can reduce intra-facility transfer delays and hence the time of stroke symptom onset to treatment, which will significantly reduce brain damage and improve outcomes for patients,\" said Nicole Cancelliere, lead author of the study and an interventional clinical research technologist at Toronto Western Hospital.\nThe lead PI on this study, Professor Vitor Mendes Pereira, concluded by saying, \"By reducing intra-facility transfer times, patients can receive EVT treatment sooner, which can significantly impact patient outcomes\".\nThe study, New Multiple CT Assessment of Acute Stroke Patients: Are We Ready for Prime Time?, shows that recent advances in imaging software in the angiosuite give neurointerventionalists the essential details required to diagnose a patient with large vessel occlusion (LVO) for an endovascular thrombectomy (EVT).\nThe imaging allows accurate detection of hemorrhage, occlusion site, ischemic core, and tissue at risk, suggesting that baseline imaging can be performed in the angiosuite using cone beam imaging.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Harms aren\u2019t discussed. Are there potential risks associated with using the new software? The release doesn\u2019t say one way or the other. As noted previously, the study involved adding the new technology to standard care. So it may have actually harmed study patients. More broadly, the study was not designed to assess the relative benefits/harms of this new technique compared to the current standard.", "answer": 0}, {"article": "Scientists are inching closer to a drug that may protect peanut allergy sufferers from potentially life-threatening complications that can occur due to accidental consumption.\nWe were pleased to find that two thirds of people in the study were able to tolerate the equivalent of two peanuts per day after nine to 12 months of treatment, and half the patients tolerated the equivalent of four peanuts.\u201d\n\nFDA WARNS AGAINST HONEY PACIFIERS AFTER TEXAS INFANTS HOSPITALIZED WITH 'RARE' ILLNESS\n\nThe results, which were presented Sunday at the College of Allergy, Asthma and Immunology Annual Scientific Meeting and published in the New England Journal of Medicine, were based on study participants ranging in age from 4 to 55 years old.\nIn addition, the symptoms caused by the 100-fold higher dose at the end of the study were milder than the symptoms on the lower dose at the beginning of the study.\u201d\n\nEXPERTS: CHILDREN AT RISK OF LEAD POISONING IN CHATTANOOGA\n\nWith FDA approval this drug would mark the first treatment available by prescription for peanut allergies.\n\u201cWe\u2019re excited about the potential to help children and adolescents with peanut allergy protect themselves against accidentally eating a food with peanut in it,\u201d said allergist Stephen Tilles, MD, ACAAI former president, study co-author and consulting advisor for Aimmune Therapeutics, according to EurekAlert.\n\u201cThis is not a quick fix, and it doesn\u2019t mean people with peanut allergy will be able to eat peanuts whenever they want,\u201d Jay Lieberman, MD, vice chair of the ACAAI Food Allergy Committee and study co-author, said, according to EurekAlert.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention harms \u2014 and harms were significant. The CNN story reported that 11% of participants dropped out of the study as a result of untoward effects of treatment, and other participants (who completed the study) had allergic reactions requiring treatment.\nIt also left out important issues such as the high dropout rate among those who received the treatment, and unknown long-term effects.", "answer": 0}, {"article": "The average age of people in both groups was 73.\n\"We could tell that the individuals who went on to develop dementia have these differences on diffusion MRI, compared with scans of cognitively normal people whose memory and thinking skills remained intact,\" Raji said.\nThe findings, presented Sunday, Nov. 25 at the Radiological Society of North America meeting in Chicago, suggest that doctors may one day be able to use widely available tests to tell people their risk of developing dementia before symptoms arise.\n\"Right now it's hard to say whether an older person with normal cognition or mild cognitive impairment is likely to develop dementia,\" said lead author Cyrus A. Raji, MD, PhD, an assistant professor of radiology at Washington University's Mallinckrodt Institute of Radiology.\n\"We showed that a single MRI scan can predict dementia on average 2.6 years before memory loss is clinically detectable, which could help doctors advise and care for their patients.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release did not delve into potential harms, including anxiety and false results. If a test is accurate 95% of the time, five out of 100 people will get either a false positive, which can lead to more tests and anxiety, or a false negative, which can be wrongly reassuring.", "answer": 0}, {"article": "Abroms and her team wanted to find out if a more intensive mobile phone program called Quit4baby would be more effective.\nWASHINGTON, DC (Oct. 2, 2017) -- An intensive text messaging program provides some pregnant women help in fighting the urge to light up a smoke, according to a study out today.\n\"Our findings show that a text messaging program helped some groups of pregnant women quit smoking during pregnancy,\" says lead author Lorien C. Abroms, ScD, MA, an associate professor of prevention and community health at Milken Institute School of Public Health (Milken Institute SPH) at the George Washington University.\nThe combo of Text4baby and Quit4baby helped women age 26 and older and those in the second and third trimester of pregnancy quit through the delivery date and in some cases beyond.\nThe messages help educate the women about the health risks associated with smoking and they are interactive--allowing a woman to text back for more help if she is experiencing a craving or goes back to smoking.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention of harms but it\u2019s hard to imagine there are any harms from voluntarily receiving from 1 to 8 text messages a day. We\u2019ll rate this Not Applicable.", "answer": 2}, {"article": "The ancient art of applying suction cups to the body has gotten a boost from several new studies that show it helps relieve a variety of painful conditions. But scientists say larger, more rigorous studies are needed.\n\nCupping, as the practice is called, was performed traditionally in China and other countries, and is now available from acupuncturists, and some chiropractors and massage therapists in the U.S. In the traditional method, called fire cupping, a ball of burning cotton is briefly placed inside a glass cup to heat...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Possible harms are never discussed in the story. The story does mention that cupping \u201cshouldn\u2019t be done on pregnant women, people with heart conditions or people with bleeding disorders,\u201d but why not? There are other possible harms, such as spread of resistant bacteria by not properly cleaning instruments.", "answer": 0}, {"article": "However, some patients developed new tumors in that time period, the researchers noted.\nFunding for their work was provided by Galil Medical, a medical device manufacturer based in Arden Hills, Minn.\n\nBecause this study was presented at a medical meeting, the conclusions should be considered preliminary until published in a peer-reviewed journal.\nThe result: Among the 15 patients seen roughly three months post-procedure, tumor control was found to be 100 percent, although six patients were found to have developed new lung tumors in the interim.\nThe U.S. National Cancer Institute points out that while cryoablation (also known as cryosurgery) is a well-known practice, researchers are still in the process of assessing its long-term benefits.\nFor his part, Dr. David Carbone, a professor and director of the James Thoracic Center at the Ohio State University Wexner Medical Center, said that the findings regarding cryoablation are \"not incredibly novel,\" given that the procedure has been around for years.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story was cautious in reporting:\n\u201cThe authors noted that side effects were minimal, typically involving air or fluid around the lungs after the procedure, and in all cases were resolved quickly.\nThe team concluded that cryoablation appears to be both safe and effective, at least in the short-term. But they acknowledged that more research needs to be done to track the treatment\u2019s impact over the long haul.\u201d\nA further caution could have been that we don\u2019t know what patients think about such side effects being described as \u201cminimal\u201d and that we were only hearing this from the researchers announcing their findings.", "answer": 1}, {"article": "New research analyzing more than 22,000 U.S. cases of aortic aneurysm repair is likely to hasten the trend toward more procedures being done with a device called a stent-graft instead of the typical surgery that requires up to eight weeks of recovery.\n\nThe study by doctors at Harvard Medical School and the federal Centers for Medicare and Medicaid Services found the death rate in surgery, 4.8%, was four times that of the 1.2% death rate in placing stent-grafts to seal off the aneurysm. Surgery tended to provide a more permanent...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story compared the percentage of patients dying during the two procedures as well as the percentage who would need re-treatment at a later point in time. \u00a0But the story did not mention that there is evidence that the endovascular repair in those who are not physically well enough to undergo the open procedure does not provide benefit in terms of mortality. Thus for a subset of patients, undergoing the procedure and accompanying recovery involves the harm of discomfort and risk without benefit.", "answer": 0}, {"article": "The main stages of NAFLD are:\n\n1.\nCirrhosis - the most severe stage, occurring after years of inflammation, where the liver shrinks and becomes scarred and lumpy; this damage is permanent and can lead to liver failure (where the liver stops working properly) and liver cancer\n\nIt can take years for fibrosis or cirrhosis to develop and the presence of this scarring predicts those people with the worse prognosis.\nNon-alcoholic steatohepatitis (NASH) - a more serious form of NAFLD, where the liver has become inflamed; this is estimated to affect up to 5% of the UK population \n\n3.\nIt is the first time an epigenetic signature in blood has been discovered which is diagnostic of the severity of fibrosis for people with Non-alcoholic Fatty Liver Disease (NAFLD).\nTeam develop a DNA-based test that determines the degree of fibrosis in the liver -- this could be a replacement for a liver biopsy\n\nNewcastle scientists and medics have developed a new type of genetic blood test that diagnoses scarring in the liver - even before someone may feel ill.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There\u2019s no discussion of potential harms. How accurate is the new blood test? Is there a risk of false positives or misdiagnosis \u2014 and, if so, how high is that risk? The investigators assembled only a small number of carefully selected patients. Many were excluded if they had other liver diseases as well as complications from alcohol. And\u00a0the as-yet undetermined potential for both false positive and false negative results could certainly undermine its value in reassuring patients.", "answer": 0}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/03/12/national/a180226S32.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "", "answer": 1}, {"article": "\u201cBut there were other components to it -- there was oppositional defiant disorder, there were some [autism] spectrum-like behaviors, and difficulty later on socializing with other children.\u201d\n\nOppositional defiant disorder is one of the most common conditions linked to ADHD in children and is characterized by anger, tantrums, opposition to authority and, sometimes, aggressive behavior.\nThe spectrum of ADHD and related disorders is broad, and there is no one-size-fits-all treatment.\nShe has since gone on to complete two more cycles of Brain Balance learning and no longer takes medication to manage her condition.\n\u201cWhat thinking really is is really coordinating different networks in the brain so that we can bring all of those networks together at one time,\u201d Melillo told FoxNews.com.\nParents are a big part of the learning experience and are tasked with at-home exercises to do with their kids.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not discuss any potential harms.", "answer": 0}, {"article": "Marion Nestle, a nutrition professor at New York University, says longer studies conducted among people in their own environments, not with such controlled meals, have shown \"little difference in weight loss and maintenance between one kind of diet and another.\"\nThe research finds that dieters who were trying to maintain their weight loss burned significantly more calories eating a low-carb diet than they did eating a low-fat diet.\nThe diets had the same number of calories, but the fat, protein and carbohydrate content varied.\nA new study is raising questions about the age-old belief that a calorie is a calorie.\nParticipants were fed food that was prepared for them by diet experts.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes that the low-carb diet raised some risk factors for heart disease.", "answer": 1}, {"article": "Hoberman is chief of the general academic pediatrics division at Children's Hospital of Pittsburgh of UPMC.\n\"Given significant concerns regarding overuse of antibiotics and increased antibiotic resistance, we conducted this trial to see if reducing the duration of antibiotic treatment would be equally effective along with decreased antibiotic resistance and fewer adverse reactions,\" Dr. Alejandro Hoberman said in a university news release.\nWEDNESDAY, Dec. 21, 2016 (HealthDay News) -- A shorter period of antibiotic treatment for ear infections in young children does more harm than good, a new study finds.\n\"The results of this study clearly show that for treating ear infections in children between 9 and 23 months of age, a five-day course of antibiotic offers no benefit in terms of adverse events or antibiotic resistance,\" Hoberman said.\nThe children ranged in age from 9 months to 23 months, and were randomly selected to receive either a standard 10-day course of antibiotics or a shortened five-day course of antibiotics followed by five days of placebos.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions there were no differences in the rate of antibiotic resistance, diaper rash or diarrhea. This is just enough information to rate satisfactory\u2013but barely.\nBut unfortunately we know those markers would likely be higher in a cohort of kids taking antibiotics, versus those taking nothing (placebo). \u00a0Without a placebo arm in this trial, we have no idea what the rate of adverse effects would have likely been. A stronger story would have pointed this out.", "answer": 1}, {"article": "For the work, a cohort of 541 9- to 11-year-olds in China, 54 percent boys and 46 percent girls, completed a questionnaire about how often they consumed fish in the past month, with options ranging from \"never\" to \"at least once per week.\"\n\"It really has to be a concerted effort, especially in a culture where fish is not as commonly served or smelled.\nPrevious studies showed a relationship between omega-3s, the fatty acids in many types of fish, and improved intelligence, as well as omega-3s and better sleep.\n\"Children should be introduced to it early on.\"\n\"This area of research is not well-developed.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Current dietary recommendations include warnings about some commonly eaten types of fish that are high in mercury, but this or any other potential drawbacks associated with consuming fish were not mentioned.", "answer": 0}, {"article": "\u201c[PRP] works, and the results have been amazing,\u2019\u2019 says John Ferrell, the sports medicine physician who treated me.\nWe will be able to treat ailments noninvasively, and at an earlier stage.\u2019\u2019\n\nThe procedure involves collecting several ounces of blood from a patient\u2019s arm, spinning the blood in a centrifuge to concentrate the platelets and injecting the concentrated platelets into the injury site to stimulate healing.\nThe American Academy of Orthopaedic Surgeons \u2014 which says PRP \u201cholds great promise\u2019\u2019 \u2014 describes the risk as minimal.\nThe researchers call the results \u201cclinically relevant,\u2019\u2019 despite the study\u2019s small size, and say the next step should be a larger, controlled clinical trial.\nThe average treatment is two injections, which costs about $1,000 at his practice, whereas rotator-cuff surgery runs about $13,000, he says, although insurance often covers most of the costs of surgery.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The only mention of potential harms in the story comes in this statement:\u00a0 \u201cThe American Academy of Orthopedic Surgeons \u2014 which says PRP \u2018holds great promise\u2019 \u2014 describes the risk as minimal.\u201d\u00a0 That\u2019s not\u00a0acceptable given that there is no explanation of what those risks might be. Readers are\u00a0left\u00a0clueless when it comes to questions of potential harms.", "answer": 0}, {"article": "That's according to a study just published in the journal CANCER.\nThe new study discrediting the test, coupled with persistent questions about how useful prostate screening is for most men anyway, add up to a whole lot of discussion points patients should take to their doctors.\nBefore treatment recommendations are made, doctors put most prostate tumors through other tests, too, like the Gleason score, and they look at the percentage of biopsies that are positive for cancer cells.\nResearchers Say Common Test For Prostate Cancer May Not Work\n\nMore bad news on the prostate cancer front: A widely used test that's supposed to help doctors and patients predict the outcome of most prostate cancers is basically worthless.\n\"Our findings question the utility of our current staging system for localized prostate cancer,\" says Dr. Adam Reese of the University of California at San Francisco, lead author of the study.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentioned that doctors \u2018erred 35% of the time\u2019 with clinical staging and this leads doctors to conclude that a given prostate cancer \u201cis less serious than it really is.\u201d\u00a0 However \u2013 this is only half of the story.\u00a0 There\u2019s also a significant harm that occurs from overtreatment of lesions that were never destined to be problematic. \u00a0To be balanced and complete, the story should have mentioned this as well because it is another important problem.\nFor example, a MedPageToday story addressed this issue:\u00a0 \u201cFor those men with prostate cancer found to have been staged incorrectly, the assigned clinical stage was too low 55.1% of the time \u2014 and too high in 44.9% of cases.\u201d", "answer": 0}, {"article": "The results have been published in the Journal of Clinical Oncology.\nThere is currently no cure and few treatment options for advanced pancreatic cancer, which is the late stage when pancreatic cancer is usually diagnosed\", explains Carl Borrebaeck, professor at the department of Immunotechnology at Lund University.\nA new blood test developed by researchers at Lund University in Sweden, Herlev Hospital, Knight Cancer Center and Immunovia AB, can detect pancreatic cancer in the very earliest stages of the disease.\nIn the future, the screening method could be used to screen people who are at a higher risk of developing pancreatic cancer, such as those with a hereditary risk, newly onset diabetes patients and patients with chronic inflammation of the pancreas.\nThe blood test is developed on a so-called antibody microarray that consists of hundreds of recombinant antibody fragments.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Harms are not discussed and two types of harms are relevant here. The study \u2014 but not the news release \u2014 mentions a false-positive rate of 6%; that\u2019s the fraction of people erroneously diagnosed with a cancer they don\u2019t have. (Who might then go on to endure the costs and risks involved with subsequent evaluation.)\nThe flip side would be: what\u2019s the false-negative rate? That\u2019s the number of people who are told they\u2019re cancer-free but really aren\u2019t. The potential emotional harm in this case is quite clear.\nThis is important as well because pancreatic cancer is a rare condition. We know that a good screening test works best when the disease has high prevalence in a population, so when dealing with something rare, the 6% leading to harms may mean something very different.", "answer": 0}, {"article": "The pain relief could last for weeks.\n\u201cBut it\u2019s not.\u201d The pain associated with tendinopathies tends to fall somewhere around a 7 or so on a 10-point scale of pain.\nThe evidence for cortisone as a treatment for other aching tendons, like sore shoulders and Achilles-tendon pain, was slight and conflicting, the review found.\nThere will always be a longing for a magical pill, the quick fix, especially when the other widely accepted and studied alternatives for treating sore tendons are to do nothing or, more onerous to some people, to rigorously exercise the sore joint during physical therapy.\nThe injuries were, as a group, given the name tendinitis, since the suffix \u201c-itis\u201d means inflammation.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\nThe article provided adequate detail on the main harms associated with steroid injections: disruption of the long-term healing process and relapse into pain and disability. It might have been useful to also mention other potential side effects and potential harms related to steroid injections.\n", "answer": 1}, {"article": "The U.S. Food and Drug Administration approved the first therapy to treat an underlying cause of cystic fibrosis, a pill that targets a genetic mutation affecting a small minority of patients suffering from the life-threatening breathing disorder.\n\nThe drug, Kalydeco, from Vertex Pharmaceuticals Inc., will be among the most expensive therapies on the market, costing $294,000 a year.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion of potential harms from the drug.\nThe prescribing information for the drug states: \u201cOverall, the most common adverse reactions in 353 patients with CF were headache (17%), upper respiratory tract infection (16%), nasal congestion (16%), nausea (10%), rash (10%), rhinitis (6%), dizziness (5%), arthralgia (5%), and bacteria in sputum (5%).\u201d", "answer": 0}, {"article": "The researchers did not study nasal zinc remedies, however.\nAlthough the precise estimate is still uncertain, researchers found that people who started taking zinc-loaded lozenges or syrups within 24 hours of showing symptoms \u2014 a sore throat, say, or runny nose \u2014 shortened their cold by one day.\nExactly how well zinc works is a matter of future research, and the one day estimate may well change, the researchers note.\nWhile the episodes usually aren\u2019t serious, the resulting visits to the doctor alone cost the U.S. an annual $7.7 billion, according to the new report.\nThe review, published by the Cochrane Collaboration, an international organization that evaluates medical research, also shows that people taking the supplements tended to have milder symptoms.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story didn\u2019t quantify the potential harms, but did discuss the side effects. This story says, \u201cSingh said the side effects of zinc lozenges, which can be bought for a few dollars in any drug store in the U.S., come down to bad taste and some cases of nausea.\u201d\u00a0The full listing in the article includes constipation, diarrhea, abdominal pain, dry mouth and oral irritation. Because the story downplayed the side effects in a story that is essentially encouraging long-term zinc use, we rate this unsatisfactory.", "answer": 0}, {"article": "In another study released during the Wednesday press conference, researchers from M.D.\nSpeaking at the teleconference, Dr. Jennifer Obel, chair of the American Society of Clinical Oncology's communications committee, said: \"This study adds to our knowledge of mammogram performance in this age group.\nThat recommendation met with outrage from breast cancer specialists, while other organizations, including the American Cancer Society, continued to recommend annual mammograms for women in their 40s.\nIn all, more than 1 million women were involved in the study and the follow-up period was a lengthy 16 years.\nThe findings will no doubt do little to quell a controversy that has existed since the 1980s over the value of mammography screenings for women in their 40s.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does a poor job discussing any harms of screening women starting at age 40.\u00a0 We are not told if women 40-44 had more false positive and unncessary biopsies ,or unncessary breast cancer surgery or treatments\u00a0 for pre-cancerious lesions. We are also not told of the risks of additional radiation exposure on the risk future of breast cancers.\u00a0 We are not given the number needed to harm (NNH) for additional radiation exposure over 10 years of screening. ", "answer": 0}, {"article": "They returned at weeks 26, 39 and 52 for safety assessments, which included an evaluation of adverse events, clinical laboratory tests and physical examinations.\n\u2022 LPCN 1021 was well tolerated and had a favorable safety profile in the long-term management of hypogonadal patients\n\u2022 No hepatic, cardiac or drug-related serious adverse events were reported\n\u2022 The most common drug-related adverse events for LPCN 1021 and T gel 1.62 percent were acne (2.9 percent vs. 2.9 percent, respectively), headache (0.5 percent vs. 3.8 percent, respectively), weight increase (2.4 percent vs. 0 percent, respectively), hematocrit increase (1.9 percent vs. 0 percent, respectively), liver enzyme level increase (1.4 percent vs. 0 percent, respectively), fatigue (0.5 percent vs. 1.9 percent, respectively), and hypertension (0.5 percent vs. 1.9 percent, respectively)\n\u2022 Lipid parameters (i.e., cholesterol, LDL, HDL, and TG) were comparable between treatment groups at Week 52\n\u2022 Androgenic parameters including hematocrit, hemoglobin, platelet, prothrombin, and prostate-specific antigen (PSA) showed no significant differences in change from baseline to end of study between treatments\n\n\"Based on the results of this study, we might be closer than ever to having an oral form of therapy to treat the millions of men with hypogonadism,\" said Dr. K\u00f6hler.\nThe research will be highlighted by study authors during a special press conference to be moderated by Tobias S. K\u00f6hler, MD, MPH, FACS, AUA spokesperson and associate professor of Surgery at Southern Illinois University on May 8, 2016 at 7:30 a.m. PT in the San Diego Convention Center.\n\"Making sure an oral treatment is safe and effective for men and for the children and partners at risk for inadvertent testosterone transference is the top priority, and what we've found so far has shown we're on the right track.\"\nThere is currently no oral form of testosterone therapy approved for use in the United States by the Federal Drug Agency; however researchers from Houston, TX and Torrance, CA have been evaluating the long-term safety and tolerability of LPCN 1021, a novel oral testosterone undecanoate formulation for the treatment of low testosterone.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release does describe adverse effects reported in the study, including that there were no \u201chepatic, cardiac or drug-related serious adverse events.\u201d It lists the percentages of patients in each of the treatment groups who had certain adverse effects, and notes that lipid levels were comparable in the two groups and androgenic measurements showed no significant differences during the study period. However, the news release fails to acknowledge long-term safety concerns, including the FDA\u2019s call last year for manufacturers to conduct a controlled clinical trial to clarify how testosterone might affect cardiac health. The abstract presented at the medical conference (the only available information about the study) states that the total numbers of adverse events was almost the same in both groups (67% in oral group compared with 65% in the topical group) without specifying the statistical significance of that result or the types of adverse effect in these groups. \u00a0The adverse events given only add up to about 10% in both groups.", "answer": 0}, {"article": "The study's authors acknowledged that their preliminary data offers \"promise for the use of time-restricted feeding as a weight loss technique in obese adults, but longer-term, large-scale randomized controlled trials [are needed].\"\nVarady stressed that \"when it comes to weight loss, people need to find what works for them, because even small amounts of success can lead to improvements in metabolic health.\"\nKrista Varady, one of the study's authors and associate professor of kinesiology and nutrition at the University of Illinois at Chicago's School of Applied Health Sciences, said in a statement that the take-home message from the study is that cutting out certain foods or counting calories aren\u2019t the only effective methods for losing weight.\nFasting diets have gained popularity in the past few years, but the scientific evidence proving that they keep us healthy while they help us lose weight is sparse.\n\"But one of the benefits of the 16:8 diet may be that it is easier for people to maintain.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Fasting for brief periods is pretty safe, although the story could have mentioned risks of dehydration, sleep problems, or headaches that might come from getting too hungry.", "answer": 1}, {"article": "\u201cThis paper,\u201d Dr. Hu said, \u201cdemonstrates that there are hidden risks for patients who opt for laparoscopic or robotic surgery.\u201d\n\nIn laparoscopy, a surgeon inserts instruments through small cuts in the skin instead of making large incisions to expose the organs.\nThe study, published on May 10 in The Journal of Clinical Oncology, examined a sample of 2,702 Medicare patients undergoing radical prostatectomy, the complete removal of the prostate, from 2003 to 2005.\nThe laparoscope is a slender tube that allows the surgeon to see inside the body.\nThe widely advertised procedure is becoming more popular, said Dr. Jim C. Hu, the lead author of the study and an instructor in surgery at Harvard.\nLaparoscopic operations for prostate cancer, a minimally invasive surgery that is in rising demand, result in fewer immediate complications and quicker recovery than the more common open procedure, a new study reports.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story explictly compares the harms of the two surgical approaches in terms of short-term complications and longer-term consequences. ", "answer": 1}, {"article": "People who have chronic inflammation because of chronic infection, autoimmune disease or conditions such as obesity have a higher cancer risk because of damage to normal cells.\n\"After screening a natural compound library, we developed an unbiased look at combinations of nutrients that have a better effect on prostate cancer than existing drugs,\" says corresponding author Stefano Tiziani, assistant professor in the Department of Nutritional Sciences and Dell Pediatric Research Institute at UT Austin.\nThe most promising active ingredients were then tested on model animals: ursolic acid, a waxy natural chemical found in apple peels and rosemary; curcumin, the bright yellow plant compound in turmeric; and resveratrol, a natural compound common to red grapes or berries.\nNew research from The University of Texas at Austin identifies several natural compounds found in food, including turmeric, apple peels and red grapes, as key ingredients that could thwart the growth of prostate cancer, the most common cancer afflicting U.S. men.\nWhen you dine on curry and baked apples, enjoy the fact that you are eating something that could play a role starving -- or even preventing -- cancer.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Plant chemicals are generally considered safe, but there\u2019s potential for toxicity if they\u2019re consumed in combination with certain drugs or at high concentrations. There\u2019s added risk for consumers who buy these substances in the form of dietary supplements, which are not tightly regulated by the FDA.", "answer": 0}, {"article": "Bringing this program into the mainstream presents some challenges, however.\nOverall, the trained group found 51 early melanomas during the study, compared to 18 melanomas found by a comparison group of patients and partners who didn\u2019t receive training.\nFor now, she said people can go to the American Academy of Dermatology's website to learn the steps - known as the ABCDEs - of finding melanoma (bit.ly/2h9zl0Y).\n\u201cTheir confidence level goes up and plateaus at eight to 12 months, and it doesn\u2019t go down,\u201d said Robinson.\n\u201cThere was concern that they might be embarrassed by examining areas of the body that aren\u2019t normally seen close up,\u201d said lead author Dr. June Robinson, of Northwestern University Feinberg School of Medicine in Chicago.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Having a partner check for melanomas doesn\u2019t have immediate harms, so we\u2019ll rate this N/A. It could be harmful if a person relies too heavily on a friend\u2019s assessment versus a physician\u2019s though.", "answer": 2}, {"article": "Prologo consults for Galil Medical, which funded the study.\n\"That's about what you see with standard drug therapy,\" says researcher J. David Prologo, MD, assistant professor of interventional radiology at Case Western Reserve University\u2019s School of Medicine in Cleveland.\nThey lasted an average of 110 seconds before ejaculation, or nearly two minutes, over the three months they were followed, compared with 36 seconds before treatment.\nDec. 2, 2011 (Chicago) -- An experimental approach in which penile nerve tissue is frozen to knock out overactive nerves helped men with premature ejaculation last three times longer.\nIts supporters say the technique, or a similar one involving heat therapy, could someday become a standard treatment for the condition.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story states that there were \u201cno side effects\u201d from the procedure, but then goes on to explain that three men reported that their erections weren\u2019t as firm after the procedure.\u00a0Call us picky, but wouldn\u2019t that count as a side effect? We were pleased to see some mention of the potential for nerve damage if the procedure needs to be repeated in order to maintain its effectiveness. But there should have been some\u00a0acknowledgment that this study\u00a0was\u00a0far too small to accurately assess potential harms of the procedure. A mixed bag, but enough concerns were raised to give the benefit of the doubt on this one.", "answer": 1}, {"article": "Check out more than one clinic and make sure you know what it defines as a \u201csuccess\u2019\u2019 \u2014 a viable transferring of an egg leading to a baby, or just a safely thawed egg.\n\u25a0 The \u201csuccess\u2019\u2019 rates of egg freezing may vary widely from one fertility center to another.\nDiscarding an unused embryo, which has the potential to develop into a baby, has weightier implications for many than discarding unused eggs.\n\u25a0 After a woman\u2019s mid-30s, her eggs may not be of high enough quality to produce a baby.\nThings to consider before freezing your eggs\n\n\u25a0 Beware of a false sense of security.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The sidebar has a list of bullets of \"things to consider before freezing your eggs\" that is, in essence, a list of potential harms. ", "answer": 1}, {"article": "\"Sometimes [the mother] is a bit uncomfortable, or sometimes Dad has to go on a business trip or Grandma wants to fly in,\" Lavin said.\nAll of the women had previously had C-sections.\nOf those, more than 13,000 had elective C-sections.\n\"This happens to me every day,\" Lavin said.\nThe Associated Press and McClatchy Newspapers contributed to this story.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story adequately describes the harms of C-section.", "answer": 1}, {"article": "\u201cThe goal is to develop a blood test, such as this one, that can accurately identify cancers in their earliest stages.\u201d\n\nKlein added: \u201cIt is several steps away and more research is needed, but it could be given to healthy adults of a certain age, such as those over 40, to see if they have early signs of cancer.\u201d\nThe test had particularly good results for ovarian and pancreatic cancers, though the number of cancers detected was small.\nThe number of patients in whom cancers were detected was small.\n\u201cNow, as the NHS marks its 70th anniversary, we stand on the cusp of a new era of personalised medicine that will dramatically transform care for cancer and for inherited and rare diseases,\u201d said Stevens.\nLung cancer was detected in 59% of patients.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story includes no mention of what many experts consider to be the most important considerations when it comes balancing the harms vs. benefits of liquid biopsies. These include:", "answer": 0}, {"article": "The procedure, called a prostatic urethral lift, does not improve flow as much as surgery, in which a physician cuts away some of the inside of the prostate to allow better flow. But the lift procedure and recovery are much quicker, with no hospital stay and fewer complications. And patients who get the sutures can always come back for surgery later.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The minimally invasive surgery seems safer than other kinds of surgery, but without any specific details on the potential for harms, we can\u2019t be sure. We are told that most patients experienced more frequent urination after the procedure, but that the improvements\u00a0may take four weeks or so to be seen.", "answer": 0}, {"article": "\"We estimate that use of [Brilinta] instead of [Plavix] for one year in 1,000 patients with acute coronary syndromes and who are planning to undergo an invasive strategy at the start of drug treatment would lead to 11 fewer deaths, 13 fewer myocardial infarctions, and six fewer cases of stent [clotting] without an increase in the rates of major bleeding or transfusion,\" conclude study researcher Christopher P. Cannon, MD, and colleagues.\nAnd since the drugs irreversibly bind to blood-clotting platelets, a patient has to stop taking these drugs for five to seven days before the body can make enough new platelets.\nThat's probably why the 6,732 study patients who got Brilinta were 16% less likely to die, or have a heart attack or stroke, than were the 6,676 patients who got Plavix.\nThe new kid on the block is AstraZeneca's ticagrelor, to be named Brilinta if the experimental drug gets FDA approval.\nStone has in the past received honoraria from the makers of both Plavix and Brilinta and serves on the advisory boards of Boston Scientific and Abbott Vascular.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0The story did discuss the main harm \u2013 the difference in bleeding \u2013 and that since\u00a0 ticagrelor must be taken twice a day, missing a dose can be very dangerous since the drug wears off so quickly.", "answer": 1}, {"article": "By March, Ramas could hardly walk.\n\"In the past, we would have had to wait to diagnose Parkinson's or chosen different medications to test, which might have had different side effects, and this would have delayed the timely diagnosis of Parkinson's,\" Xie said.\nA new scan to help in difficult-to-diagnose cases of Parkinson's disease or other parkinsonian syndromes is available at more than 80 U.S. hospitals, including some in the Chicago area, since receiving federal approval earlier this year.\nIn cases where a diagnosis isn't necessarily clear-cut, the DaTscan offers important advances in patient care and treatment, said Dr. Michael Rezak, director of the Movement Disorders Center at Central DuPage Hospital, where the scan is offered.\nAs part of the study, recently diagnosed Parkinson's patients and healthy subjects are tested with DaTscan, and clinical and behavioral assessments are done to identify biomarkers of Parkinson's disease progression.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nThe story does not mention potential harms, including the potential cancer risk from radioactive iodine that is injected into patients as part of the DaTscan. The drug label warns that clinicians must use a blocking agent to prevent the patient\u2019s thyroid from taking up the radioactive iodine.\nThe story should have also reported that although adverse reactions were uncommon in clinical studies, some people did have hypersensitivity reactions such as rash and itching, and that less than 1 percent of patients reported mild to moderate headache, nausea, vertigo, dry mouth or dizziness. The story would have been better if it also noted that since the studies included fewer than 300 patients, side effects that occur only rarely might not have shown up.\nFDA-approved label for DaTscan:\nhttp://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022454sOrig1s000Lbl.pdf", "answer": 0}, {"article": "\"They have a lot of promise and are potentially very important,\" said Katherine Hamilton, a headache specialist at Penn Medicine. The drugs, which are injected under the skin, offer hope for patients who have not responded to other treatments, but Hamilton said that what is \"potentially even more clinically relevant is they have a lower side-effect profile\" than other medications commonly used for migraine. She added, though, that it remains to be seen how patients who take them for long periods will fare. As new drugs, their long-term impact is not yet known.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story addressed the major concern with these medications: that it \u201cremains to be seen how patients who take them for long periods will fare. As new drugs, their long-term impact is not yet known.\u201d\nThe story story also reported the new drugs have \u201ca lower side-effect profile\u201d than other medications commonly used for migraine, and mild constipation was the most serious side effect of the drugs in the trials.\nThe story could have mentioned other adverse events. For example, with Emgality, hypersensitivity reactions such as rashes were reported in clinical studies.", "answer": 1}, {"article": "The World Health Organization estimates that more than 300 million people suffer from clinical depression world-wide. But cost, time, stigma, distance to travel, language barriers and other factors prevent many from seeking help.\n\nNow, a growing group of health-care providers are betting that technology\u2014from web-based courses to mobile apps that send prompts via text\u2014can help bridge that gap.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Risks are not broached here. This is an issue for a topic such as this, as one could imagine readers expressing concern about the efficacy of a non-human \u201ctherapist.\u201d The story actually acknowledges that concern in its second paragraph (\u201cIt [the use of technology] might seem surprising, since therapy, more than many other kinds of medicine, is so focused on the relationship between patient and therapist.\u201d But it never digs into the possible debits of wrestling with moderate depression online. We also think the story should have discussed the risk patients being victimized in an open source or relatively open chat room or other online group setting. One important element of psychiatry is privacy and patient confidentiality.", "answer": 0}, {"article": "So far, however, there is little scientific proof of their effectiveness\u2014many studies of probiotics have involved less-than-rigorous...\nOne of the fastest-growing dietary supplements, probiotics are now prominent on drug and big-box store shelves.\nThey are live microorganisms\u2014or \"good\" bacteria\u2014that when consumed in capsules or yogurt are said to confer a health benefit.\nProbiotics are widely used to aid digestion and help restore gut bacterial balance after antibiotics.\nProbiotics, believed to help with digestion, are increasingly being studied to treat wide-ranging conditions, from colic to cholesterol and the common cold.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story says that probiotics are generally considered safe except for individuals with a compromised immune system. That\u2019s accurate.", "answer": 1}, {"article": "Newswise \u2014 Bethesda, Md.\nThe researchers acknowledge that statin drugs can contribute to liver damage in some people, but for people with advanced liver disease, \u201c[s]tatins are cost-effective, generally well-tolerated by patients and the benefits of statin treatment in most patients outweigh their potential hepatotoxic risk.\u201d\n\nRead the full article, \u201cRationale for the use of statins in liver disease\u201d published ahead of print in the American Journal of Physiology\u2014Gastrointestinal and Liver Physiology.\nStatin use may also lead to:\n\u2022 Decreased fibrosis (hardening or scarring of tissue),\n\u2022 Less development of fatty liver,\n\u2022 Slowed or halted spread of hepatitis C virus,\n\u2022 Improvement of portal hypertension (high blood pressure in the liver\u2019s blood vessels),\n\u2022 Destruction of existing liver tumor cells, and\n\u2022 Reduced risk of developing liver cancer.\nBut in a new review of more than 50 studies, researchers cite reductions in liver inflammation and improvements in other related factors as reasons why statins make good candidates for treating chronic liver disease.\nReducing cholesterol can have a positive effect on many chronic liver disorders, including non-alcoholic fatty liver disease and non-alcoholic steatohepatitis, as well as in biliary disorders.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The researchers acknowledge that statin drugs can contribute to liver damage in some people, but the statement that \u201cstatins are cost-effective, generally well-tolerated by patients and the benefits of statin treatment in most patients outweigh their potential hepatotoxic risk,\u201d doesn\u2019t seem to adequately address the potential harms.\nPeople who are prescribed statins must undergo liver function tests since this class of drugs can cause rare but serious liver dysfunction. Deciding to give someone with advanced liver disease a statin as a means to help the patient\u2019s liver is unproven and has the potential for real harm.\nWe aren\u2019t provided any context on how significant the damage can be to those with advanced liver disease, or even in otherwise healthy people.", "answer": 0}, {"article": "Parkinson's is a disease that affects nerve cells in the brain that control the movement of muscles.\nThose who took the largest doses of ibuprofen were less likely to have developed Parkinson's than were those who took smaller amounts of the drug, the study found.\nThe findings came from an analysis of data on 136,474 people who did not have Parkinson's at the start of the study.\nThe exact cause is unknown, but experts believe it's a combination of genetic and environmental factors.\nBut in the meantime, Tagliati said, he would \"definitely discuss ibuprofen use\" with his patients because, if it works to protect against the disease, it could very well benefit those who already have it.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did at least mention that \"persistent use of ibuprofen can lead to gastritis, or inflammation of the stomach lining.\"", "answer": 1}, {"article": "A California company has developed a genetic test that can predict whether patients treated for early-stage colon cancer are likely to suffer a recurrence of the disease, the third leading cause of cancer deaths in the U.S.\n\nThe results of the test, based on an analysis of seven different genes found in colon-cancer tumors, yield a score that tells whether patients are at low, intermediate or high risk of having the disease come back after it is removed through surgery.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Because the study failed to prove that the Oncotype DX test could identify the patients most likely to benefit from chemotherapy, the risk is that the test would be used for this purpose anyway.\u00a0\nThis triggers the risk of \"false reassurance\"\u2013that a resassuring test result would lead to no aggressive treatment yet a bad outcome.\u00a0 \nThe story fails to warn about the potential risks of clinical over-use and over-reliance on a test that may not improve survival rates. ", "answer": 0}, {"article": "(Reuters Health) - When the results of a test wouldn\u2019t change how doctors manage a patient\u2019s care, most say it\u2019s not worth doing.\n\u201cDoes it actually change what you would tell them to do in terms of screening, prevention, or risk management?\u201d\n\nAccording to the new results, at least for some women, it would change their clinical management, he said.\nEven among all appropriate candidates who are sent for genetic testing, only nine percent will test positive for the BRCA mutations, so an additional four percent who have non-BRCA mutations is a significant number, Ellisen said.\nAnd for many, family testing would be recommended for first-degree relatives, according to the report in JAMA Oncology.\nThe BRCA1 and BRCA2 gene mutations put women at high risk for breast, ovarian and other cancers, but mutations of other genes are believed to confer extra risk as well.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Potential harms, including having uncertain results leading to psychological difficulties, were mentioned in a quote from the lead author, who also discussed the complexity of interpreting the results. The article also quoted him as saying that misinterpretation could potentially lead to \u201ca drastic, unnecessary surgical procedure\u201d.", "answer": 1}, {"article": "; Karen L. Margolis, M.D., M.P.H.\nThe study was also limited by the relatively small number of strokes that occurred during the follow-up period (just 3.4 percent of the women experienced a stroke during the study period and 1.6 percent reported having had a stroke prior to the study) and by the Women's Health Initiative's exclusion of women who had already had severe strokes at the time of recruitment.\n\u2022 Available multimedia including photos and an audio interview are on the right column of the release link - https:/\n\u2022 Story on previous JAHA study (June 21, 2018): Breastfeeding may reduce a mother's heart attack and stroke risk\n\u2022 For updates and new science from JAHA, follow @JAHA_AHA\n\nStatements and conclusions of study authors published in American Heart Association scientific journals are solely those of the study authors and do not necessarily reflect the association's policy or position.\nRecent findings point to the benefits of breastfeeding on heart disease and other specific cardiovascular risk factors,\" said Lisette T. Jacobson, Ph.D., M.P.A., M.A., lead author of the study and assistant professor in the department of preventive medicine and public health at the University of Kansas School of Medicine-Wichita.\nDALLAS, Aug. 22, 2018 -- Breastfeeding is not only good for babies, there is growing evidence it may also reduce the risk for stroke in post-menopausal women who reported breastfeeding at least one child, according to new research in Journal of the American Heart Association, the Open Access Journal of the American Heart Association/American Stroke Association.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Breastfeeding may be \u201cnatural,\u201d but it\u2019s not effortless. Breastfeeding can be time-consuming and exhausting, and carries risks of dehydration and breast pain. That said, these are not necessarily medical issues that rise to the level of discussion in a news release about an observational study like this one. As such, we\u2019ll rate this criterion as not applicable.", "answer": 2}, {"article": "You've probably heard about it \u2014 maybe you even remember seeing it once \u2014 but you're not really sure what it is or even where to find it.\n\nThe female condom (FC2), or internal condom, is a non-hormonal barrier method of birth control. But instead of going on a penis, it goes in a vagina, which is why it's also sometimes referred to as an internal condom. For more information, BuzzFeed Health spoke with two experts who could demystify this lesser-known contraceptive:\n\n* Dr. Harry Fisch, clinical professor of urology and reproductive medicine at Weill Cornell Medical College, and chief corporate officer of Veru Healthcare, which distributes FC2\n\n* Dr. Lauren Streicher, associate clinical professor of obstetrics and gynecology at Northwestern University\u2019s Feinberg School of Medicine", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is a good discussion of the drawbacks of condom use, for both male and female condoms.", "answer": 1}, {"article": "MIT scientists find evidence that Alzheimer\u2019s \u2018lost memories\u2019 may one day be recoverable\n\n\u2019Siri, I want to commit suicide\u2019 and other statements likely to yield unhelpful responses from your phone\n\nRoots of Napoleon complex may be justified: Study finds short men get short of end stick in life.\nThe study did caution that 30 of the 103, or about one-third, of the participants in the meditation group reported an \"adverse event,\" most often an increase in pain due to yoga.\nIn an editorial, Madhav Goyal and Jennifer A. Haythornthwaite of the Johns Hopkins University School of Medicine said that the mechanisms for why meditation might work on back pain is still a mystery but that this question is merely \"academic\" for many clinicians and their patients who need immediate relief.\n\"These findings suggest that MBSR may be an effective treatment option for patients with chronic low back pain,\" the authors wrote.\nThe study looks at adults with chronic low back pain, one of the leading cause of disabilities in the United States and one reason why more and more people are addicted to painkillers.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes: \u201cThe study did caution that 30 of the 103, or about one-third, of the participants in the meditation group reported an \u2018adverse event,\u2019 most often an increase in pain due to yoga.\u201d It\u2019s good to see that included. Since the story is effectively comparing MBSR to CBT and conventional treatment, it would also have been worth noting \u201cadverse events\u201d for those groups in the study. According to the study, 10 percent of the CBT group also experienced \u201cadverse events,\u201d and no adverse events were mentioned for the control group.\nDefining \u201cadverse events\u201d would also have been good, since it\u2019s not clear whether they mean momentary pain or a debilitating flare-up of long-term pain. According to the study, the pain\u2013for both MBSR and CBT groups\u2013was \u201cmostly temporary\u201d and no \u201cserious\u201d adverse events were reported. Those things are worth mentioning. (It\u2019s also worth finding out what \u201cmostly\u201d and \u201cserious\u201d mean.)", "answer": 1}, {"article": "Months of recovery are needed while the transplant grows and reconstitutes the patient\u2019s immune system.\n\u201cIt is possibly a cure, that\u2019s for sure, you won\u2019t know for absolute sure until the person dies and undergoes extreme PCR (genetic) analysis of post-mortem tissue.\u201d\n\nThe mutation affects a receptor, a cellular doorway, called CCR5, that the AIDS virus uses to get into the cells it infects.\nWASHINGTON (Reuters) - German researchers who used a bone marrow transplant to treat a cancer patient with the AIDS virus, have declared him cured of the virus \u2014 a stunning claim in a field where the word \u201ccure\u201d is barely whispered.\n\u201cIt\u2019s not practical and it can kill people,\u201d said Dr. Robert Gallo of the Institute of Human Virology at the University of Maryland, who helped discover the human immunodeficiency virus that causes AIDS.\nNearly four years after the transplant, the patient is free of the virus and it does not appear to be hiding anywhere in his body, Thomas Schneider of Berlin Charite hospital and colleagues said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes that bone marrow transplants are risky and in fact , \u201c\u2026can kill people.\u201d But it should have told readers that for some types of leukemia, up to 40 percent of patients die have receiving a bone marrow transplant from a donor. What\u2019s more the list of serious complications is harrowing. According to the National Cancer Institute, leukemia patients treated with a bone marrow transplant may have less than a 50-50 chance of successful treatment and even when the treatment works, it is often very painful and may cause serious to kidneys, liver, heart and lungs. So even though this story does tell readers that transplants are risky, it fails to provide numbers that would make clear just how perilous this course of treatment is.", "answer": 0}, {"article": "They found people in the bottom 25% scored lower on such mental tests as problem solving, multi-tasking and abstract thinking.\nTan said the MRI images showed those with lower levels of omega-3 fatty acids were also more likely to have minute but significant structural changes in the brain.\nThe only people who should avoid DHA are patients on a blood thinner like Cumadin, he added.\nDHA has the added benefit of improving mood and reducing symptoms of depression, he said.\nPeople with diets short on omega-3 fatty acids \u2013 the kind found in fish oil \u2013 were more likely to experience accelerated brain aging, a new study found.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does mention that DHA has the potential to cause problems in people taking blood-thinning medication.", "answer": 1}, {"article": "To place an electronic embedded link to this study in your story This link will be live at the embargo time: http://jamanetwork.\nNicholas S. Reed, Au.D., of the Johns Hopkins School of Medicine, Baltimore, and colleagues compared five of these devices (costs, approximately $350 to $30) with a conventional hearing aid (cost, $1,910) among 42 adults (average age, 72 years) with mild to moderate hearing loss.\nPersonal sound amplification products (PSAPs) are less-expensive, over-the-counter devices not specifically labeled for hearing loss treatment, but some are technologically comparable with hearing aids and may be appropriate for mild to moderate hearing loss.\nPresently, hearing aids can only be purchased in the United States through a licensed professional, with an average cost of $4,700 for two hearing aids (uncovered by Medicare).\nAccording to nationally representative estimates, less than 20 percent of adults with hearing loss report hearing aid use.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release should have mentioned the potential harms of these devices compared to hearing aids so people have the full picture when considering their potential. One problem is that less expensive PSAPs don\u2019t selectively amplify speech, which could conceivably worsen hearing loss by blasting too loud and broad a range of sound.", "answer": 0}]